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Abstract 
Chapter 1 reviews DNA structure and DNA molecular recognition by synthetic 
agents, including supramolecular helicates and cisplatin. An overview of various types 
of helicates and cisplatin anticancer drugs and their mechanisms of action is discussed. 
Examples of non-platinum anticancer drugs are also presented.  
In Chapter 2, the synthesis of novel metal-based supramolecular helicates and 
attempts to combine them with the cisplatin anticancer agent are described. In some 
cases X-ray crystallography data are presented and discussed in detail. In addition, the 
synthesis of the fluorescent europium helicate is described. 
In Chapter 3, stability and DNA binding properties of the synthesised metallo-
helicates are investigated using UV/Vis spectroscopy, CD and LD techniques. The 
ability of the complexes to unwind plasmid DNA and stabilise DNA three-way junction 
formation is explored by gel electrophoresis experiments. The results demonstrate that 
the geometry and size of the helicates are crucial for DNA three-way junction 
recognition. 
In Chapter 4, biological evaluation of antineoplastic activity of the metallo-
helicates synthesised in this work, as well as of the compounds supplied by other 
members of the group, is studied using an MTT colorimetric assay. The results of the 
study reveal that some of the complexes exhibit a potent cytotoxic activity. 
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Chapter 1 
 
 
Introduction
 2 
 
1.1 Overview  
The structures and effects of many biologically active molecules within biological 
systems are mediated by non-covalent interactions. It is essential to study these 
interactions, in order to understand function and mechanisms of action and to design 
synthetic analogues that will possess similar or even better biological activity. DNA, for 
instance, is a key molecule of the cell and its structure is held together by non-covalent 
interactions. Some proteins are able to bind to specific sites of the DNA and take part in 
gene regulation. Understanding the mechanism and principle of these interactions gives 
an opportunity to design new synthetic agents similar to their biological counterparts 
that could control gene expression. Supramolecular chemistry is a powerful tool in the 
creation of such synthetic analogues that could be used as therapeutic agents. 
 
1.2 Supramolecular chemistry 
The term supramolecular chemistry was first introduced by French chemist Jean-
Marie Lehn.
1
 Supramolecular chemistry is a field of chemistry based on non-covalent 
interactions between molecules including electrostatic interactions, van der Waals 
forces, hydrophobic effects, aromatic π-π stacking, metal coordination, dipole-dipole 
bonds, and hydrogen bonding.
2
 Covalent bonds introduce some rigidity within 
molecules whereas non-covalent intermolecular interactions introduce some flexibility 
to the molecular assemblies. Control of the geometry and rigidity of the molecular 
components gives opportunities to build molecules which can spontaneously generate 
well deﬁned supramolecular assemblies. Thus, supramolecular chemistry allows the 
development of highly complex, functional chemical systems from individual 
components which are held together by intermolecular forces.
3
 
 3 
 
1.3 DNA  
1.3.1 Background 
DNA or deoxyribonucleic acid is a highly ordered molecule with a helical 
structure. DNA was first isolated by the Swiss scientist Friedrich Miescher in 1869 from 
cell nuclei.
4
 The structure of DNA remained unknown for many years and only in 1953 
the double helical structure of DNA was identified by James Watson and Francis 
Crick.
5
 DNA encodes the genetic information of most living organisms and thus is 
responsible for their development and functioning. Moreover, DNA is used as a 
template for the synthesis of RNA which in turn encodes amino-acid sequence as 
proteins. Understanding the structure of DNA and the mechanisms of DNA recognition 
provides opportunities to control genetic information. 
 
1.3.2 DNA structure 
The DNA molecule consists of individual units called nucleotides which are 
linked together by 3’-5’ phosphodiester bond (Fig. 1.0).6  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.0 Schematic representation of B-DNA.
7
  
(a) (b) 
 4 
 
The B-form of the DNA, as established by Watson and Crick
8
, consists of two 
polynucleotide strands which form a ~ 20 Å diameter double helix by winding about a 
common axis. The helix is right-handed and the two strands run in opposite directions. 
Four different nitrogenous bases are present in the DNA: purines (adenine (A) and 
guanine (G)) and pyrimidines (cytosine (C) and thymine (T)). Bases from one strand of 
the DNA are paired with bases on the other strand of the DNA by hydrogen bonds thus 
forming base pairs (Fig. 1.1). Adenine is always paired with thymine and cytosine is 
paired with guanine. These interactions are called complementary base pairing.
8
  
 
                                                                               
 
 
        
                                                                                                  
Figure 1.1 Watson-Crick base pairs. 
 
 The paired bases are perpendicular to the helix axis and are π-stacked on each 
other forming a hydrophobic core of the DNA. Thus, the center of the helix is a 
chemically inert place to store genetic information. The DNA itself is negatively 
charged due to the presence of phosphate groups. One of the most important 
characteristics of B-DNA is the occurrence of two distinct grooves known as the major 
groove and the minor groove. These grooves play a significant role in the recognition of 
DNA, providing distinct surfaces with which proteins, certain chemicals and drugs can 
interact.
6, 8
 
Thymine (T) 
Adenine (A)
Cytosine (C) 
Guanine (G) 
 5 
 
The DNA molecule can exist in several various conformations. A, B and Z forms 
of the DNA have been found in living organisms (Fig. 1.2). The B-DNA is the 
prevailing form present in the cell. A-DNA is a right-handed double helix with inclined 
base pairs wrapping around a cylindrical hole. It is wider and flatter than B-DNA with a 
shallow minor groove and deep major groove. The A-form of DNA occurs in 
dehydrated samples of DNA and it can be found in hybrid DNA and RNA strands or in 
protein-DNA complexes.
9
 Z-DNA is a left-handed double helix with a zigzag pattern 
which has only one deep and narrow minor groove and no distinct major groove. The Z-
conformation of the DNA is not a stable feature; the Z-structure is induced by biological 
activity and then it disappears.
10
 
 
 
 
 
 
 
 
                    B-DNA                                    Z-DNA                                  A-DNA 
Figure 1.2 DNA conformations (a) B-DNA (b) Z-DNA
10
 (c) A -DNA.
11
 
 
Other unique DNA structures that are believed to play important roles in gene 
expression include DNA junctions and DNA tetraplex.
12
 DNA junctions are 
intermediate structures that are formed during DNA replication (three-way junction) and 
homologous recombination (four-way junction) (Fig. 1.3).
13
 
(b) (c) (a) 
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Figure 1.3 DNA junction structures (a) DNA three-way junction
14
 (b) DNA four-way 
junction.
15
 
 
Tetraplex DNA or G-quadruplex has a four-stranded helical structure which 
consists of stacked quartets known as G-quartets (Fig. 1.4). Each of the quartets 
involves the planar association of four guanine bases with a cyclic hydrogen bonding 
arrangement between them.
16
  
 
 
 
 
 
 
 
Figure 1.4 DNA tetraplex (a) Schematic structure of the guanine quartet (b) Top view of the X-
ray crystal structure of a human telomeric quadruplex DNA generated with PyMol.
17, 18
 
 
 M+ 
(b) 
   
(a) 
 
(a) 
(b) 
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Telomeres, the ends of the chromosomes, are guanine rich sequences. They 
protect chromosomes from damage and recombination. Telomeric sequences of DNA 
are capable of tetraplex formation therefore there is a significant interest in these kind of 
structures as potential targets for anticancer therapy.
19
 
 
1.3.3 DNA recognition 
DNA recognition plays a crucial role in the functioning of living systems. In 
biological systems the control of genetic information occurs through the non-covalent 
recognition of DNA by regulatory proteins. Understanding the mechanism of DNA 
recognition is important to design and develop synthetic agents that are able to 
recognize and bind to the DNA with selectivity and control gene expression. Molecular 
recognition of B-DNA can take place in different ways such as sugar-phosphate 
backbone binding, intercalation between base pairs, coordinative binding, groove 
binding, DNA junction and G-quadruplex recognition.
20
 
 
1.3.3.1 DNA sugar-phosphate backbone binding 
The sugar phosphate backbone of DNA is an oxygen-rich polyanionic surface. 
Hydrogen bonding and electrostatic interactions are predominant in this type of DNA 
recognition. Farrell`s compound TriplatinNC is an example of a DNA backbone binder 
(Fig. 1.5). TriplatinNC has a strong selectivity for phosphate oxygens forming bidentate 
complexes through hydrogen bonding.
21
 
 
 
 
 
 8 
 
                                                                                                                                                 
8+ 
 
 
 
 
        
 
 
 
 
 
 
 
 
 
Figure 1.5 Farrell`s trinuclear platinum backbone binder (a) Structure of TriplatinNC (b) 
TriplatinNC bound to the DNA backbone.
21
 
 
1.3.3.2 DNA intercalation 
DNA intercalation is based on insertion of a planar aromatic molecule or a 
fragment between two adjacent base-pairs of the DNA, forming sandwich-like 
structures. Intercalation leads to an opening between base pairs and unwinding of the 
DNA. DNA intercalators are mostly polycyclic, aromatic, and planar molecules.
22
 An 
anticancer drug doxorubicin is an example of a DNA intercalator (Fig. 1.6 (a, b)).
23  
Metallo-intercalators are metal complexes containing one or several intercalating 
ligands. An example of a metallo-intercalator is [Rh(phi)(Me2trien)]
3+
 complex of 
Barton (Fig. 1.6 (c, d)).
24
 When the metal complex binds to the DNA its planar phi 
ligand is inserted between base pairs forming face-face π-π interactions while the metal 
and other co-ligands reside in one of the DNA grooves.
25  
 
 
 (a) 
(b) 
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Figure 1.6 DNA intercalators (a) Structure of doxorubicin (b) Intercalation of doxorubicin 
between DNA base pairs
23
 (c) Structure of [Rh(phi)(Me2trien)]
3+
 (d) Binding of 
[Rh(phi)(Me2trien)]
3+
 to DNA by intercalation.
24, 25 
 
1.3.3.3 Coordinative binding 
The coordinative binding of synthetic agents to the DNA is irreversible and can 
lead to cell death by interfering in the processes of DNA functioning. Nitrogen mustards 
such as the drug chlorambucil and mustine (Fig. 1.7) are examples of coordinative 
binders.
26
 They alkylate DNA primarily at the N7 position of guanine by displacement 
of the chlorine and thus, are involved in the arrest of processes of replication and 
transcription. 
(c) (d) 
(a) (b) 
 10 
 
 
 
 
 
 
Figure 1.7 Nitrogen mustards (a) Chlorambucil (b) Mustine. 
 
The most successful in clinics anticancer drug cisplatin is a DNA alkylating agent. 
It binds to DNA by forming coordinative bonds mostly to the N7 position of adjacent 
guanine residues on one strand of the DNA (Fig. 1.8).
27
 The mechanism of action of 
cisplatin is discussed in more detail in section 1.5 of chapter 1.  
 
 
 
 
 
 
 
 
 
Figure 1.8 Cisplatin bound to DNA.
28 
 
Another example of coordinative binder is antitumour antibiotic anthramycin (Fig. 
1.9) which belongs to the pyrollo(1,4)benzodiazepine antibiotic group.
30
 Antibiotics of 
(a) (b) 
 11 
 
this group are able to inhibit nucleic acid synthesis by forming coordinative adducts 
with DNA.  
 
 
 
 
Figure 1.9 Structure of anthramycin. 
 
The binding of anthramycin to DNA occurs by forming a covalent bond between 
C11 and N2 of guanine. The structure is further stabilized by hydrogen bonding. 
Anthramycin has a preference for purine-G-purine sequences and binds to the middle 
guanine.
29, 30 
 
1.3.3.4 Minor groove binding 
The minor groove of DNA is an interaction site of some enzymes and regulatory 
proteins and thus is an attractive target for small synthetic molecules. Minor groove 
binders have specificity for AT regions of DNA and bind to DNA non-covalently. An 
example of such a binder is DAPI (Fig. 1.10). DAPI (4,6-diamidino-2-phenylindole) is 
an anti-parasitic agent that binds to AT-rich regions of the DNA minor groove with 
phenyl and indole rings parallel to the groove walls covering the three-base pair 
sequence ATT.
31
 
 
 
 
 12 
 
 
 
 
 
 
Figure 1.10 Minor groove binder (a) The structure of DAPI (b) DAPI (pink) bound in the 
minor groove of the DNA.
32
 
 
One of the most well-known anti-microbial DNA minor groove binders is 
pentamidine (Fig. 1.11).
33 
It is an aromatic diamidine which is active against 
Pneumocystis pneumonia caused by yeast-like fungus. It also favors AT rich regions 
upon binding to DNA. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.11 (a) Chemical structure of pentamidine (b) Pentamidine bound in the minor groove 
of the DNA.
31, 33 
 
Dervan et al. reported polyamides as sequence specific DNA binders.
34
 A set of 
codes was established in Dervan`s laboratories by which synthetic molecules based on 
     DAPI 
(a) (b) 
(a) (b) 
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dystamycin-type structures can recognize the DNA sequence via minor groove. In the 
first step of the experimental procedure a methylpyrrole of dystamycine was substituted 
with a methylimidazole group (Fig. 1.12 (a, b)). The nitrogen in the ring system is able 
to form hydrogen bonds to NH2 group of guanine base in the minor groove. 
Interestingly, at high drug loading two pyrrole/imidazole peptide strands could bind 
side-by-side in the minor groove (Fig. 1.12 (c)). This demonstrates that DNA is not a 
rigid molecule and in order to accommodate two peptide strands the minor groove of 
DNA must increase in size. The two polyamide strands lie head-to-tail in the groove 
with guanadinium ends located away from each other. Each polyamide strand interacts 
with bases of one strand of the DNA. The pyrrole/imidazole rings of one strand form π-
stacking interactions with amide carbonyls of the other.
35
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.12 (a) Chemical structure of dystamycine (b) Chemical structure of the polyamide 
strand (c) Two polyamide strands bound in the DNA minor groove.
35
 
 
(a) 
(b) 
(c) 
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1.3.3.5 Major groove binding 
The DNA major groove is an attractive site for protein binding rather than for 
small synthetic molecules as it is wider and has a greater number of hydrogen donor and 
acceptor units than the minor groove.
35
 Binding of proteins to DNA occurs through 
DNA binding domains such as zinc finger, α-helix-turn-α-helix, leucine zipper, and etc.   
Likewise proteins, oligonucleotides can bind to the DNA major groove and form 
Hoogsteen or reverse-Hoogsteen base pairing leading to a triple-stranded DNA 
formation (Fig. 1.13). The triplex is formed in areas of the DNA rich in purines 
(adenine and guanine) which can interact with pyrimidines on the third additional strand 
of the DNA by forming additional hydrogen bonds. Triple-stranded DNA structures are 
suggested to play a role in DNA transcription, recombination and condensation.
36, 37 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.13 Hydrogen bonding involved in DNA triplex formation (a) Hoogsteen base paring 
(b) Reverse-Hoogsteen base paring (c) Structure of DNA triple helix.
37 
 
 (a) 
 (b) 
(c) 
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A synthetic metal-based supramolecular cylinder (Fig. 1.14) synthesized in 
Hannon`s laboratory can bind to the DNA major groove and induce intramolecular 
DNA coiling. The iron triple-stranded helicate is ~ 2 nm length and ~ 1nm in diameter 
and these dimensions are similar to those of the α-helical DNA recognition unit of zinc 
fingers.
38
 
 
 
 
 
 
Figure 1.14 Crystal structure of iron(II) triple-stranded helicate synthesized in Hannon`s 
laboratory.
38  
 
1.3.3.6 DNA three-way junction recognition 
 
Hannon`s tetracationic iron(II) supramolecular helicate is able to recognize DNA 
three-way junction structures. It was crystallized with DNA palindromic 
hexanucleotide. The recognition of the junction was observed with a helicate located in 
the central cavity of the junction (Fig. 1.15). The structure is stabilized by π-stacking 
interactions between the helicate surface and the adenine and thymine bases of the 
junction, and electrostatic interactions between the positively charged cylinder and 
polyanionic surface of DNA.
39
 The ability of cylinder to recognize DNA three-way 
junction is a key discovery that underpins work in this thesis and is discussed in more 
detail in chapter 3 section 3.10. 
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Figure 1.15 Crystal structure of the iron(II) triple helicate bound to the center of the DNA 
three-way junction.
39  
 
1.3.3.7 Recognition of DNA G-quadruplex 
Guanine rich regions of the DNA such as telomeres are able to form tetra-stranded 
structures known as G-quadruplexes. These DNA structures are involved in the 
regulation of some key biological processes. Promoter regions of some oncogens 
consist of G-quadruplexes. Over the last years, there has been a great interest in these 
DNA sequences as potential targets for novel anticancer drugs.
18
 An example of a 
molecule that binds to DNA G-quadruplex is a platinum molecular square developed by 
Sleiman and co-workers (Fig. 1.15). 
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Figure 1.15 (a) Structure of the platinum molecular square (b) Structure of the complex with a 
DNA G-quadruplex. The complex is displayed in grey and blue; hydrogen bonding to 
phosphates is represented by a blue dotted line.
40
 
 
It has been proposed that cylinders developed by Hannon and co-workers bind to 
G-quadruplex DNA
41, 42
 although the results were not reproducible in our laboratory.
43
 
 
In this section of chapter 1, DNA structure and DNA recognition by various 
agents was discussed. DNA molecule is considered to be one of the key targets for 
anticancer treatment therefore compounds that bind to DNA are of great interest. 
Supramolecular assemblies such as helicates have been shown to bind to the major 
groove of DNA and induce intramolecular DNA coiling. In the following section 
examples of supramolecular helicates will be presented. 
 
1.4. Supramolecular helicates 
The term helicate was first introduced by French chemist Jean-Marie Lehn in 
1987 to describe a metal-based helix with one or more ligands coordinated to metal 
ions.
44
 Metallo-helicates can be viewed as simple models of more complex natural 
 
(a) (b) 
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structures such as DNA and viruses. They play an important role in the understanding 
and development of self-processes in supramolecular chemistry.
45, 46
 
 
1.4.1 Introduction to helicate formation 
Supramolecular helicates are formed by a spontaneous self-assembly process of 
wrapping ligand strands around the metal ions. According to the concept of 
coordination chemistry, diﬀerent metal ions prefer diﬀerent coordination environments 
such as square planar, tetrahedral, or octahedral. This geometrical preference of the 
metal ion can be used to control the orientation of coordinating ligands in space.
47
 
Generally, helicates are Werner-type coordination compounds consisting of two or 
several units connected by a spacer. Depending on the number of coordinated ligands, 
helicates are divided into single, double and triple-stranded. If helicates are formed from 
symmetrical ligand strands they are homotopic, whereas helicates formed from 
asymmetrical ligand strands are heterotopic (Fig. 1.16).
46  
 
 
 
 
 
 
Figure 1.16 Homotopic and heterotopic helical configurations.
46 
 
 
One of the intrinsic characteristics of helicates is chirality. They can be right-
handed (plus, P) or left-handed (minus, M), depending on whether the rotation is 
 19 
 
clockwise or anticlockwise when a helicate is considered to wind from the eye of the 
viewer towards a distant point. The self-assembly of helicates from achiral ligands and 
metal ions results in racemates containing both right-handed and left-handed helicates.
48
 
 
1.4.2 Single-stranded helicates 
Mononuclear single-stranded helical compounds can be formed when a central 
metal ion is too small to fit in the cavity of a bound multidentate ligand. A small twist of 
the ligand decreases the steric constraints of the molecule.
46
 Monohelices with chiral 
ligands are of particular interest due to their high asymmetry, well-defined reaction 
centers, and potential as asymmetric catalysts. Single-stranded monohelical molecules 
are synthetically complicated targets since flexible multidentate ligands often prefer to 
bridge metal centers and produce helicates.
49
  
Constable and co-workers have shown that the 2,2’:6’,2’’:6’’,2’’’:6’’’,2’’’’- 
quinquepyridine ligand (qpy) (Fig. 1.17) and its substituted analogues are able to form 
mononuclear single-stranded complexes. When the qpy ligand is reacted with Ag(I), the 
ligand wraps around the small silver metal ion forming a helical structure.
50
 
 
 
                                                               
                                                                                       
   
Figure 1.17 The structure of 2,2’:6’,2’’:6’’,2’’’:6’’’,2’’’’- quinquepyridine ligand. 
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Another example is a mononuclear Co(II) complex, with a 4’,4’’’-bis(p-
chlorophenyl)- 2,2’:6’,2’’:6’’,2’’’:6’’’,2’’’’- quinquepyridine  (bcpqpy = L) acting as a 
pentadentate  ligand with a shallow helical  twist  about the metal centre (Fig. 1.18). The 
helical configuration is achieved through individual twisting about the interannular C-C 
bonds of the adjacent pyridine rings.
51
 
 
                                                                                 
 
               
                                               L              
                                     
Figure 1.18 (a) Structure of ligand L (b) Space filling model of [Co(L)(CH3OH)(OH2)]
2+
.
51 
 
Recently, Levy and co-workers synthesized a monohelical zinc complex of a salen 
ligand containing benz[α]-anthracene side arms (Fig. 1.19). The benz[α]anthryl 
sidearms are significantly overlapped, but the large angle between them and the 
relatively large space shows that little face-to-face π-π interaction can occur.49  
 
 
 
 
 
                                                                                       M = Zn 
Figure 1.19 (a) Structure of Levy`s Zn complex (b) Space filling model of Levy`s Zn 
complex.
49  
(a) (b) 
(a) (b) 
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More recently, Datta et al. reported a mononuclear single helicate of 
europium(III). The ligand employed in complexation with europium metal ion is a 
condensate of benzildihydrazone and 2-acetylpyridine (Fig. 1.18 (a)). The europium 
metal centre in the complex is coordinated to three molecules of nitrate and four 
nitrogen of the ligand in a bidentate fashion (Fig. 1.20 (b)).
52
 
 
 
 
 
 
 
Figure 1.20 (a) Structure of the ligand reported by Datta (b) A space-filling model of 
europium(III) metal compex (Eu, white; N, black; C, dark gray; O, light gray).
52  
 
 
1.4.3 Double-stranded helicates 
Since early studies by the groups of Lehn, Constable, and Potts, versatile 
complexation properties of the oligo-pyridine derivatives and a wide range of 
polydentate ligands has been developed for the formation of helicate complexes.
53
 
Double-stranded helicates are formed by the reaction of binucleating ligands with metal 
cations with tetrahedral coordination geometry such as Cu(I) and Ag(I).
54
  
Lehn`s group developed a ligand containing 6,6’-dimethyl-2,2’-bipyridine 
moieties which form a double-stranded helicate with copper(I) ions (Fig. 1.21).
55
 
 
 
(b) (a) 
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Figure 1.21 Structure of the ligand developed by Lehn`s group. 
 
Jeffery et al. designed a double-stranded dinuclear copper(I) helicate based on the 
pyridyl-thiazole ligand L1 (Fig. 1.22). Two ligands are being divided into two bis-
bidentate pyridine-thiazole binding domains by rotation about the central pyridine-
pyridine bond. The metal ions are coordinated to one pyridyl-thiazole binding domain 
from each ligand. The formed complex exhibits strong π-π interactions between pyridyl-
thiazole rings on adjacent strands.
53  
 
 
 
 
 
 
        
Figure 1.22 (a) Structure of the pyridyl-thiazole-based ligand L1 (b) Solid state structure of the 
double stranded copper(I) complex of L1.
53  
 
(a) (b) 
n = 2-5 
 L1 
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Metals subject to octahedral coordination, e.g. Ni(II), Co(II), Zn(II) will form 
double-strand helicates with ligands having terdentate subunits. In 1992, Crane and 
Sauvage reported the synthesis of a dinuclear double helix from a bis-terpyridine ligand 
system using both iron- and ruthenium(II) ions as templates (Fig. 1.23).
55 
 
 
 
 
 
 
 
 
 
                                                    M = Fe(II), Ru(II) 
 
 
Figure 1.23 Self-assembly of double-stranded helicate reported by Sauvage and Crane.  
 
More recently, Kwong and co-workers reported binuclear double-stranded 
manganese(II) helicates
56 
which are formed by the reaction of manganese(II) 
perchlorate and chiral phenyl- and polyphenyl-bridged oligopyridines (Fig. 1.24). 
 
 
 
 
 
M 
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                                                                           L2 
 
 
 
 
 
 
 
Figure 1.24 (a) Chemical structure of the ligand L2 (b) Crystal structure and space-filling model 
of the [Mn2(L2)2(H2O)(CH3OH)(CH3CN)(ClO4)]
3+
 complex.
56  
 
The manganese(II) complex of L2 contains one diastereomer which is a double-
stranded helicate with P chirality. Both manganese metal centers have distorted 
octahedral geometry and are coordinated to two nitrogen binding sites from each L2 
ligand. Additional manganese binding sites are filled by solvent molecules and a 
perchlorate ion. The major helical twists take place between the 2,2’-bipyridine units 
and bridged phenyl rings.
56
 
A number of cyclic molecules with double-helical structures have also been 
synthesized. A Schiff based helical microcycle containing pyridine-2,6-diiyldiimine 
moieties and divalent metals have been reported in literature (Fig. 1.25 (a)).
55 
 
 
 
(a) 
(b) 
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Figure 1.25 (a) Double-helical Schiff based macrocyclic complex with divalent metal ions.
55 
(b)
 
Space-filling representation of [CuL3(SO4)]6: top view and side view. The six ligands L3 are 
drawn in different colours, Cu in orange, N in blue, O in red, S in yellow; H atoms are omitted 
for clarity.
57
 
 
According to the X-ray crystal structures of the complexes, the orientation of the two 
ligating groups induce helicity within the macrocycle in a six-coordinate nucleus.
55 
 
A hexanuclear circular copper(II) meso-helicate based on the bis-pyridylimine 
ligand has been reported by Gloe et al. (Fig. 1.25 (b)).
57
 Topological control of the 
  
L3 
(a) 
(b) 
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assembly process is associated with the bidentate coordination of the sulfate anions to 
the metal center which direct the formation of a double-stranded stracture. The formed 
complex is a neutral circular helicate assembled around Cu(II) metal centres by 
hydrogen bonding and π–π stacking interactions.  
 
1.4.4 Triple-stranded helicates 
An early triple-stranded helicate was structurally characterized by Raymond and 
co-workers in 1985.
58
 It is formed by self-assembly of three 1,5-bis[(1,2-di-hydro-1-
hydroxy-2-oxopyridin-6-yl)carbonyl]-1,5-diazapentane (5,“3-HOPOCAM-1,2”) ligands 
(Fig. 1.26) with three iron (III) metal ions. The ligand has similarity with rhodotorulic 
acid which is a naturally occurring siderophore.
59
 
 
 
 
 
Figure 1.26 Structure of the 5,“3-HOPOCAM-1,2” ligand developed by Raymond and co-
workers. 
 
Triple-stranded helicates are formed by the coordination of bidentate ligands to 
metals with octahedral coordination and wrapping around them. The europium(III) 
complex developed by Albrecht-Gary and co-workers is an example of such a helicate 
(Fig. 1.27). Albrecht-Gary`s helicate is based on a ligand L4, containing tridentate 
bis(benzimidazolyl)pyridine subunits. Two europium metal ions are coordinated by six 
nitrogen atoms of the benzimidazole moieties and three nitrogen atoms of the pyridine 
groups.
60
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Figure 1.27 (a) Structure of the ligand L4 (b) Molecular structure of the [Eu2(L4)3]
6+
 complex.
60
  
 
Hahn`s group prepared triple-stranded helicates with titanium(IV) metal ions 
using bis(benzene-o-dithiol) based ligands and a reactive metal compound [Ti(OC2H5)4]  
(Fig. 1.28).
61
 Titanium metal ions are coordinated to six thiolato donors in a slightly 
distorted octahedral fashion and the rigid ligand L5 leads to a helical twist of the 
molecule. 
 
 
 
       
        
 
           
                                    
Figure 1.28 Schematic procedure for the synthesis of [Ti2(L5)3]
4-
 complex.
61 
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Hannon and co-workers developed a dinuclear iron(II) triple-stranded helicate in a 
simple reaction by mixing imine-based ligand with an iron(II) chloride salt (Fig. 1.29).
62
  
 
 
 
 
 
 
 
 
 
Figure 1.29 Schematic representation of iron(II) triple helicate formation.
62 
 
 
Three strands of the ligand are coordinated to two octahedral iron(II) metal ions. 
Coordination to the metal centre induces twisting between the phenylene ring and the 
pyridylimine unit and as a result, the formation of a triple-helical assembly. The helicate 
is chiral and has two enantiomeric forms (M and P).
62
 
Recently, Dolphin et al. described diamagnetic cobalt and gallium triple-stranded 
helicates based on β,β`-linked bis(dipyrromethene) ligand L6 (Fig. 1.30).
63  
 
 
 
 
 
FeCl2 
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Figure 1.30 (a) Chemical structure of the ligand L6 (b) Crystal structure of the [Co2(L6)3] 
helicate. Phenyl groups and hydrogen atoms have been omitted for clarity.
63
  
 
The formed triple helicates are uncharged due to the nature of the ligand. 
Deprotonated dipyrromethenes (known as dipyrrins) act as monoanionic ligands that 
can produce uncharged complexes upon coordination to di- or tri-valent metals.
63
 
 
1.4.5 Quadruple-stranded helicates. 
The first example of a quadruple-stranded helicate was reported by McMorran and 
Steel in 1998 (Fig. 1.31). The helicate was prepared using four 1,4-bis(3-
pyridyloxy)benzene ligands L7 and two square planar Pd(II) centers. The complex 
formed represents a helical cage in which a hexafluorophosphate anion is 
incapsulated.
64
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Figure 1.31 Self-assembly of McMorran and Steel quadruple-stranded helicate. 
 
More recently, Raymond reported a quadruple-stranded helical complex 
containing bis-diketonate 4-acyl-2-pyrazolin-5-one ligands L8 and thorium(IV) as a 
metal (Fig. 1.32). Each actinide metal center in the helicate is nine coordinated by four 
bisbidentate 4-acylpyrazolone chelating units and N,N’-dimethylformamide solvent 
molecules. This complex
 
is the first example of a structurally characterized bisbidentate 
quadruple-stranded helicate.
65
 
 
 
  
 
 
 
 
 
 
Figure 1.32 (a) Structure of the ligand L8 (b) Structure of the [Th2(L
8
)4(DMF)2] quadruple-
stranded helicate.
65
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Chand and co-workers described palladium quadruple-stranded metallohelicate 
with N,N’-bis(3-pyridylformyl)piperazine ligand (Fig. 1.33).66 
 
 
 
 
 
 
Figure 1.33 (a) Structure of the ligand L9 (b) Crystal structure of [Pd2(L9)4]
2+
 viewed 
perpendicular to the four fold axis and along the Pd–Pd axis.66  
 
The synthesised molecule represents a helical cage where each metal centre has a 
planar square geometry and each plane consists of four pyridyl nitrogen atoms from 
different ligands. The crystal structure of [Pd2(L9)4]
2+
 revealed that the metallohelicate 
encapsulates nitrate anion between two metal centres.
66
 
 
Various supramolecular metallo-helicates formed in a self-assembly process have 
been discussed in section 1.4. Our interest in metal-based helicates originates from the 
discovery of their anticancer activity and this stimulated us to explore the effect of the 
synthesised cylinders in combination with cisplatin anticancer agent. The focus of the 
next two sections (1.5 and 1.6) of this chapter is platinum-based anticancer drugs and 
cisplatin anticancer therapy.  
 
 
 
L9 
(a) (b) 
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1.5 Platinum based anticancer drugs 
 
Metal-based compounds have an enormous impact on medicine as they offer 
possibilities to design new therapeutic agents to treat different types of disease.
67
 The 
variety of coordination numbers and geometries, intrinsic properties of the cationic 
metal ion and ligand give a wide range of reactivities that can be exploited.
 
Platinum 
coordination compounds have found application as active antitumour agents after the 
discovery of the biological activity of cisplatin. Nowadays, this drug remains one of the 
most effective therapeutic agents in a clinical use.
68, 69 
 
1.5.1 Cisplatin 
Cisplatin (cis-[PtCl2(NH3)2]) or cis-diamminedichloroplatinum(II) possesses high 
cytotoxic activity and is used to treat epithelial malignancies such as lung, head and 
neck, bladder and cervical cancer but it was found to be particularly effective in the 
treatment of testicular and ovarian cancers.
70
 The drug molecule contains a square-
planar platinum(II) center coordinated to two ammonia and two chloride ligands. This 
platinum complex exists in two different isomeric forms, trans- and cis- (Fig. 1.34). 
Trans-structures are inactive however at high concentration they start to restrain cell 
growth.
27
 
 
 
    
   
 Figure 1.34 Chemical structures of (a) Cisplatin (b) Transplatin. 
 
(a) (b) 
 33 
 
Cisplatin was first identified in 1847 and was known as peyrone`s chloride.
71
 The 
antitumour activity of cisplatin was discovered by chance in 1970 by Barnett Rosenberg 
while investigating the effect of the electric field on the growth of the bacteria 
Escherichia coli. It was found that a platinum compound generated by the reaction of 
platinum electrodes with ammonium chloride in a buffer solution stopped cell division 
and caused filamentous growth of the bacteria cells. Further testing of the compound 
revealed its anticancer activity.
 27
 
The synthesis of cisplatin is based on the Dhara method reported in 1970 (Scheme 
1.0).
72 
The success of this procedure depends on the trans effect introduced by 
Chernyaev in 1926. According to this concept, the rate of substitution of a ligand in a 
square planar or octahedral metal complex depends on the group opposite (trans) to it.
73 
 
The stronger trans-directing influence of the iodo ligand relative to the ammonia ligand 
in the intermediate means that the ligand trans to the iodide is more liable and is the 
first one to be displaced, resulting in a desired cis-configuration.
71  
 
 
 
 
 
 
 
 
 
Scheme 1.0 Dhara synthesis of cisplatin.  
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1.5.2 Mechanism of action 
DNA is considered to be the primary target of cisplatin. The drug is injected into 
the bloodstream and is believed to stay in a neutral state due to the high concentration of 
chloride ions that prevent hydrolysis. Cisplatin enters the cell by passive diffusion 
through the cell membrane or it can be partly transferred by an active transport 
mechanism. The concentration of chloride ions inside the cell is quite low and this 
results in the formation of aquated forms of cisplatin (cis-[Pt(NH3)2Cl(H2O)]
+
 or cis-
[Pt(NH3)2(H2O)2]
2+
) which are more reactive molecules. Inside the cell the activated 
platinum complexes of cisplatin react with different components of the cell (proteins, 
membrane phospholipids, RNA, thiol-containing molecules), including DNA however, 
it is not fully understood how platinum complexes reach their biological targets.
74
 
Because of the high nucleotide concentration in the cell nucleus, cisplatin will react 
primarily with DNA. The mechanism of action is based on substitution of aqua or 
chloride ions of these cationic aqua complexes and interaction with DNA bases mostly 
at N7 position of purine bases (with guanine favored over adenine).
75
 Cisplatin binds to 
a guanine N7 on DNA and if the complex contains another exchangeable ligand it 
provides different crosslinks: intra- or interstrand with available binding sites. Cis-
diamminedichloroplatinum(II) predominantly forms intrastrand adducts with the 
adjacent bases. 1,2 Intrastrand GG adducts account for more than 70 % of all adducts 
formed; 1,2 intrastrand AG adducts are the next most common at around 20 %: 1,3 
adducts and monoadducts are much less common.
27, 76 
The formation of a cisplatin-
DNA adduct alters the structure of DNA. The 1,2 intrastrand adducts unwind the DNA 
at the site of platination, bending it towards the major groove and creating a shallow 
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minor groove. The interstrand DNA-cisplatin adducts bend the helix towards the minor 
groove, where the platinum moiety is located (Fig. 1.35).
69  
 
 
 
 
 
 
 
 
 
 
Figure 1.35 Platinum-DNA adduct structures. Duplex DNA containing (a) Cisplatin 1,2-
d(GpG), (b) 1,3-d(GpTpG) Intrastrand, and (c) Interstrand cross-links, generated by PyMol. The 
DNA sequences are d(CCTCTG*G*TCTCC)∙d(GGAGACCAGAGG), d(CTCTAG*-
TG*CTCAC)∙d(GTGAGCACTAGAG), and d(CCTCG*CTCTC)∙d(GAGAG*CGAGG) for the 
cisplatin 1,2-d(GpG), 1,3-d(GpTpG) intrastrand, and interstrand cross-links, respectively. 
Guanine residues cross-linked by cisplatin at the N7 position are indicated by asterisks.
69  
 
The alteration in DNA structure caused by cisplatin is recognized by proteins of 
the High Mobility Group class. High Mobility Group (HMG) is a group of 
chromosomal proteins that help with transcription, replication, recombination, and DNA 
repair.
77 
When the protein is bound to DNA it inserts a phenyl group of the 
phenylalanine from the minor groove into a wedge-like interaction site created by the 
bent (Fig. 1.36). This causes destacking of nucleotide bases resulting in the DNA helix 
(a) (b) (c) 
 36 
 
being kinked. With HMG protein bound to DNA, the modified strand is not repaired 
properly and the cell dies.
78, 79 
 
 
 
 
 
 
 
 
 
 
Figure 1.36 A model of HMG protein (violet) binding to the platinated DNA with 
phenylalanine (yellow) as the intercalating residue.
80
 
 
1.5.3 Cisplatin Pharmacology 
Cisplatin (cis-DDP) is an effective antineoplastic agent, however its clinical 
application is limited due to its severe side effects. Cisplatin is administered as an 
intravenous infusion, with extensive hydration of the patient before and after 
administration in order to reduce kidney damage.
81
 The typical frequency of 
administration of cis-DDP is every three weeks or for high dosages every four weeks. 
Cisplatin acts nonselectively and affects the growth of rapidly dividing cancer cells as 
well as other healthy rapidly dividing cells in the body such as cells from 
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gastrointestinal tract, hair follicles and bone marrow. This causes hair loss, nausea and 
toxicity of blood forming elements. 
The main side effects of cisplatin are:  
 Nephrotoxicity (kidney damage) 
 Gastrointestinal toxicity (nausea, vomiting) 
 Neurotoxicity (abnormalities of the nervous system, including muscle cramps, 
seizures and a loss of taste) 
 Ototoxicity (hear loss resulting from damage to the sound-detecting hair cells in 
the inner ear)
82
 
 Hematologic toxicity (low levels of platelets, white blood cells, red blood cells) 
 Hyperuricemia (an increase in uric acid) 
To minimize adverse toxic side effects, cisplatin can be used in combination with two or 
more chemotherapeutic agents. The use of cisplatin is also limited by the tumour 
resistance to the drug. Resistance takes place when the cancer cell is treated with a drug 
and destroyed and then does not respond to that drug treatment again. Some tumours are 
intrinsically resistant to cisplatin (e.g. colon cancer) whereas others gain their resistance 
after exposure to the drug over a period of time (e.g. ovarian cancer).
27
 The resistance is 
believed to be caused by low drug uptake by the cell or accumulation in the cell, 
increased levels of intracellular thiols that can bind to cisplatin and deactivate it, and 
increased level of repair of the DNA damage caused by cisplatin due to the presence of 
certain DNA repair proteins.
83, 84, 85 
Inside the cell cisplatin can interact with thiol 
containing species (e.g. metallotheonein, glutathione) by coordination of sulfur donor to 
the platinum(II).
86
 It is suggested that altered expression of oncogens limits the 
formation of DNA-cisplatin adducts and activates antiapoptotic mechanisms.
87 
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1.5.4 Third and second generations of platinum drugs 
The success of cisplatin as an anticancer agent stimulated the design and 
development of more effective and less toxic platinum-based anticancer agents. Thus 
the second generation platinum drugs carboplatin and nedaplatin has been synthesized 
(Fig. 1.37).
88
  
 
 
 
 
Figure 1.37 Structures of the second generation platinum drugs: (a) Carboplatin (approved 
worldwide) (b) Nedaplatin (approved for clinical use in Japan). 
 
Carboplatin was synthesized by the substitution of the chloride ligands of cisplatin 
with a bidentate 1,1-cyclobutanedicarboxilic acid ligand. Carboplatin is less reactive, 
more stable, with lower binding to the plasma proteins. It is administered by infusion 
into vein and is used to treat ovarian, head and neck, lung, breast, and cervical cancers. 
The side effects of the carboplatin therapy are less severe than in the case of cisplatin. 
Reduced nephrotoxicity and neurotoxicity are observed for carboplatin, while 
hematological side effects are prevalent.
89
 Carboplatin has a lower cytotoxicity 
compared to cisplatin therefore it has to be administered at much higher doses in order 
to achieve a similar antineoplastic effect to cisplatin. However, the equivalent 
anticancer activity is observed for ovarian cancer. The mechanism of action of 
carboplatin, through generation of aqua species, is believed to be similar to cisplatin and 
therefore the formation of DNA adducts is identical.
90
 
(a) (b) 
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Nedaplatin (cis-diammine-glycolate-O,O’-platinum(II)) is a square planar 
platinum(II) complex that is comprised of a glycolic acid bidentate ligand with one 
carboxylic acid and one hydroxyl donor. This agent has shown high antitumour activity, 
less renal, gastrointestinal and neurotoxicity. Nedaplatin is efficient against lung, head 
and neck, testicular, and gynecological cancers.
91
 
The third generation of platinum-based drugs includes oxaliplatin, lobaplatin, 
satraplatin, picoplatin, heptaplatin (Fig. 1.38). They show less toxicity, wider 
antitumour activity, little or no resistance compared to cis- or carboplatin.  
 
 
 
 
      
 
 
 
 
 
 
Figure 1.38 The third generation platinum drugs: (a) Oxaliplatin (approved worldwide) (b) 
Lobaplatin (approved for clinical use in China) (c) Satraplatin (in clinical trials) (d) Picoplatin 
(in clinical trials) (e) Heptaplatin (approved in South Korea). 
 
Oxaliplatin is a square planar platinum(II) complex incorporating a 1,2-
diaminocyclohexane (DACH) ligand and an oxalic acid leaving group. Compounds 
 
(a) 
(b) 
(c) (d) 
(e) 
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containing DACH have lower solubility than cisplatin. In combination with other 
anticancer agents oxaliplatin is used to treat colorectal cancer. Oxaliplatin has shown 
minimal toxicity in clinical studies, except for reversible damage to peripheral sensory 
nerves.
92
 However, the efficacy and toxicity of the drug varies from patient to patient, 
mostly because of the intrinsic or acquired resistance.
93
  
Lobaplatin, a square planar platinum(II) complex, is a mixture of diastereomers 
(50:50) with a 1,2-diaminomethylcyclobutane ligand and a lactic acid as a leaving 
group. It is a water soluble and stable compound that exhibits antitumor effects on 
human esophageal, ovarian, breast and small cell lung cancers. Lobaplatin has a higher 
antineoplastic activity than cisplatin or carboplatin and is less toxic. The main drawback 
of lobaplatin is associated with myelosuppression.
94, 95
 
Satraplatin is a platinum(IV) complex with octahedral geometry around the metal 
center. It has ammine and cyclohexylammine ligands as well as two chloride ions in a 
cis-conformation and two axial acetate ligands. It is believed to be reduced to 
platinum(II) complex, the active form, by losing acetate ligands. The inertness of the 
platinum(IV) drug and the presence of carboxylate ligands increase lipophilicity and 
thus, the oral bioavailability of the drug. Satraplatin has a smiliar activity to cisplatin 
and carboplatin but it is also active against some cisplatin-resistant cell lines. It is in 
phase III clinical trials to treat prostate, ovarian and lung cancers.
96, 97
 
  
Picoplatin is a platinum drug with cis-conformation of ammine, and methyl 
pyridine and chloride ligands at the metal center. It was designed in an attempt to 
overcome cisplatin resistance. Picoplatin contains a bulky methylpyridine ligand and 
therefore has a lower rate of interaction with sulphur containing molecules. Picoplatin 
has a poor solubility and is administered intravenously. Low solubility in water causes 
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problems to create effective oral dosage forms. Picoplatin is active against lung, 
ovarian, prostate and colorectal cancers. There is no nephrotoxicity observed for 
picoplatin, however, myelosupression is the main drawback of the drug.
97, 98 
Heptaplatin exhibits equivalent antitumor activity and less toxicity compared to 
cisplatin. Moreover, it is effective against cisplatin-resistant L1210 leukemia cells, 
probably owing to its unique amine carrier. Heptaplatin is used in the South of Korea 
for the treatment of advanced gastric cancer and lung cancer. Nonetheless, treatment 
with heptaplatin causes significant side-effects including nephrotoxicity, 
myelosuppression, heptatoxicity, and nephrotoxicity.
99
 
 
1.5.5 Platinum(IV) complexes 
There is a great interest in platinum(IV) compounds as potential antineoplastic 
agents, with higher anticancer activity than cisplatin. These compounds may act as pro-
drugs which can be reduced in hypoxic environment of cancer cells to their active form 
and are believed to be able to overcome cisplatin-resistance and severe side-effects. 
Platinum(IV) complexes have some advantages over platinum(II) compounds. They are 
relatively inert and thus undergo less side-reactions upon reaching their target. 
Platinum(IV) species can offer greater structural variety of the complexes due to the 
higher coordination number and good aqueous solubility.
100
 As it was previously 
discussed, the platinum(IV) complex satraplatin is an orally administrable drug. 
Some platinum(IV) compounds, such as iproplatin and tetraplatin, (Fig. 1.39) 
entered into clinical trials.  
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Figure 1.39 Structures of platinum(IV) complexes (a) Iproplatin (b) Tetraplatin. 
 
Iproplatin (JM9, cis,trans,cis-[PtCl2(OH)2 (isopropylamine)2]) has a high 
solubility but turned out to be less active than cisplatin and therefore has not been 
approved. Tetraplatin (ormaplatin, [PtCl4(D,L-cyclohexane-1,2-diamine)]) showed great 
results in preclinical studies in cisplatin-resistant cell lines but caused severe 
neurotoxicity in treated patients and was abandoned.
101
  
Introducing specific functionality to platinum compounds can help to improve 
drug uptake or overcome drug resistance. Lippard and co-workers proposed the trans-
Pt(IV) carboxylate moiety for incorporation of functional groups into platinum-based 
compounds. They introduced an estrogen fragment to the platinum(IV) carboxylate 
structure by using a succinate linker (Fig. 1.40 (a)) and that resulted in increased 
sensitivity of the estrogen receptor of mammalian tumour cells to treatment.
102
 
                              
 
 
 
 
 
Figure 1.40 Structures of platinum(IV) complexes (a) Lippard`s estrgogen-platinum(IV) 
complex (b) LA-12  complex. 
(a) (b) 
(a) (b) 
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Kozubik and collaborators have reported the synthesis of a highly lipophilic 
platinum(IV) complex LA-12 ((OC-6-43)-bis(acetato)adamantlylamine(ammine) 
dichloroplatinum(IV)) (Fig. 1.40 (b)) which showed similar activity to satraplatin and 
no cross-resistance with cisplatin. It exhibits higher activity than cisplatin in A2780 and 
A2780 cis-resistant cell lines. The mechanism of action of LA-12, as other platinum(IV) 
complexes, is considered to be through reduction to the active platinum(II) species. The 
drug has entered phase I clinical trials.
103
 
Sadler and Bednarski have developed trans-dihydroxo platinum(IV) complexes 
that have azide ligands instead of chloro leaving groups as in cisplatin (Fig. 1.41). These 
complexes are stable in the dark and, upon irradiation with light of different 
wavelengths, they undergo reduction and bind to DNA nucleotides. The synthesized 
compounds are active against 5637 human bladder cancer cell lines including cis-
resistant cell lines.
100, 104 
 
 
 
 
 
Figure 1.41 Structures of Sadler and Bednarski`s photoactive platinum(IV) complexes.   
 
Kim and co-workers reported a cis,trans-[PtCl2(OAc)2(1,4-butanediamine)] 
complex which showed improved activity against colorectal and breast cancers (Fig. 
1.42). The drug had lower toxicity in experiments with mice and was chosen for further 
studies.
96 
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Figure 1.42 Chemical structure of Kim`s platinum(IV) complex. 
 
Numerous platinum(IV) complexes with anticancer activity have been synthesized but 
only a few have entered into clinical trials. 
 
1.6 Cisplatin combination therapy 
 
1.6.1 Cisplatin in combination with other therapeutics 
Cisplatin is a potent anticancer drug that can be used in cancer therapy as a 
single agent or in combination with other drugs. The multicomponent strategy is 
becoming of great importance as combination therapy can offer a significant advantage 
over monotherapy. Treatment with a single agent often fails due to developed drug 
resistance in cancer cells. Combining drugs that have different modes of action can 
exhibit synergism in activity and can even help to overcome the problem of drug 
resistance.
105
 The drug synergy effect takes place when one drug interacts with the other 
in such a way that leads to a significantly greater activity than each single component 
itself. Synergism in multicomponent therapy depends on various factors such as the 
mechanism of action of individual drugs, phenotypes of targeting cells, dosing period 
and combination ratio of each drug.
106
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Combination chemotherapy consisting of gemcitabine hydrochloride with 
cisplatin is used to treat non-small cell lung cancer and advanced stage bladder, 
cervical, pancreatic and epithelial ovarian cancers. Gemcitabine or 2’,2’-difluoro-2’-
deoxycytidine is a nucleoside type molecule where the two hydrogen atoms in the 
second position of deoxycytidine are substituted by fluorine atoms (Fig. 1.43). 
 
 
 
 
 
 
Figure 1.43 Chemical structure of gemcitabine. 
 
 
Gemcitabine acts as a prodrug which is converted in the body to the 
corresponding 5’-diphosphate and triphosphate metabolites by deoxycitidine kinase. 
These two molecules are responsible for the cytotoxic effects of gemcitabine. The 
diphosphate molecule is capable of inhibiting ribonucleotide reductase which is 
involved in the catalysis of the reaction to produce deoxyribonucleotides, essential 
components for DNA synthesis and repair. Therefore, the number of DNA monomers in 
the cell is reduced. The triphosphate metabolite acts by competing with the natural 
deoxycytidine 5-triphosphate by incorporation into replicating DNA. Once the 
triphosphate molecule has incorporated into the DNA, another deoxyribonucleotide is 
included and thus DNA synthesis is prevented.
107, 108
 It is believed that when 
administered together with cisplatin, gemcitabine helps to prevent cell resistance to 
cisplatin treatment. 
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Combining cisplatin with doxorubicin has improved its anticancer efficacy in 
endometrial carcinoma in phase III clinical trials. Doxorubicin, or Adriamycin, (Fig. 1.6 
(a), page 9) is anthracycline antibiotic intensively used in anticancer therapy to treat 
hematological cancers, several carcinomas and soft tissue sarcomas. Doxorubicin itself 
is cardiotoxic but together with cisplatin in combination therapy it induces a higher 
level of hematological and gastrointestinal toxicity.
109
 Doxorubicin acts by intercalation 
between the bases of the DNA, binding to the DNA polymerase and inhibiting DNA 
synthesis.
110
 
Cisplatin in combination with 5-fluorouracil (5-FU) is widely used to treat 
advanced nasopharyngeal carcinoma and advanced gastric carcinoma.
111,
 
112
 5-
Fluorouracil is an analogue of uracil with a hydrogen atom at C5 position being 
substituted by a fluorine atom (Fig. 1.44 (a)). 
 
 
                                             
 
Figure 1.44 (a) Structure of 5-fluorouracil (b) Structure of capecitabine. 
 
5-Fluorouracil as a single agent is used to treat colorectal and pancreatic cancers. 
Within the cell, the drug is converted into toxic metabolites fluorodeoxyuridine 
monophosphate, fluorodeoxyuridine and fluorouridine triphosphates, which are then 
incorporated into RNA and DNA molecules inhibiting the DNA synthesis.
112 
Previous 
clinical studies revealed that platinum-based multicomponent therapy for treatment of 
(a) (b) 
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metastatic and recurrent nasopharyngeal carcinoma results in higher response rates than 
any other drug combinations, approximately 50 - 90 % with a complete response rate of 
5 - 30 %. However, continuous infusion of 5-FU requires chronic venous excess which 
is inconvenient, expensive and very often leads to a venous thrombosis and sepsis. 
Therefore to overcome these complications an alternative to 5-FU was created; the oral 
drug fluoropyrimidine capecitabine.
113
  
Capecitabine (Fig. 1.44 (b)) is an oral prodrug that is converted into 5-
fluorouracil by a series of enzymatic reactions in tumour tissue. It inhibits DNA 
synthesis and precludes cell growth. Capecitabine shows a single-agent activity against 
advanced pancreas and metastatic breast cancers.
114,
 
115
 It was reported that in 
combination with cisplatin it is effective and well-tolerated by patients with advanced 
gastric cancer, biliary cancer and squamous cell carcinoma of the head and neck.
111
 
Capecitabine combined with oxaliplatin shows a good activity profile and thus this 
combination of drugs can be used as a first-line therapy in advanced gastric cancer. 
Oxaliplatin is less toxic than cisplatin and no renal or ototoxicity is observed. The 
combination of capecitabine and oxaliplatin does not require hydration, like cisplatin, 
and therefore is more convenient to use.
113 
 
The cisplatin combination therapy was proven to be more effective in treatment of 
some types of cancers than drug monotherapy however high toxicity of cisplatin 
remains the main drawback of its dose-limiting application. Oxaliplatin was found to be 
a good alternative for cisplatin with lower toxicity and good antitumour profile.  
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1.6.2 Cisplatin conjugates. 
In the search for novel anticancer agents with higher cytotoxic activity and less 
toxicity, numerous compounds have been synthesised by modifying the cisplatin moiety 
and incorporating it into various molecules. 
Brunner and co-workers incorporated the cisplatin moiety to a porphyrin system 
by attaching it to the carboxylate groups of the propionic acid side chains of porphyrin 
in order to accumulate cisplatin specifically in a tumour tissue (Fig. 1.45).
116
 Porphyrins 
are used to treat tumours in photodynamic therapy. When irradiated with light of 630 
nm, they produce singlet oxygen which kills tumour cells. The cytotoxic activity of the 
synthesised compounds was investigated in breast cancer cell line MDA-MB-231. It 
was found that porphyrin ligand itself is not active without irradiation; however upon 
irradiation it reduces cell proliferation to ~ 81 %. The porphyrin complex with cisplatin 
showed activity without irradiation decreasing cell proliferation to ~ 63 % and upon 
irradiation to ~ 38 %. Cisplatin alone was found to reduce cell proliferation by ~ 50 % 
upon irradiation. This demonstrates the additive effect of porhpyrins and cisplatin.
116
 
                                                                            
 
 
 
 
 
 
 
Figure 1.45 Structure of porphyrin (a) with propionic acid side chains (b) with cisplatin moiety. 
(a) (b) 
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Brabec and co-workers combined the cisplatin moiety with the DNA minor 
groove binder distamycin (Fig. 1.46). Distamycin is a known antibacterial, antiviral and 
antineoplastic agent whose activity is thought to be associated with its ability to bind to 
DNA. This molecule has a preference for AT rich regions of DNA. Cisplatin-
distamycin complex binds to DNA and induces a higher number of interstrand cross-
links than cisplatin itself. This in turn causes a bend of the helix of ~ 35º towards the 
DNA minor groove and unwinding of the DNA by approximately 95º. However, there 
is no systematic data and evidence of the activity of the cisplatin-dystamycin 
complex.
117
 
 
 
 
 
 
 
Figure 1.46 Cisplatin moiety attached to distamycin. 
 
Reedijk et al. have reported mononuclear and dinuclear platinum(II) compounds 
containing a 5,7-dimethyl-1,2,4-triazolo[1,5-a]pyrimidine (dmtp) moiety as a ligand 
(Fig. 1.47). Triazolopyrimidine derivatives are similar in structure to purines and differ 
from them by the presence of an additional pyrimidine nitrogen.
118
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Figure 1.47 (a) Structure of cis-[PtCl2(NH3)(dmtp)] (b) Structure of cis-[PtCl2(dmtp)2] (c) 
Crystal structure of [Pt2(μ-dmtp)2Cl2(dmtp)2]
2+
.
118 
 
The reaction of the synthesised compounds with 5’-GMP revealed the site of 
platination at the N7 position of 5’-GMP. The complexes have been tested for their 
antitumor activity in T47D breast and HCV29T bladder cancer cell lines. Cis-
[PtCl2(NH3)(dmtp)] and cis-[PtCl2(dmtp)2] did not show any activity, whereas the 
dinuclear complex {H
+
[Pt2(μ-dmtp)2Cl2(dmtp)2]
2+
(NO3)3(H2O)6} was active against 
T47D breast cancer cell line with an IC50 of 2.3 μM compared to that of cisplatin (10.7 
μM).118  
Herman and co-workers reported a heteronuclear ruthenium(III)-platinum(II) 
complex that resembles cisplatin and NAMI-A anticancer compounds (Fig. 1.48).
119
 
(a) (b) 
(c) 
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This trinuclear complex contains two ruthenium(III) metal centres that can undergo 
reduction to Ru(II) under biological conditions and one platinum(II) metal centre.  
 
 
 
 
 
 
 
Figure 1.48 Structure of mixed ruthenium(III)-platinum(II) complex. 
 
DNA binding studies by gel electrophoresis showed that the compound binds 
strongly to the DNA and has a higher effect on the DNA electrophoretic mobility than 
cisplatin. The complex has been tested for its cytotoxic activity, together with cisplatin 
as a control, in CCRF-CEM leukemia cells (IC50 = 4.3 and 4.8 μM, respectively), HOP-
62 NSC lung cells (IC50 = 5.0 and 4.5 μM, respectively), and BT-549 breast cells (IC50 
= 14.4 and 14.8 μM, respectively). The IC50 values revealed that the heteronuclear 
mixed-metal complex has a moderate activity. The activity of the complex was mostly 
associated with the presence of cisplatin moiety group.
119
 
More recently Brewer et al. described mixed-metal ruthenium(II)-platinum(II) 
complexes with substituted terpyridine ligands (Fig. 1.49).
120  
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Figure 1.49 Structures of the ligands and the mixed-metal ruthenium(II)-platinum(II) 
complexes; grey-carbon, blue-nitrogen, green-chlorine, gold-ruthenium, and white-platinum.  
 
Mixed-metal complexes consisting of ruthenium light absorbers and bioactive 
molecules such as cisplatin attracted a lot of attention for their potential anticancer 
properties. Mixed-metal complexes show enhanced covalent binding to DNA compared 
to cisplatin itself, and the positive charge introduced by Ru(II) improves water 
solubility. The coordinative binding of the synthesised complexes was demonstrated by 
agarose gel electrophoresis using linear DNA. The retardation of migration through the 
gel was greater for these compounds than for cisplatin. Introduction of bulky 
t
Bu3 
groups caused slower migration through the gel due to steric factors. All the complexes 
have been shown to bind to the guanine residues of DNA. The photocleavage studies 
using gel electrophoresis with plasmid DNA were carried out. The compounds were 
shown to photocleave DNA upon irradiation with visible light. The 
[(MePhtpy)RuCl(dpp)PtCl2](PF6) complex is significantly more efficient in 
tpy   MePhtpy 
t
Bu3tpy   dpp 
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photocleaving DNA, whereas for the [(
t
Bu3tpy)RuCl(dpp)PtCl2](PF6) metal complex 
minimal to no photocleavage was observed.
120
 
Guo et al. from China linked the cisplatin moiety to bisphosphonate tetraethyl 
esters (Fig. 1.50).
121
 Biphosphonates are well known for their bone targeting properties 
and they are widely used as therapeutics to treat bone–related diseases. According to the 
CD studies data obtained compounds 1 - 4 hardly interact with the DNA, suggesting 
that DNA is not the primary target of these compounds. Interestingly, compounds 2 and 
4 exhibit cytotoxic activity in MG-63 osteosarcoma and COC1 ovarian cancer cell lines 
with IC50 values higher than cisplatin whereas compounds 1 and 3 do not show any 
activity, which can be explained by the length of the linker between the chelating 
moiety and the bisphosphonate esters.
121
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Figure 1.50 Structures of platinum(II) complexes synthesised by Guo et al. 
 
Rusling and co-workers combined cisplatin and epidermal growth factor (EGF) 
with a single wall carbon nanotube (SWNT) in order to specifically target head and 
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neck squamous cancer cells (Fig. 1.51).
122
 The synthesised nanotubes are able to enter 
the cells by endocytosis and other mechanisms. Functionalised SWNTs provide high 
surface area for drug loading and the ability to transport the drug across the cell 
membrane with low toxicity. Functionalised with cisplatin and epidermal growth factor, 
SWNTs have an affinity to the cell-surface receptor (EGFR) which is overexpressed in 
squamous cancer cells. By using these EGF-EGFR interactions, SWNTs can selectively 
target and kill cancer cells. The synthesised SWNT-cisplatin-EGF conjugate has been 
tested for its antitumor activity in head and neck squamous carcinoma cell lines, and a 
significant decrease in a tumour volume has been observed.
  
 
 
 
 
 
 
 
 
Figure 1.51 Schematic representation of SWNTs targeting the EGFR receptor on the cell 
surface.
122
 
 
In the previous sections 1.5 and 1.6, platinum anticancer drugs and cisplatin 
combination therapy were discussed. Cisplatin is one of the most common drugs used in 
clinics to treat patients with different types of cancers. However, severe side effects, 
 55 
 
absence of specificity of this drug and efficiency against platinum-resistant and 
metastasis tumours stimulated research in the area of non-platinum-based anticancer 
drugs.
123
 The success of advances in this area is discussed in the following section. 
 
1.7 Non-platinum metal compounds as anticancer drugs 
1.7.1 Ruthenium metal complexes 
Ruthenium compounds show great promise as potential therapeutics, although 
there are no analogues in the clinic as yet. Nevertheless two ruthenium compounds 
entered human clinical trials, NAMI-A and KP-1019 (Fig. 1.52).
124
 
                                                                         
 
 
 
 
 
 
Figure 1.52 Structures of (a) NAMI-A (b) KP1019. 
 
NAMI-A shows anti-metastatic properties and it is active against lung metastasis. 
KP1019 is active against colorectal cancer and primary explants of tumours that are 
resistant to standard chemotherapeutic agents. It is believed that ruthenium compounds 
convert to their active form after entering the cell. Ruthenium complexes tend to 
accumulate in tumour cells rather than healthy tissues by utilising the transferrin 
molecule to enter the cell.
124
  
(a) (b) 
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Several ruthenium arene-based compounds with cytotoxic properties have been 
designed. Sadler et al. developed ruthenium anticancer compounds consisting of an aryl 
ruthenium with a “piano-stool” type of conformation, with a bidentate ethylenediamine 
and a chloride occupying the remaining coordination sites (Fig. 1.53).
125
 The 
compounds showed a wide spectrum of activity including cisplatin resistant tumours. 
Interestingly, the activity of Sadler`s ruthenium compounds is dependent on the size of 
the aryl unit, the more extended aryls exhibit higher activity. The complexes can bind to 
DNA with a preference for guanine residues and large aryl groups can partially insert 
between DNA bases creating a bifunctional lesion.
126
 
 
 
 
 
 
Figure 1.53 Sadler`s piano-stool ruthenium complex. 
 
Dyson and co-workers synthesised RAPTA-C and RAPTA-T (RuCl2(η
6
-
arene)(PTA)) ruthenium(II) arene complexes based on the 1,3,5-triaza-7-
phosphaadamantane (PTA) ligand (Fig. 1.54). RAPTA-C is based on p-cymene whereas 
RAPTA-T is toluene based.
127
 
 
 
 
 
 
 57 
 
 
 
                                                                           
 
 
 
Figure 1.54 Structures of ruthenium arene-based compounds (a) RAPTA-C (b) RAPTA-T. 
 
RAPTA compounds showed moderate cytotoxic activity in various cancer cell 
lines and significant activity in metastatic cancers, by reducing number and weight of 
solid metastases without affecting the primary tumour. The anticancer activity of 
RAPTA-T is associated with interaction of the compound with extracellular 
components such as collagenIV and fibronectin. Treatment of Ehrlich ascites carcinoma 
cells with RAPTA-C induces high accumulation of tumour suppressor gene p53 
responsible for cell apoptosis in response to DNA damage and cell stress, and thus the 
arrest of the cell cycle occurs. RAPTA-C also provokes high levels of the p21 gene 
associated with cell cycle inhibition, differentiation, and cellular senescence.  Low 
levels of cyclin E, a central regulator in transition of G1-S/G2-M was observed, which 
demonstrates the ability of RAPTA-C to slow down cell division.
124, 128 
More recently, Navarro and co-workers reported a half-sandwiched ruthenium(II) 
complex that binds non-covalently to DNA.
129
 Cationic cyclic polynuclear half-
sandwiched ruthenium(II) complexes of general formula [(cymene)4Ru4(μ-
Hoxonato)2(μ-N,N′-L)2]-(CF3SO3)4 (L = 4,4’-bpy; L = 4,7-phen) contain  Hoxonato 
bridges (H3oxonic = 4,6-dihydroxy-2-carboxy-1,3,5-triazine acid) and N,N’-linkers 
(4,4’-bipyridine (4,4’-bpy), 4,7-phenanthroline (4,7-phen) (Fig. 1.55). Both compounds 
(a) (b) 
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were shown to bind to the DNA and induce significant alterations in its conformation. 
They were found to change shape of the DNA strands, mainly by stiffening and strand 
aggregation. The compounds exhibited a good cytotoxic profile in A2780 and A2780 
cisplatin-resistant cancer cell lines with significant activity in the A2780cisR cell line 
(IC50 = 2.4 μM for compound 5, 4.6 μM for compound 6 and 3.7 μM for cisplatin) 
which is quite striking due to their non-covalent nature of binding. 
 
 
                                                                       
 
 
 
 
 
 
 
 
Figure 1.55 Structures of half-sandwiched ruthenium(II) complexes (a) Schematic 
representation of [(cymene)4Ru4(μ-Hoxonato)2(μ-N,N’-L)2]-(CF3SO3)4 (b) Molecular force field 
models of [(cymene)4Ru4(Hoxonato)2(4,4’-bpy)2]
4+ 
5 and [(cymene)4Ru4(Hoxonato)2(4,7-
phen)2]
4+ 
6.
129
 
 
 
 
 
 
 
 
 
 
5 
6 
(a) (b) 
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1.7.2 Rhodium metal complexes 
There has been a significant interest in rhodium compounds and their antitumor 
properties since the discovery of dirhodium(II) carboxylates. The dirhodium 
tetracarboxylate complexes of formula [(RCOO)4L2Rh2(II)] (where R = Me, Et, Ph or 
CF3; L = H2O or other solvents) (Fig. 1.56) exhibit cytotoxic activity in leukemia L1210 
tumors, Ehrlich ascites, sarcoma 180, and P388 murine leukemia tumour cell lines.
130
 
The rhodium(II) carboxylate compounds are known to bind to the DNA and inhibit 
DNA, RNA and protein synthesis, however, the mechanism of their action is not fully 
understood.
131
 It was found that with increasing lipophilicity of the alkyl group, the 
compounds showed higher activity, with pentanoate being the most active in Ehrlich 
ascites tumor cell lines.
130 
 
 
 
 
 
Figure 1.56 General structure of dirhodium(II) tetracarboxylate. 
 
Sheldrick et al. recently reported several complexes of general formula 
[RhCl3(DMSO-κS)(pp)] with a series of aromatic polypyridyl ligands (Fig. 1.57). 
Interestingly, these compounds do not show binding to the DNA neither by intercalation 
nor by covalent binding. The characteristic DNA CD spectrum is unchanged upon 
titration of the rhodium(III) polypyridyl compounds with ct-DNA.
132
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Figure 1.57 Structures of the trichloridorhodium (III) polypyridyl complexes mer-
[RhCl3(DMSO-κS)(pp)] 7 - 11 (pp = bpy, phen, dpq, dppz, dppn). 
 
Despite the absence of DNA binding, the trichloridorhodium(III) polypyridyl 
complexes exhibit potent cytotoxic activity in MCF-7 breast cancer and HT-29 colon 
cancer human cell lines.  The IC50 values for the complexes 7 - 9 are strongly dependant 
on the size of the polypyridyl ligand (bpy > phen > dpq). There is no further significant 
increase for complexes 10 and 11. Compounds 9 - 11 showed significantly high 
antitumor activity with IC50 values in the range of 0.069 - 0.079 μM, which is two times 
lower than for cisplatin (IC50 range 2 - 7 μM). Moreover, a high level of cellular uptake 
of these complexes was observed, with compound 9 causing a significant decrease in 
cellular oxygen consumption and rate of cellular acidification.
132, 133 
Lorenz and co-workers described a new rhodium(III) complex with 1-nitroso-2-
naphthol chelating as a 1,2-naphthoquinone-1-oximato ligand (Fig. 1.58).
134
 This 
compound binds to the DNA in a suggested non-covalent manner and has no effect on 
the stability of the DNA.  
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Figure 1.58 Chemical structure of rhodium(III) chelate complex. 
 
The cytotoxic activity of the rhodium(III) chelate complex was tested on HeLa 
cervical carcinoma and HL60 leukemia cancer cell lines. The compound showed a good 
activity profile in both cancer cell lines, however the highest activity was observed in 
the HeLa cancer cell line with IC50 values higher (IC50 = 6.5±5.9 μM) than those of 
cisplatin (IC50 = 25±4.2 μM).
134
 
The drive to synthesise metal-based anticancer compounds with a high antitumour 
activity is not limited to ruthenium and rhodium chemistry. Various iron and gold 
compounds with anticancer activity have also been reported. 
 
1.7.3 Iron metal complexes 
The salts of ferrocenium picrate and ferrocenium trichloroacetate were the first 
iron compounds to be discovered to have cytotoxic activity.
135
 Substituted ferrocene 
compounds are active, though ferrocene itself does not exhibit any activity. The 
antitumour activity of ferrocene derivatives is linked to the oxidative DNA damage 
caused by oxygen species produced by the compounds. Iron(II) ferrocene is 
interconverted into iron(III) ferrocenium ions within cancer cells which are then 
involved in the production of reactive oxygen species. Ferrocifens are ferrocene 
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derivatives of anti-estrogen tamoxifen with one phenyl ring of tamoxifen replaced with 
ferrocene (Fig. 1.59).  
 
 
 
 
 
 
 
Figure 1.59 Structure of (a) Tamoxifen (b) Ferrocifen.  
 
Ferrocifens are highly active towards breast cancer cell lines that are ERα –ve 
(ERβ +ve) as well as breast cancers that are ERα +ve, whereas tamoxifen itself is active 
only in cancers that are rich in ERα (ERα +ve).126, 135  
Iron(II)-bleomycin compounds have shown antineoplastic activity against various 
malignancies including testicular cancer and certain types of lymphomas.
136
 Bleomycins 
are a group of glycopeptides isolated from bacterium Streptomyces verticillus. 
Bleomycin (BLM) has four functional domains: the metal binding domain responsible 
for DNA recognition and oxygen activation, the bithiazole and C-terminal substituents 
involved in DNA binding, the linker region for DNA cleavage and carbohydrate moiety 
for cell surface recognition and efficient DNA cleavage (Fig. 1.60).  
 
 
 
 
(a) (b) 
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Figure 1.60 Structure of BLM A5.
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When complexed to Fe(II) metal ions bleomycins have been shown to degrade 
DNA by forming single-stranded lesions and double-stranded breaks in the DNA 
backbone. Single-stranded lesions are caused by both direct breaks in the DNA 
backbone and release of bases from deoxyribose moiety. Regions in which the bases are 
removed then undergo to alkaline lysis. Double-stranded breaks in the DNA are thought 
to be due to two independent breaks on opposite strands of the DNA. The ability of 
iron(II)-bleomycin complex to degrade DNA is believed to be responsible for its 
antineoplastic activity.
137
  
An iron(III)-salophen compound recently reported in the literature is an 
organometallic complex with antitumour properties.
138
 Salophens are organic 
compounds composed of two Schiff`s bases linking three aromatic moieties (Fig. 1.61). 
It was shown that iron(III)-salophen complex is a potential candidate for the treatment 
of ovarian cancer. Treatment of SKOV-3 cancer cell line with iron (III)-salophen 
complex for 24 hours caused reduction of cell proliferation with an IC50 value of 300 
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nM. At a concentration of 2 μM in the SKOV-3 cell line the complex caused nuclear 
fragmentation, chromatin condensation and DNA fragmentation leading to apoptosis. It 
is believed that iron (III)-salophen forms active hydroxyl radicals that cleave DNA.
138
 
 
 
 
 
 
 
 
Figure 1.61 Chemical and X-ray structures of iron(III)-salophen complex.
138
  
 
Recently, Chakravarty and co-workers described photoactive ternary iron(III) 
complexes containing tertiary butyl groups with a tetradentate phenolate-based ligand 
and phenanthroline (phen, 12), dipyridoquinoxaline (dpq, 13) and dipyridiphenazine 
(dppz, 14) moieties (Fig. 1.62).
139
 These compounds bind to the DNA in a groove-
binding nature rather than intercalation due to the presence of the steric bulky 
tetradentate ligand. They induce photocleavage of the DNA in the presence of visible 
light through the formation of active hydroxyl radicals. Among the series of 
compounds, complex 14 was found to show high cytotoxicity in HeLa cervical (IC50 = 
3.59 μM) and keratinocyte HaCaT (IC50 = 6.07 μM) cancer cell lines in visible light and 
low toxicity in the dark. Rapid cancer cell death observed after 2 hours of 
photoirradiation of this compound makes it a potential candidate for photodynamic 
anticancer therapy.
139
 
 
 65 
 
 
 
 
 
 
 
 
 
Figure 1.62 Structures of iron(III) complexes reported by Chakravarty. 
 
1.7.4. Gold complexes 
Gold compounds have attracted the interest of many research groups for their 
great potential in anticancer treatment, however, the mechanism of their action is not yet 
fully understood. It is suggested that gold compounds induce apoptosis through various 
cellular processes such as direct DNA damage, modification of the cell cycle, 
mitochondrial damage, proteasome inhibition, modulation of specific kinases and 
others.
140
 
Gold(I) compounds have been extensively studied for their antiarthritic properties 
and moreover, several gold compounds such as Auranofin and related thiolate gold 
phosphane derivatives have shown a good cytotoxic activity (Fig. 1.63). Gold(I) 
complexes act by inhibiting mitochondrial functions and induce conditions for the 
release of cytochrome c which leads to apoptosis.
140, 141 
  =    
Phen  (12) 
 
 Dpq   (13) 
Dppz (14) 
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Figure 1.63 Structures of gold (I) complexes with antiarthritic and antitumour properties. 
 
Dyson et al. have developed alkynyl phosphane gold(I) complexes with the PTA 
and DAPTA co-ligands (Fig. 1.64).
141
 The antitumour properties of these compounds 
were analysed using A2780 and A2780cisR ovarian cancer cell lines. All the complexes 
15 - 18 showed from good to moderate anticancer activity with IC50 values falling in the 
0.8 - 14 μM range. The compound 15b is the most cytotoxic and it exhibits 20-fold 
higher activity than cisplatin in the A2780cisR cancer cell line. The synthesised 
complexes do not damage DNA, they act via interactions with proteins and enzymes.
  
 
 
 
                                                        
 
 
 
 
 
Figure 1.64 Structures of alkynyl gold(I) derivatives. 
 
   15   16 
   17   18 
a 
b 
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Messori and co-workers reported dinuclear gold(III) compounds where two 
square-planar gold(III) moieties are linked together by nitrogen atoms from the 
bidentate 2,2’-bipyridine ligand and two adjacent oxygen atoms (Fig. 1.65).142 The 
cytotoxic activity of the synthesised compounds was explored on A2780 and 
A2780cisR ovarian cancer cell lines. All the compounds 19 - 24 exhibit antitumour 
activity, however compound 24 possess the highest activity with IC50 values comparable 
to cisplatin (IC50 in A2780cisR = 1.79 μM 24, 2.1 μM cisplatin; A2780 IC50 = 4.81 μM 
24, 24.4 μM cisplatin).  
 
 
 
 
 
 
 
 
 
        
     
Figure 1.65 Chemical structures of dinuclear gold (III) complexes. 
 
The CD experiment data obtained suggest that compounds 19 and 24 bind to the 
ct-DNA, with compound 24 showing more effective binding which is most likely due to 
its specific redox processes.
142
 
19 20 
24 R = Me 21, R = CH2CMe3 22         R 
= C6H3Me2-2,6 23 
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Gold(III) dithiocarbonato complexes have recently attracted lot of attention for 
their high in vitro and in vivo anticancer activity and low renal toxicity.
143
 
Dithiocarbamates are bidentate chelating ligands and coordination of the metal ions to 
these ligands results in a chelating complex (Fig. 1.66).  
 
 
 
 
 
Figure 1.66 Chemical structures of gold(III) dithiocarbonato complexes (DMDT = N,N-
dimethyldithiocarbamate, ESDT = ethylsarcosinedithiocarbamate). 
 
Gold(III) dithiocarbonato complexes showed in vitro activity higher than cisplatin 
and more interestingly even in cisplatin-resistant cancer cell lines. Treatment of PC3, 
DU145 and R-PC3 (cisplatin-resistant) human prostate cancer cell lines with 
compounds 25 and 26 inhibited cell proliferation, with compound 25 being the most 
effective. In vivo testing in prostate cancer-bearing mice showed that compound 25 
actively inhibited the tumour growth. The mechanism of action of these compounds is 
believed to be different from cisplatin. It was found that compound 25 changes 
mitochondrial functions, induces formation of reactive oxygen species and inhibits 
selenoenzyme overexpressed in prostate cancer. The reported results demonstrate that 
the gold(III) dithiocarbamato complexes have a great potential to be used for prostate 
cancer treatment.
14
 
[AuCl2(DMDT)]  
           25 
[AuBr2(ESDT)]  
          26 
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Chapter 2 
 
Introducing new properties on cylinders
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2.1 Introduction 
Cisplatin is the most effective antineoplastic agent used in clinics to treat various 
types of cancers, particularly head and neck, testicular, ovarian, bladder and small cell 
lung cancers. However, undesirable side-effects such as nephrotoxicity, ototoxicity, 
neurotoxicity, bone marrow suppression and acquired resistance associated with 
cisplatin treatment are the main drawbacks which limit the use of this drug.
1
 In the 
search for more effective and less toxic antitumor agents, various metal-based 
compounds have been synthesised. Among them is an iron(II) triple stranded helicate 
developed in Hannon`s laboratory.
2
  
The synthesised supramolecular helicate (see Fig. 1.29, page 28) is a dinuclear 
tetracationic metal-based complex which is similar in size (approximately 2 nm in 
length and 1 nm in diameter) and shape to the DNA zinc finger motif present in some 
regulatory proteins. The iron(II) helicate is based on bis-pyridylimine ligands wrapped 
around two iron(II) metal centres in a helical fashion. The compound binds non-
covalently to the DNA major groove and induces intramolecular DNA coiling.
3
 
Moreover, the iron(II) triple helicate can also bind to the DNA three way junction with a 
helicate located in the centre of the junction.
4
 Biological testing of the synthesized 
complex revealed a good cytotoxic profile. The iron(II) tetracationic cylinder affects 
mitochondrial function by reducing its activity, inhibits the cell cycle and induces 
apoptosis, programmed cell death.
5
 
Cisplatin and the iron(II) triple-stranded helicate are examples of compounds with 
anticancer properties that act by different molecular mechanisms. Cisplatin is a 
coordinative DNA binder whereas Hannon`s iron(II) helicate binds non-covalently to 
the DNA major groove or in the cavity of a DNA three way junction. It would be an 
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interesting approach to design a synthetic agent that would combine these two different 
modes of action as that might result in higher cytotoxic activity. 
   
2.2 Research aims and molecular design  
The aim of this project is to synthesise novel supramolecular cylinders by using 
simple metal–ligand interactions and combine them with cisplatin in order to create a 
synthetic agent that will act in biological systems by two different molecular 
mechanisms and have enhanced antitumor properties against a wide spectrum of 
cancers. Additional metal binding units will be introduced onto the outside of the 
supramolecular architecture to attach a cisplatin moiety (Fig. 2.0). The mixed-metal 
iron(II)–platinum(II) helicate will possess a high cationic charge which will contribute 
to the interaction with negatively charged DNA.  
 
 
 
 
 
 
Figure 2.0 Schematic illustration of iron(II) pyrazine supramolecular cylinder
6
 (iron, brown; 
nitrogen, blue; hydrocarbon framework, yellow) with attached cisplatin (R).  
 
 Using various techniques from chemistry and biology, the properties and biological 
activity of the synthesised polynuclear metal compounds will be characterised and 
explored. 
 
R 
R 
R 
R 
R 
R 
R = cisplatin 
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2.3 Multinuclear platinum metal complexes 
A few multinuclear platinum metal complexes, where several platinum metal 
centres are linked together by ligand have been reported in the literature, including 
Farrell’s trinuclear platinum compound that binds to the DNA sugar phosphate 
backbone
7
 (see chapter 1, 1.3.3.1) and a tetranuclear platinum molecular cage reported 
by Sleiman and co-workers
8
 that binds to the DNA G-quadruplex (see chapter 1, 
1.3.3.7).
 
Examples of other multinuclear platinum agents are relatively rare and only a 
few of them are presented in this thesis. 
Lippert and co-workers have reported a mixed-metal molecular triangle formed 
from [(en)Pd(2,2’-bpz-N1,N1’)]2+ and trans-(NH3)2Pt(II) (Fig. 2.1).
9
 
 
 
 
 
 
 
 
Figure 2.1 Lippert’s mixed-metal molecular triangle.  
 
The palladium(II) ions form three vertices of molecular triangle whereas 
platinum(II) ions are located in the sides. The NH3 ligands of platinum(II) metal ions 
are roughly perpendicular to the triangle plane. The triangle encapsulates a single ClO4
-
 
anion which is held by hydrogen bonding.9 The activity of the synthesised triangle has 
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not been reported however, the anticancer properties of related compounds will be 
discussed in chapter 4 (see 4.3.2). 
Lowe et al. have synthesised polynuclear 2,2’:6’,2’’-terpyridineplatinum(II) 
complexes that exhibit cytotoxic activity against a number of ovarian cancer cell lines 
including cell lines resistant to cisplatin and doxorubicin (Fig. 2.2).
10
 
 
 
 
 
 
 
 
 
Figure 2.2 Structures of Lowe`s platinum(II) complexes. 
 
2,2’:6’,2’’-Terpyridineplatinum(II) complexes are known to intercalate into DNA. 
The antitumour activity of these compounds is strongly dependent on the nature of the 
linker. The complexes with a short and rigid linker are among the most effective 
however, complex 2 (X = H and Cl) with a long linker exhibited high activity in most 
ovarian cancer cell lines which suggests that activity may correlate with charge density 
and electrostatic stress within these molecules caused by the double positive charge on 
each Pt(II). The bis-intercalator 1 (X = H, M = trans-CH=CH-) showed the lowest IC50 
values in CH1, A2780 and SKOV-3 and was found effective against cisplatin-resistant 
cell lines.
10  
  1 
  2 
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Sun and Shao have described a trinuclear cyclometalated Pt(II) 4,6-diphenyl-2,2’-
bipyridyl complex with a bis-(diphenylphosphinomethyl)phenylphosphine bridging 
ligand (Fig. 2.3).
11 
 
 
 
 
 
 
 
Figure 2.3 Structure of trinuclear platinum complex reported by Sun and Shao.
11 
 
 
According to the X-ray crystal structure, each platinum(II) metal center has a 
distorted square-planar geometry. Three cyclometalated platinum(II) 4,6-diphenyl-2,2’-
bipyridyl moieties are arranged in a linear face-to-face configuration by the bridging 
ligand and are almost parallel to each other. This complex has relatively strong Pt-Pt 
interactions.
11
 The activity and DNA binding studies of these polynuclear species has 
not been reported. 
Lusby et al. reported a tetranuclear platinum square containing 4,4’-bipyridine 
units and 2,6-diphenyl pyridine as a ligand (Fig. 2.4).
12
 Remarkably, the complex 
assembles in the presence of acid and dissembles in the presence of base. The X-ray 
structure confirmed the formation of tetrameric molecular-square structure. The 4,4’-
bipyridine units that are located trans- to the nitrogen donor of the ligand have a planar 
conformation and lie perpendicular to the plane of the four platinum metal ions. The 
other 4,4’-bipyridine units have nonplanar conformation with two hydrogen atom from 
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each pyridine component slightly pointing to the centre of the square. Such a 
conformation of the complex is due to π-π interactions between these constituent 
pyridine components and phenyl groups of the ligand. To avoid steric effects the phenyl 
moieties are located above or below the plane of the four platinum metal ions.
12
 
 
 
 
 
 
 
 
Figure 2.4 X-ray structure of molecular square reported by Lusby. The carbon atoms of 4,4’-
bipyridine are shown in red, carbon atoms of ligand in dark blue, platinum atoms in pink, and 
nitrogen atoms in pale blue. Four PF6 counteranions and five nitromethane solvent molecules 
have been omitted for clarity.
12 
 
 
Despite the similarity to the Fujita`s square studied by Moreno and Sleiman,8 
DNA binding studies and cytotoxic activity of this cationic square have not been 
investigated. 
More recently, Brabec and co-workers described dinuclear platinum(II) 
complexes containing aromatic linkers (Fig. 2.5).
13
 Both of the compounds exhibited 
antineoplastic activity in A2780 cancer cell lines comparable to cisplatin with 
compound 4 being less cytotoxic. Importantly, 3 and 4 were more active than cisplatin 
in cisplatin-resistant A2780cisR cancer cell line and again 4 was less active than 3.  The 
compounds were shown to bind to ct-DNA and form a higher percentage of interstrand 
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cross-links (3 ~ 48 %; 4 ~ 20 %) than cisplatin. A considerably lower level of repair 
synthesis was observed for DNA adducts formed by 3 and 4 than for cisplatin 
suggesting enhanced resistivity against repair processes which contribute to the ability 
of these compounds to overcome resistance of cancer cells to cisplatin. 
 
 
 
 
 
Figure 2.5 Structures of the platinum complexes reported by Brabec. 
 
2.4 Synthesis of metal-based supramolecular helicates and combining them with 
cisplatin. 
2.4.1 Ligand L1 
 
 
 
 
 
 
 
Scheme 2.0 Schematic procedure for the synthesis of ligand L1 
 
Ligand L1 was synthesised according to a similar procedure reported in the 
literature.
14
 Two equivalents of 2-acetylpyrazine were mixed with one equivalent of 
  L1 
  3 
   4 
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4,4’-methylenedianiline using a few drops of acetic acid as a catalyst. The reaction 
mixture was heated to reflux for 3 hours under an atmosphere of nitrogen to yield the 
crude product as a yellow sticky oil. The ESI mass spectrum data shows a dominant 
single peak at m/z = 429 which corresponds to [L1 + Na]
+
 and a small peak at m/z = 325 
which corresponds to C19H18N4 (incomplete ligand). 
1
H NMR confirms the formation of 
the ligand L1 as the major product, however unreacted starting materials and incomplete 
ligand were also present in the mixture (Fig. 2.6).  
  
Figure 2.6 300 MHz
 1
H NMR spectrum (CD3CN, 298 K) of the ligand L1. 
 
 Attempts to separate the ligand L1 from the impurities using column 
chromatography failed. Therefore the following step was carried out without 
purification of the ligand.  
 
2.4.1.1 Synthesis of iron(II) complex of L1 
To a solution of ligand L1 in methanol, iron(II) chloride tetrahydrate was added 
and the reaction mixture was heated to reflux for 1 hour.
14
 The formed purple solution 
was cooled down and the metal complex was precipitated with diethyl ether. The
 1
H 
NMR spectrum revealed a broad set of signals for the iron(II) complex of L1 with 
impurities present in the mixture. In order to purify the compound, it was crystallised in 
H3 H5 
 H6 
H11 
 H12 
H14 
 H8 
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an H-tube. One arm of the H-tube was filled with a methanolic solution of the chloride 
salt of the crude mixture of the complex and the other with a saturated methanolic 
solution of ammonium hexafluorophosphate. Both arms of the H-tube were filled to the 
top with methanol and covered with parafilm. After 4 - 5 days crystals of the 
[Fe2(C25H22N6)3](PF6)4 complex were formed and those were collected from the H-tube 
by filtration.  
The ESI spectrum shows a peak at m/z = 332 which corresponds to a 
[Fe2(C25H22N6)3]
4+
 species. The UV/Vis absorption spectrum reveals a broad band 
located at 570 nm (ε = 16500 mol-1dm3cm-1) corresponding to a metal-ligand charge 
transfer which confirms coordination of the iron(II) to L1 ligands.  Partial elemental 
analysis supports the formation of the complex with an empirical formula of 
[Fe2(C25H22N6)3](PF6)4•H2O. The 
1
H NMR spectrum of the iron(II) complex was 
recorded in CD3CN (Fig. 2.7). 
 
 
Figure 2.7 300 MHz
 1
H NMR spectrum (CD3CN, 298 K) of [Fe2(L1)3](PF6)4. 
 
The 
1
H NMR spectrum shows a single set of peaks corresponding to a single 
symmetrical species of the complex formed in solution. The resonance corresponding to 
H3 
H5/6 
H11/12 
H11/12 H11/12 H11/12 
    H8 
H14 
H5/6 
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the methyl protons H8 appears as a singlet in the aliphatic region of the spectrum. 
Pyrazine protons H3, H5, H6 experience reduced electronic density due to the presence 
of electronegative nitrogen atoms and their chemical shifts appear downfield in the 
spectrum. The 
1
H NMR signal of one of the pyrazine protons H5/6 overlaps with one of 
the signals arising from phenyl rings. Phenyl resonances H9, H10 appear as four separate 
resonances as the phenyl rings are spinning slowly. It was previously reported by the 
Hannon group that with an increase in temperature the spinning of the phenyl rings 
increases and these resonances appear as two sharp singlets.
15
 
 
2.4.1.2 Combining [Fe2(L1)3](PF6)4 with cisplatin 
 
 
 
 
 
 
 
 
 
 
Scheme 2.1 Schematic procedure for combining cisplatin with [Fe2(L1)3](PF6)4 
 
Silver nitrate was stirred with cisplatin overnight in DMF with light exclusion.  
The [Fe2(L1)3](PF6)4 complex in DMF was then added to the resulting solution and the 
reaction mixture was stirred for 3 hours at -18 ºC and 1 hour at room temperature. The 
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resulting blue solution was passed though celite to remove silver chloride that had 
precipitated. Direct precipitation of the complex from DMF with diethyl ether resulted 
in [Fe2(L1)3](PF6)4 without cisplatin attached which was confirmed by NMR. Therefore 
the solvent was removed in vacuo without heating to avoid decomposition of the 
complex. The synthesised compound is poorly soluble in water but very soluble in DMF 
and thus it is unsuitable for DNA-binding studies where solubility is a crucial criterion. 
The complex itself is not stable at room temperature when dissolved in water or DMF 
and therefore the solution was kept at low temperatures. Attempts to grow crystals of 
the synthesised complex for X-ray analysis were unsuccessful.  
Various mass spectrometry techniques such as MALDI, FAB and ESI were used 
in order to characterise the synthesised compound, however no peaks corresponding to 
the desired complex were observed. The ESI spectrum of counteranions of the iron(II)–
platinum(II) complex was recorded. The spectrum shows two peaks corresponding to 
NO3
- 
and PF6
-
 species present in the complex. The infrared spectrum shows signals that 
can be assigned as υN-H stretching at 3210 cm-1 and υN-H symmetrical bending at 1323 
cm
-1
. Partial microanalysis is consistent with the empirical formula of 
[Fe2(C25H22N6(Pt2Cl2(NH3)4))3](PF6)4(NO3)6. A
 1
H NMR spectrum of the complex was 
recorded in d6-DMF solution and compared to the one of the [Fe2(L1)3](PF6)4 complex 
in d6-DMF (Fig. 2.8).  
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Figure 2.8 300 MHz
 1
H NMR spectra (d6-DMF, 298 K) (a) [Fe2(L1)3](PF6)4 with attached 
cisplatin (b) [Fe2(L1)3](PF6)4 
 
The 
1
H NMR spectrum of the [Fe2(L1)3](PF6)4 complex with attached cisplatin 
shows a significant shift some of the proton
 
resonances downfield (Table 2.0) compared 
to non-platinated complex and thus, indicate coordination of cisplatin to 
[Fe2(L1)3](PF6)4. Two single peaks, both with integration three which appear at 5.35 
ppm and 4.35 ppm, correspond to two ammine groups of cisplatin and confirm a cis-
configuration. 
H3 H5/6 
DMF 
H5/6 
 
H11/12 H11/12 H11/12 H11/12 
H14 
H8 
H3 H5/6 H5/6 H11/12 H11/12 H11/12 
H11/12 H14 
NH3 
NH3 
H8 
 (a) 
(b) 
DMF 
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Table 2.0 H
1
 NMR chemical shifts of [Fe2(L1)3](PF6)4 and [Fe2(L1)3](PF6)4 with attached 
cisplatin in d6-DMF. 
 
The UV/Vis spectrum of [Fe2(L1)3](PF6)4 complex with attached cisplatin 
recorded in DMF reveals shift of the MLCT band from 570 nm to 599 nm (ε = 9400 
mol
-1 
dm
3
cm
-1
) with a shoulder at 695 nm (ε = 6800 mol-1 dm3cm-1)  which indicates 
that the coordination of cisplatin to [Fe2(L1)3](PF6)4 was achieved and a new complex is 
formed. 
 
 
 
 
H
1
 NMR Chemical shift 
δ (ppm) 
Protons 
 
[Fe2(L1)3](PF6)4 
 
[Fe2(L1)3](PF6)4 
with attached 
cisplatin 
H3 9. 97 10.10 
H5/6 8.92   
7.84            
9.21 
8.23 
H11/12 7.54 
6.84 
5.90 
4.79 
7.56 
6.83 
6.10 
4.75 
H14 4.10 4.11 
H8 2.89 2.95 
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2.4.1.3 Combining [Fe2(L1)3]Cl4 with cis-bis(dimethylsulphoxide)dichloro-
platinum(II) 
 
 
 
 
 
 
 
 
 
Scheme 2.2 Schematic procedure for [Fe2(C25H22N6Pt2Cl4S2O2(CH3)4)]3Cl4 synthesis. 
 
Cis-bis(dimethylsulphoxide)dichloroplatinum(II) was synthesised from potassium 
tetrachloroplatinate and dimethylsulfoxide according to the published procedure.
16
 One 
equivalent of the [Fe2(L1)3]Cl4 metal complex was stirred with six equivalents of 
PtCl2(SO(CH3)2)2 in methanol overnight at room temperature. The resulting violet 
complex precipitated from the methanol. All attempts to crystallise the synthesised 
complex were unsuccessful. 
 As in the case of the iron(II) complex with attached cisplatin, there were no peaks 
corresponding to the synthesised complex observed in the ESI and MALDI mass 
spectra. The IR spectrum shows a υS=O stretching band at 1127 cm-1, CH3 rocking 
mode at 1020 cm
-1
 and υC-S assymetrical stretching at 740 cm-1.  The complex is not 
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soluble in water and methanol but rather soluble in acetonitrile and DMF. A 
1
H NMR 
spectrum of the obtained compound was recorded in CD3CN (Fig. 2.9). 
 
 
 
Figure 2.9 300 MHz 
1
H NMR spectra (CD3CN) of (a) [Fe2(C25H22N6Pt2Cl4S2O2(CH3)4)3]Cl4 (b) 
[Fe2(L1)3](PF6)4. 
 
The 
1
H NMR spectrum shows a single set of peaks confirming the presence of a 
single symmetrical species in the solution. A slight shift of the proton resonances of 
platinated complex compared to non-platinated is observed.  The signal resulting from 
H3 
H5/6 
H11/12 
H5/6 
H11/12 H11/12 H11/12 
H14 
     H8 
H3 
H5/6 
H5/6 
H11/12 
H11/12 H11/12 H11/12 
H14 
H8 
DMSO 
methyls 
(a) 
(b) 
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the methyl protons of ketimine bond is observed as a doublet or two adjacent singlets 
with integration of three. The proton resonance appearing as a doublet at 3.30 ppm with 
integration of six was assigned as a signal for DMSO methyls indicating the 
coordination of cis-bis(dimethylsulphoxide)dichloroplatinum(II) to the iron(II) complex 
of L1. Additional single peak of unknown origin is observed at 3.51 ppm with 
integration of three. Interestingly, the methyl groups of platinum bound DMSO exhibit 
a single peak in 
1
H NMR spectrum in chlorinated solvents (Fig 2.10 (a)). However in 
non-chlorinated solvents the band is split into a doublet (Fig. 2.10 (b)). 
 
Figure 2.10 300 MHz
 1
H NMR spectra of DMSO methyls recorded at 298 K in (a) Chloroform 
(b) Acetonitrile. 
 
If the non-chlorinated solvent is evaporated and the sample is dissolved in a 
chlorinated solvent, the signal will be displayed as a singlet suggesting there must be an 
unknown solvent effect present. The similar solvent effect was previously reported by 
the Hannon group.
17
  
In the case of the iron(II) complex with attached Pt(DMSO)Cl2 there were two 
peaks observed in the region of  3.20 - 3.60 ppm one of which was assigned as a signal 
for DMSO methyls. The presence of additional single peak as well as the splitting of H8 
signal at 2.25 ppm is unclear.  
 
(b) (a) 
DMSO 
methyls 
DMSO 
methyls 
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2.4.2 Ligand L2 
 
 
 
 
 
 
 
 
 
Scheme 2.3 Schematic procedure for the synthesis of ligand L2 
 
Ligand L2 was synthesised by stirring two equivalents of quinoxaline-2-
carboxaldehyde with one equivalent of spacer (4,4’-methylendianiline). The ligand was 
prepared in 55 % yield from these commercially available starting materials. The ESI 
spectrum shows a peak at m/z = 501 which corresponds to [L2 + Na]
+
. Partial elemental 
analysis supports the formation of the ligand with an empirical formula of C31H22N6.    
A
 1
H NMR spectrum of the ligand was recorded in CDCl3 (Fig. 2.11). 
The 
1
H NMR spectrum displays 9 proton resonances consistent with a single 
solution species with a symmetrical configuration. The H3 and H11 protons are shifted 
downfield as they experience reduced electronic density due to proximity to a 
negatively charged nitrogen atom. The resonances from phenyl protons appear as 
mutliplet at 7.40 – 7.30 ppm. The signals from quinoxaline protons H6, H9, H7, and H8 
are displayed as multiplets.   
 
   L2 
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Figure 2.11 300 MHz 
1
H NMR spectrum (CDCl3, 298 K) of ligand L2 with an expansion of the 
aromatic region. 
 
Coordination of the ligand L2 with metals of tetrahedral and octahedral 
configuration was investigated.  
 
2.4.2.1 Silver(I) complex of L2 
The reaction of one equivalent of L2 with one equivalent of silver acetate in 
methanol resulted in a yellow solution, from which a yellow solid precipitated upon 
addition of ammonium hexafluorophosphate. Partial microanalytical data is consistent 
with the empirical formula of {[Ag(C31H22N6)](PF6)}n. The ESI mass spectrum displays 
peaks corresponding to [[Ag2(C31H22N6)2](PF6)]
+
 (m/z = 1317) and [Ag2(C31H22N6)2]
2+
 
H6 
H9 
H7 
H8 
H14 
H15 
H3 
H11 
H6 
H9 H7 
H8 
H17 
H14 
H15 
CDCl3 
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(m/z = 586) which are consistent with a dinuclear complex formation. A 
1
H NMR 
spectrum of the complex was recorded in d6-DMF (Fig. 2.12). 
 
 
 
Figure 2.12 300 MHz 
1
H NMR spectrum (d6-DMF, 298 K) of {[Ag(C31H22N6)](PF6)}n. 
 
The 
1
H NMR spectrum shows a single set of peaks that suggest that single 
symmetrical species are present in the solution. The resonances of the H3 and H11 
protons are readily identified in the downfield region of the spectrum. The quinoxaline 
protons H6 and H9 appear as doublets and H8 as a triplet. The H7 proton of quinoxaline 
is obscured by the solvent peak. 
On reaction of the ligand L2 with tetrahedral metal ions there are two possible 
conformations that can be obtained: helix or box (Fig. 2.13). Both structures differ from 
each other by the fashion in which ligands are surrounding the metal ion. In the helix 
conformation both of the ligand strands are located above one metal ion and below 
another metal ion. In the box conformation one ligand strand lies above the metal axis 
and another one below.
18
 The CH2 signal in the 
1
H NMR spectrum is crucial in 
determination of the presence of box or helix species in solution. In the helix the CH2 
protons are equivalent which gives a single peak on the spectrum, whereas in the case of  
H3 
 H11 
H6 
H9 
H8 
H14/15 
H17 
H14/15 
 H7 
 CDCl3 
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Figure 2.13 Schematic representation of box and helix conformations.
18
 
 
the box conformation these protons are non-equivalent with one proton pointing out of 
the box and another proton pointing down towards the plane of the box assembly which 
gives a split CH2 signal in the spectrum.
15 
 
In the case of {[Ag(C31H22N6)](PF6)}n in d6-DMF solution at 298 K a single set of 
peaks have been observed. In solution the complex interconverts between helix and box 
conformations and in order to identify if there are any other species present, 
1
H NMR 
experiments were performed at low temperatures (Fig. 2.14). In some cases there can be 
a rapid exchange between two species that cannot be recorded by NMR even at low 
temperatures. 
 
 
 
 
 
 
 
 
 
Box meso isomer Helix rac isomer 
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 Figure 2.14 400 MHz 
1
H NMR spectra (d6-DMF, 303 K, 273 K, 253 K, 233 K, 223 K) 
of {[Ag(C31H22N6)](PF6)}n. 
223 K 
233 K 
253 K 
  273 K 
 303 K 
 H3 
 H11 
 H6 
 H17 
 H9 
 H14/15  H14/15 
 H8 
 DMF 
 H7 
 Water 
 101 
 
1
H NMR experiments of {[Ag(C31H22N6)](PF6)}n in d6-DMF performed at low 
temperatures did not reveal any distinct species present in the solution. If there are two 
species in the solution as was previously found in similar ligand systems, they exist in a 
rapid exchange on the NMR timescale.
19
  
Crystals of the {[Ag(C31H22N6)](PF6)}n complex for X-ray analysis were obtained 
by slow diffusion of diethyl ether into a solution of the complex in DMF, however they 
were found to be of too poor quality to obtain the crystal structure. 
 
2.4.2.2 Copper(I) complex of L2 
The formation of the copper(I) complex of ligand L2 was achieved by refluxing L2 
with [Cu(MeCN)4](PF6) (1:1) in methanol overnight. The dark brown solid precipitated 
upon addition of ammonium hexafluorophosphate. Partial microanalytical data are 
consistent with the empirical formula of [Cu2(C31H22N6)2](PF6)2. The ESI mass 
spectrum displays a peak at m/z = 542 which corresponds to [Cu2(C31H22N6)2]
2+
. The 
brown color of the complex arises from the metal-to-ligand charge transfer (MLCT) 
transition. UV/Vis absorbtion spectrum shows a broad band at 577 nm (ε = 2200 mol-1 
dm
3
cm
-1
) which is a characteristic of copper(I) in a bis-diimine environment.  
The 
1
H NMR spectrum of the [Cu2(C31H22N6)2](PF6)2 complex was recorded in 
CD3CN solution. At room temperature there is a single set of resonances observed as 
the ligand exchange is very rapid in acetonitrile at this temperature (Fig. 2.15). The 
resonance corresponding to the CH2 appears as a singlet in the aliphatic region of the 
spectrum. Some of the quinoxaline peaks are broadened with the H3 resonance 
overlapping with H11 signal. Phenyl protons appear as two sharp doublets at 7.49 ppm 
and 7.24 ppm respectively. 
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Figure 2.15 300 MHz 
1
H NMR spectrum (CD3CN, 298 K) of the [Cu2(L2)2](PF6)2 
complex. 
 
In order to define the presence of other species in the solution, 
1
H NMR 
experiments were performed at variable temperatures in (CD3)2CO. At 333 K additional 
peaks are observed, however they are not very distinctive. At lower temperatures 
another set of peaks becomes more obvious, revealing the presence of box 
conformation. The CH2 protons are non-equivalent and split into two doublets (Fig. 
2.16). 
 
 
 
 
 
 
 H11 
  H3 
  H6  H7  H17 
 H14/15 
 H14/15 
 H9 
 H8 
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Figure 2.16 400 MHz 
1
H NMR spectra ((CD3)2CO, 333 K, 273 K, 253 K, 233 K, 223 K, 193 K) 
of [Cu2(L2)2](PF6)2 complex. 
 
To identify the ratio helix:box in the solution, the integration of box and helix 
proton resonances was performed. At 273 K the ratio between helix and box is around 
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3:1. When the temperature is decreased up to 193 K the ratio is 2:1. The change in ratio 
helix:box with a temperature demonstrates that the helix conformation is favoured 
entropically whereas box conformation is enthalpically favoured.  
Brown crystals of the [Cu2(L2)2](PF6)2 complex suitable for X-ray analysis were 
obtained by slow diffusion of diethyl ether into a solution of the complex in acetonitrile. 
The X-ray structure confirms the formation of a double-stranded dinuclear copper(I) 
helicate (Fig. 2.17). 
 
                                                                     
 
 
 
Figure 2.17 X-ray structure of [Cu2(L2)2](PF6)2 complex (a) Perspective view (b) Space-filling 
representation of [Cu2(L2)2]
2+
 cation.  Solvent molecules, hydrogen atoms and anions are 
omitted for clarity.  
 
Each metal centre is four-coordinate and has a pseudo-tetrahedral geometry with 
Cu-Nimine bond distances of  2.005(13)-2.108(13) and Cu-Nquinoxaline distances of 
1.999(10)-2.035(10) Å with N-Cu-N angles of 80.4(5)-82.7(5)º. Two ligand strands are 
coordinated to the copper(I) metal ions in such a way that leads to a Cu-Cu distance of 
11.1 Å. The angles between the central phenyl rings are of 112.6º(14) and 113.7(13)º. 
The phenylene rings are slightly twisted with respect to the imine metal chelating unit 
with torsion angles of 9º and 170º. The quinoxaline rings from different ligand strands 
are located at angles of 121.3(5)º and 126.0(5)º with respect to each other. The copper(I) 
cylinder has two PF6 counteranions and bears a double charge. The highly disordered 
(a) (b) 
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solvent molecules were present in the structure however the attempts to identify them 
failed. The crystal packing diagram of [Cu2(L2)2](PF6)2 is shown in Figure 2.18. 
 
 
 
 
 
 
 
Figure 2.18 Packing diagram of [Cu2(L2)2]
2+
 showing π-π stacking interactions between phenyl 
and quinoxaline rings. Solvent molecules, hydrogen atoms and anions are omitted for clarity. 
 
The crystal packing diagram shows that the helical architectures are arranged in a 
chain network with face to face π-π stacking interactions between the phenylene and 
quinoxaline rings of different helical assemblies. The centroid-centroid distances of the 
aromatic rings involved in π-π stacking are in the range of 3.5 - 3.9 Å. 
Attempts to synthesise a helicate with metal ions of octahedral geometry were 
unsuccessful. No metal complex was formed upon stirring ligand L2 with octahedral 
metal ions suggesting there are steric constraints due to the presence of bulky 
quinoxaline rings that prevent the formation of the complex.  
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2.4.3 Ligand L3 
A multiple step synthesis has been performed in order to obtain ligand L3. L3 is 
based on 4,4’-bypiridine units connected by an imine bond with a 4,4’-
methylenedianiline. 4,4’-Bipyridine-2-carboxaldehyde is not commercially available 
therefore the first task was to synthesize the aldehyde through a three-step procedure. 
 
2.4.3.1 Synthesis of 4,4’-bipyridine-2-carboxaldehyde 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.4 Synthetic procedure for 4,4’-bipyridine-2-carboxaldehyde synthesis. 
 
The first step was carried out according to the published literature procedure.
20
 2-
Methyl-4,4’-bipyridine was prepared by radical alkylation of commercially available 
4,4’-bipyridine using the procedure of Minisci et al.21 4,4’-bipyridine was dissolved in a 
solution of 98 % sulfuric acid and water. Subsequently acetic acid and a solution of 
silver nitrate in water were added to the mixture. The mixture was heated to 110 ºC and 
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maintained at that temperature for 30 min, after which ammonium persulfate was added 
portionwise. Ammonium persulfate is a very strong oxidizing agent and together with 
catalytic amounts of silver it is used for decarboxylation of acids and radical formation. 
When the release of carbon dioxide ceased the reaction was heated for another 30 
minutes then cooled down and made alkaline with ammonia to pH ~ 8. The reaction 
products were extracted with ether, dried over MgSO4 and evaporated in vacuo to yield 
a yellow solid. The crude mixture was purified by HPLC column chromatography using 
water-methanol in a ratio of 60:40. The separation gave 4 bands. The first band eluted 
was identified as unreacted 4,4’-bipyridine, the second band was 2-methyl-4,4’-
bipyridine, the third band 2,2’-dimethyl-4,4’-bipyridine and the fourth band 2,2’,6 – 
trimethyl-4,4’-bipyridine. 
The second step involved enamination of 2-methyl-4,4’-bipyridine using 
Bredereck reagent, tert-butoxybis(dimethylamino)methane. The formation of enamine 
with Bredereck reagent is facilitated by the acidity of the methyl group.
22
 2-Methyl-
4,4’-bipyridine with Bredereck reagent in DMF were heated at 140 ºC under an argon 
atmosphere for 18h. The pale orange solution was cooled down, hydrolyzed by addition 
of water and extracted with dichloromethane. The combined organic layers were dried 
and the solvent evaporated in vacuo to yield brown oil. The desired product was 
recrystallized from DCM-pentane to give orange crystals. The advantage of this 
procedure is the formation of enamine crystals upon cooling of the crude mixture. The 
synthesized 2-methyl-(N-dimethylaminovinyl)-[4,4’]-bipyridine is unstable and slowly 
decomposes.
23
 
The synthesised enamine was then converted to the aldehyde by oxidation with 
sodium periodate in aqueous THF at 40 ºC under an argon atmosphere. The reaction 
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was stirred for 18 hours, the solvent evaporated then the crude product dissolved in 
DCM and washed with water. The organic layers were dried and the solvent evaporated 
in vacuo to yield an off white solid. The aldehyde was obtained as a white solid after 
purification on a silica column using a combination of DCM/CH3OH as an eluent.
 
The 
mechanism of this transformation from enamine to aldehyde with sodium periodate is 
unknown.
23
  
The 
1
H NMR experiment confirms the formation of the 4,4’-bipyridine-2-
carboxaldehyde (Fig. 2.19). 
 
 
Figure 2.19 300 MHz 
1
H NMR spectrum (CDCl3, 298K) of 4,4’-bipyridine-2-carboxaldehyde. 
 
The 
1
HNMR spectrum reveals five signals in the aromatic region and one signal 
corresponding to the aldehyde proton at 10.17 ppm. The H6, H2’ and H6’ resonances 
appear downfield in the spectrum as two doublet of doublets. The signal for H3 arises as 
a doublet of doublets at 8.23 ppm. The remaining peaks at 7.78 and 7.60 ppm with 
integrations of one and two were assigned as H5, H3’ and H5’ respectively.  
The EI mass spectrum shows a peak at m/z = 184 which corresponds to 
{C11H8N2O}
+
. The IR spectrum reveals a υC=O stretching band at 1708 cm-1 and υC-H 
aldehyde stretching at 2858 cm
-1 
which supports the formation of the aldehyde. The 
 CH=O 
 H6 
 H2’ 
 H6’ 
 H3  H5 
 H3’ 
 H5’ 
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obtained 4,4’-bipyridine-2-carboxaldehyde was used in the next step for the ligand L3 
synthesis. 
 
2.4.3.2 Synthesis of L3 
 
 
 
 
 
 
 
 
 
 
Scheme 2.5 Synthetic procedure for ligand L3 preparation 
 
The ligand L3 was synthesised by stirring two equivalents of 4,4’-bipyridine-2-
carboxaldehyde with one equivalent of 4,4’-methylendianiline in ethanol overnight. The 
resulting product precipitated from the mixture as a yellow solid. The ESI spectrum 
shows a peak at m/z = 553 which corresponds to [L3 + Na]
+
. 
The 
1
H NMR spectrum of the ligand L3 recorded in CDCl3 shows eight signals 
(Fig. 2.20). The resonances corresponding to H2, H2’, H6’ and H7 appear as two doublet 
of doublets and a singlet and are readily identified downfield in the spectrum. The H3 
signal appears as a doublet at 8.51 ppm, the remaining doublet of doublets at 7.67 ppm 
and at 7.64 ppm with integration of two and one were assigned as H3’ and H5’ and H5 
  L3 
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respectively. The signal from the phenylene protons appears as a doublet at 7.32 ppm 
and is overlapped with a solvent peak. The resonance corresponding to the CH2 protons 
appears in the aliphatic region of the spectrum as a singlet at 4.09 ppm. 
 
 
 
 
Figure 2.20 300 MHz 
1
H NMR spectrum (CDCl3, 298K) of the ligand L3 with an expansion of 
the aromatic region.  
 
2.4.3.3 Iron(II) complex of L3 
The coordination of iron(II) metal ions to the ligand L3 was achieved by stirring 
L3 with iron(II) chloride tetrahydrate in methanol for 3 hours at room temperature. A 
dark violet solid precipitated from the solution upon addition of ammonium 
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 H6’ 
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hexafluorophosphate. The ESI mass spectrum displays a peak m/z = 426 which 
corresponds to [Fe2(C35H26N6)3]
4+
. The elemental analysis data is consistent with the 
formation of the complex, with an empirical formula of [Fe2(L3)3](PF6)4•2H2O. The 
violet colour of the complex arises from the MLCT absorption band located at 586 nm 
(ε = 15100 mol-1dm3cm-1).  
The 
1
H NMR spectrum recorded in CD3CN indicates the formation of the iron(II) 
complex of L3 (Fig. 2.21). 
 
Figure 2.21 300 MHz 
1
H NMR spectrum (CD3CN, 298 K) of [Fe2(L3)3](PF6)4. 
 
The H7, H6, H2’ and H6’ resonances are overlapped in the spectrum.  Signals for 
H3’/H5’, H3 and H5 are slightly broaden and appear as a singlet and two doublets, 
respectively. The H10/11 protons are broadened due to a slow rotation of the phenyl rings 
at room temperature and there is no coupling observed. The H13 signal appears in the 
aliphatic region of the spectrum as a singlet at 4.07 ppm. 
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Crystals of the [Fe2(L3)3](PF6)4 complex for X-ray analysis were obtained by slow 
diffusion of benzene into a solution of the compound in acetonitrile, however the 
crystals were of insufficient quality to obtain the crystal structure. 
Attempts to attach cisplatin on to the outside of the formed iron(II) triple helicate 
were unsuccessful. The complex fell apart upon addition of cisplatin in DMF resulting 
in a colourless solution.  
 
2.4.4 Ligand L4 
A two-step synthesis was employed to obtain ligand L4. The starting material 1-
pyridine-2-ylmethyl-1H-imidazole carboxaldehyde is not commercially available 
therefore the first step was to synthesise the aldehyde. 
 
 
 
 
Scheme 2.6 Schematic procedure for the synthesis of 1-pyridine-2-ylmethyl-1H-imidazole 
carboxaldehyde 
 
1-Pyridine-2-ylmethyl-1H-imidazole carboxaldehyde was synthesised according 
to a published procedure by reacting imidazole with 2-(bromomethyl)pyridine 
hydrobromide in DMF in the presence of Hunig`s base, N,N-diisopropylethylamine 
(DIPEA).
24, 25
 Hunig`s base is a non-nucleophilic strong base that is able to 
accommodate a proton between the isopropyl groups. In this experimental procedure it 
was used to deprotonate the imidazole. The reaction mixture was stirred at 80 ºC under 
a nitrogen atmosphere overnight and then quenched by the addition of NaHCO3. The 
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resulting solution was extracted with DCM; the organic layers were collected and 
washed with brine, dried over MgSO4 and evaporated in vacuo to yield a brown oil. The 
final product was purified by HPLC on a solvent gradient starting from 100 % water to 
33 % of acetonitrile.  The separation gave three peaks; the second peak eluted was 
identified as 1-pyridine-2-ylmethyl-1H-imidazole carboxaldehyde. The prepared 
aldehyde was used for the synthesis of the ligand L4. 
 
 
 
 
 
 
 
 
Scheme 2.7 Schematic procedure for the synthesis of L4. 
 
The ligand L4 was synthesized by stirring two equivalents of 1-pyridine-2-
ylmethyl-1H-imidazole carboxaldehyde with one equivalent of 4,4’-methylendianiline 
in ethanol overnight. The off-white solid precipitated from the solution upon stirring. 
The peak found at m/z = 559 in the ESI mass spectrum corresponds to [L4 + Na]
+
. 
Partial elemental analysis data are consistent with the formation of the ligand with the 
empirical formula of C33H28N8. 
The 
1
H NMR spectrum recorded in CDCl3 confirms the formation of the ligand L4 
(Fig. 2.22). All the protons were assigned using 1D and 2D NMR experiments. 
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Figure 2.22 300 MHz 
1
H NMR spectrum (CDCl3, 298 K) of the ligand L4 with an 
expansion of the aromatic region.  
 
The 
1
H NMR spectrum reveals 11 proton resonances. Two singlet peaks in the 
aliphatic region of the spectrum at 5.99 and 4.00 ppm are readily assigned as H6 and H19 
respectively. The signals for pyridine proton H11 (doublet of doublets) and imine proton 
H13 (singlet) appear downfield in the spectrum at 8.60 and 8.57 ppm. The H8 and H10 
pyridine resonances overlap with the signals from the phenylene protons, whereas H9 
appears as a triplet of doublets at 7.62 ppm. One of the imidazole proton resonances H4/5 
is partially hidden by the solvent peak. 
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2.4.4.1 Iron(II) complex of L4 
The formation of the iron(II) complex of L4 was achieved by stirring L4 with 
iron(II) chloride tetrahydrate at room temperature. A dark red solid precipitated from 
the solution upon addition of ammonium hexafluorophosphate. The ESI mass spectrum 
displays three peaks at m/z = 430 [Fe2(L4)3]
4+
, 622 [[Fe2(L4)3](PF6)]
3+
, 1006 [[Fe2(L4)3] 
(PF6)2]
2+
 which indicates the formation of the complex. The elemental analysis data is 
consistent with the empirical formula of [Fe2(C33H28N8)3](PF6)4•3H2O. The red colour 
of the complex arises from the MLCT absorption band located at 553 nm (ε = 2400 mol-
1
dm
3 
cm
-1
). A 
1
H NMR spectrum of the complex was recorded in CD3CN solution (Fig. 
2.23).  
The 
1
H NMR spectrum of [Fe2(L4)3](PF6)4 displays 10 proton resonances. The 
signals corresponding to the H13 imine and imidazole protons H4 and H5 are 
significantly shifted downfield upon coordination to iron(II) metal ions compared to the 
free ligand. The H6 protons are diastereotopic and appear as two doublets at 4.69 and 
3.02 ppm. The pyridine signals for H8 and H10 are overlapped and shown as a multiplet 
in the spectrum whereas the H9 resonance and H11 appear as a triplet of doublets and 
doublet of doublets at 7.89 and 8.66 ppm respectively.  The signal from imine proton 
H13 is overlapped with a signal from H4/5 and appears as a broad singlet at 13.65 ppm. 
The phenylene resonances H16 and H17 coalesce and appear as two broad singlets at 7.23 
and 5.96 ppm. These signals can be viewed only by increasing the magnitude of the 
spectrum. 
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Figure 2.23 300 MHz 
1
H NMR spectra (CD3CN, 298K) of (a) [Fe2(L4)3](PF6)4 (b) Ligand L4. 
 
Red crystals of [Fe2(L4)3](PF6)4 complex suitable for X-ray analysis were obtained 
by slow diffusion of benzene into a solution of the complex in acetonitrile. The X-ray 
structure confirms the formation of the triple-stranded iron(II) helicate (Fig. 2.24). 
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Figure 2.24 X-ray structure of [Fe2(L4)3](PF6)4 complex (a) Perspective view (b) Space-filling 
representation of [Fe2(L4)3]
4+
 cation. Solvent molecules, hydrogen atoms and anions are omitted 
for clarity.  
 
The metal centers are six-coordinate and have pseudo-octahedral geometry with 
Fe-Nimine bond distances of 1.970(5) - 2.026(5) and Fe-Nimidazole distances of 1.956(5) - 
1.972(5) Å with Nimine-Fe-Nimidazole angles of 80.3(2) - 80.8(2)º. Each of the three ligand 
strands binds to two metal ions in such a way that they form a triple helical structure. 
The phenylene rings are located about the central CH2 at angles to each other 113.4(5)º, 
114.0(6)º and 113.7(5)º to allow intramolecular CH…π interactions in the centre of the 
helix. The phenylene rings are twisted at 73 - 89º with respect to the plane of imine 
chelating unit. The metal centres of the molecule are separated from each other by a 
distance of 11.4 Å. The pyridine rings are bent with respect to the imidazole units at 
different angles 109.2(10) - 113.4(6)º. There are four PF6 counteranions along with 
benzene and acetonitrile solvent molecules found in the structure. The crystal packing 
diagram of the complex is shown in Figure 2.25. 
 
 
(a) (b) 
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Figure 2.25 Packing diagram of [Fe2(L4)3](PF6)4 showing π-π stacking interactions between the 
pyridine rings. Solvent molecules, hydrogen atoms and anions are omitted for clarity. 
 
The crystal packing diagram reveals that the triple-helical architectures are 
arranged in a three-dimensional network with face to face π-π stacking interactions 
between the pyridine rings of different helical assemblies. The centroid-centroid 
distances of pyridine rings involved in π-π stacking are in the range of 4.1 - 4.5 Å. 
The chloride salt of the synthesised iron(II) triple-stranded helicate is highly 
unstable when dissolved in water and falls apart within seconds. The complex is more 
stable in methanol although slow decomposition occurs as well.  
The PF6 salt of [Fe2(L4)3](PF6)4 have been used in the experiment to attach 
cisplatin moieties onto the outside of the supramolecular assembly. However as in the 
case of the 4,4’-bipyridine based cylinder, upon addition of cisplatin in DMF the 
complex fell apart resulting in a colourless solution. 
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2.4.4.1 Nickel(II) complex of L4 
The nickel(II) complex was formed by stirring nickel(II) chloride hexahydrate 
with ligand L4 under reflux in methanol overnight. The yellow solid precipitated from 
the mixture upon addition of diethyl ether. Partial microanalysis is consistent with the 
empirical formula of [Ni2(C33H28N8)3]Cl4 • 8H2O. The ESI mass spectrum shows three 
peaks at m/z = 432 [Ni2(C33H28N8)3]
4+
, 588 [[Ni2(C33H28N8)3]Cl]
3+
, 898 
[[Ni2(C33H28N8)3]Cl2]
2+
 and confirm the formation of the complex. The UV-Vis 
spectrum shows two broad bands at 260 nm (ε = 32600 mol-1dm3cm-1) and 328 nm (ε = 
55600 mol
-1
dm
3
cm
-1
).   
A paramagnetic NMR spectrum of the nickel(II) complex was recorded in 
CD3OD (Fig. 2.26). 
 
 
 
 
Figure 2.26 400 MHz paramagnetic 
1
H NMR spectrum (CD3OD, 298K) of the 
[Ni2(C33H28N8)3]Cl4 complex. 
 
The proton resonances are considerably broadened and paramagnetically shifted. 
The single set of peaks suggests that the solutions species is symmetrical and consistent 
with a single species. There are 9 well-defined resonances, however it has not been 
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possible to fully assign the spectrum. The resonances from H16 and H17 have not been 
identified; apparently they are very weak and broadened.  
Yellow crystals of the [Ni2(C33H28N8)3](PF6)4 complex suitable for X-ray 
diffraction analysis were obtained by slow diffusion of benzene into a solution of the 
complex in acetonitrile. The X-ray structure confirms the formation of a triple-stranded 
Ni(II) helicate (Fig. 2.27). 
 
 
 
 
 
 
 
Figure 2.27 X-ray structure of [Ni2(L4)3](PF6)4 complex (a) Perspective view (b) Space-filling 
representation of [Fe2(L4)3]
4+
 cation. Solvent molecules, hydrogen atoms and anions are omitted 
for clarity.  
 
The Ni(II) metal centers are six-coordinate and have pseudo-octahedral geometry 
with Fe-Nimine bond distances of 2.106(13) - 2.207(11) and Fe-Nimidazole distances of 
2.051(11) - 2.095(16) Å with Nimine-Fe-Nimidazole angles of 78.3(4) - 79.9(5)º. Three 
ligand strands of the complex are wrapped around two Ni(II) metal centres in a helical 
fashion. The phenylene rings are twisted at 80 - 89º with respect to the imine metal 
chelating unit. The Ni-Ni intermetallic distance in the complex is 11.6 Å. The pyridine 
rings are bent with respect to the imidazole units at different angles of 112.0(2) - 
119.1(13). The nickel helicate is tetracationic and has four PF6 counteranions. The 
(a) (b) 
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solvent molecules are present in the structure however they are highly disordered and it 
was not possible to successfully refine them.  
The crystal packing diagram reveals that the triple-helical architectures are 
arranged in a three-dimensional chain network (Fig. 2.28). No π-π stacking interactions 
were found between the arrays of the helicates. 
 
 
 
 
 
 
 
 
Figure 2.28 Packing diagram of [Ni2(L4)3
]4+
. Solvent molecules, hydrogen atoms and anions are 
omitted for clarity. 
 
The chloride salt of Ni(II) triple-stranded helicate is very soluble in water and was 
used for DNA binding studies and biological evaluation. 
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2.5 Lanthanide helicates 
2.5.1 Overview 
Lanthanide helicates are of great interest to many research groups due to their 
ability to emit light in the visible or near-infrared region. These complexes can be used 
as bioprobes for cell and organ imaging and for tracking processes inside the cell. 
Wrapping ligand strands around lanthanide metal centres by self-assembly processes 
affords robust molecules with interesting chemical and photophysical properties. The 
characteristic luminescent properties of trivalent lanthanide metal ions such as sharp 
emission lines, large Stokes shifts upon ligand excitation, little or no photobleaching, 
and long lifetimes of the excited states, make them attractive bioprobes.
26, 27 
A few examples of lanthanide helicates have been reported in literature.  
Pikramenou and co-workers established the synthesis of highly luminescent, triple- and 
quadruple-stranded, dinuclear Eu, Nd, and Sm(III) lanthanide complexes based on bis-
diketonate ligands (Fig 2.29).
28
  
 
 
 
 
 
 
 
 
Figure 2.29 (a) Bis-diketonate ligands used in synthesis of lanthanide complexes (b) Molecular 
model of [Eu2(L1)3] complex.
28
  
 
L1 L2 
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The ligands L1 and L2 have two conjugated diketonate binding sites which are 
connected together by a 1,3-phenylene spacer. The ligands bind to lanthanide metal ions 
to form neutral dinuclear triple-stranded complexes [M2(L1)3] (M = Eu, Nd, Sm, Y, Gd) 
and [M2(L2)3] (M = Eu, Nd) or anionic quadruple-stranded dinuclear lanthanide units 
[Eu2L
1
4]
2-
. The synthesised complexes show strong visible (red or pink) and near-
infrared luminescence when irradiated at the ligand band, around 350 nm, and have 11 
times more intense emission signals compared to their mononuclear analogues.
28
 
Bünzli et al. reported europium(III) triple-stranded helicate based on ligand L3 
which was used in experiments to study the cellular distribution and cellular uptake of 
the complex  (Fig. 2.30).
29
  
 
 
 
 
 
 
Figure 2.30 Chemical structure of the ligand L3. 
 
The synthesised [Eu2(L3)3] helicate is water soluble, highly stable and non-
cytotoxic. It displays strong luminescence and has a long luminescence lifetime. It was 
found out that europium(III) helicate is able to permeate into HeLa cells by endocytosis 
and stain their cytoplasm. The bimetallic complex was seen in endosomes and 
lysosomes which are predominantly located around the nucleus. Thus the [Eu2(L3)3] 
helicate behaves as an optical probe which can be used for the elucidation of cellular 
uptake and cellular localisation.
29
 
L3 
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More recently, Piguet and co-workers described a double-stranded bimetallic 
Lu(III) helicate using bis-tridentate ligand L4 (Fig. 2.31). The flexibility of the spacer in 
the ligand is limited by the central rigid phenyl ring.
30
  
 
 
 
 
 
 
 
 
 
 
Figure 2.31 Schematic representation of ligand L4 and [Lu2(L4)2]
6+
 complex.
30
 
 
The X-ray structure reveals the double-helical nature of the complex. Each Lu(III) 
metal centre is octa-coordinate, with two tridentate binding units and two monodentate 
triflate anions. The main torsions in the ligands are caused by the rotation about the 
interannular C-C bond which links the aromatic benzimidazole and phenyl rings, 
forming slightly distorted dodecahedrons.
30
 
Hamacek et al. reported the first pentanuclear lanthanide helicate formed from 
two different tripodal ligands and europium(III) metal ions (Fig. 2.32).
31
 One ligand 
forms the base of the tetrahedron whereas three strands of the other form side faces and 
the linear part of the helical structure. 
 
L4 
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Figure 2.32 Self-assembly process of pentanuclear helicate. View of the calculated structure of 
[Eu5(L5)(L6)3]
15+
 (SPARKLE/AM1 model). Hydrogen atoms are omitted for clarity.
31
  
 
The self-assembly of the helicate was predicted on the structural basis obtained 
for linear and tetranuclear supramolecular compounds. The formation of the complex 
was experimentally evidenced by NMR and ESMS spectra.
31
  
 
Herein we describe the synthesis of a europium(III) complex with a helical 
structure. The europium(III) complex was prepared according to a modified procedure 
reported in the literature.
32
 This work was done in collaboration with Doctor Dave 
Lewis from Dr. Zoe Pikramenou`s group, who provided advice on the design of the 
europium(III) helicate.  
 
 
 
+ 
Eu
3+
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2.5.2 Synthesis of europium(III) helicate 
2.5.2.1 Synthesis of ligand L5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.7 Schematic procedure for the synthesis of [Eu2(L5)3]Cl6 complex 
 
The ligand L5 was developed to facilitate coordination of europium(III) to two 
pyridyl nitrogens and 2,6-dicarboxylic amides. The ligand was prepared by a multiple 
step synthesis from commercially available starting materials.  
In the first step of the synthesis, 2,6-pyridinecarboxylic acid 1 was reacted with 
benzyl alcohol in the presence of ion exchange resin DOWEX 50-X8 H
+
 to form 2,6-
1 2 
 3   4 
  L5 
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pyridinecarboxylic acid mono benzyl ester 2 by a Fisher esterification mechanism.
32, 33
 
The reaction was refluxed for 1.5 hours and after work up the crude product was 
obtained as a colourless oil. Recrystallisation from ethyl acetate afforded the desired 
product as a white powder. 
 In the second step, the monoprotected 2,6-pyridine carboxylic acid 2 was reacted 
with  6-aminoquinoline using carbodiimide coupling methodology to yield 6-(quinoline-
6-ylcarbamoyl) picolinate 3. The reaction was carried out for 18 hours and the resulting 
crude product was purified by column chromatography using 2% DCM/CH3OH 
solution as an eluent. The second band eluted was identified as the desired product 3. 
The third step of the synthesis involved deprotection of the benzyl ester using the 
hydrogenation technique. The intermediate compound 3 was stirred with 10 % Pd/C 
catalyst in a THF/CH3OH (50:50) solution under a hydrogen atmosphere to yield 6-
(quinoline-6-ylcarbamoyl) picolinic acid 4. Completion of the reaction was followed by 
TLC. The isolated product, a yellow solid, was used in the next step without further 
purification. 
The formation of the ligand L5 was achieved by reacting intermediate 4 with 4,4’-
methylenedianiline via a carbodiimide peptide coupling reaction. The crude product was 
purified on a silica column using 5 % DCM/CH3OH solution as an eluent. The ligand 
was obtained as an off-white solid in approximately 37 % yield. The product was 
characterized by mass spectrometry and NMR techniques. The ESI mass spectrum of L7 
displays a peak at m/z = 771 which corresponds to {C45H32N8O4 + MeOH}
+
. Partial 
elemental analysis is consistent with the formation of the ligand of the empirical 
formula of C45H32N8O4. The IR spectroscopy reveals several characteristic bands 
relating to the functional groups of ligand L5. The υN-H strecthcing vibration of peptide 
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bond appears at 3303 and 3229 cm
-1
. The strong band at 1525 cm
-1
 results from υN-H 
bending. Bands at 3027 and 1658 cm
-1
 are assigned as υC-H aromatic and υC=O 
stretching.  
A 
1
H NMR spectrum of the ligand was recorded in d6-DMSO (Fig. 2.33). The 
spectrum displays 14 proton resonances and one solvent residue peak. All the protons 
were assigned using 1D and 2D NMR techniques. 
 
 
 
 
 
Figure 2.33 300 MHz 
1
H NMR spectrum (d6-DMSO, 298 K) of L5 with an expansion of the 
aromatic region. 
 
The single peak appearing at 4.02 ppm is readily assigned as H24. Phenylene 
protons H20 and H21 are displayed in the spectrum as two sharp doublets at 7.80 and 
7.36 ppm respectively. The resonances H11 and H19 of the peptide bond appear 
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downfield at 11.34 and 11.09 ppm as two singlets. The signal for H2, displayed as a 
doublet of doublets at 8.86 ppm appears downfield due to its proximity to the nitrogen 
atom. The aminoquinoline proton resonances H5 (doublet) at 8.68 ppm, H7 (doublet of 
doublets) at 8.23 ppm, H8 (doublet) at 8.11 ppm and H3 (doublet of doublets) at 7.54 
ppm can be assigned according to their characteristic splitting patterns. The signal from 
H4 is overlapped with the signals from H14 and H16 of the pyridine.  The resonance at 
8.33 ppm appearing as a triplet results from H15. 
 
2.5.2.2 Synthesis of europium(III) complex of L5 
The europium(III) complex of L5 was obtained by reacting two equivalents of the 
ligand with three equivalents of europium(III) chloride hexahydrate in a mixture of  
CH3OH/CHCl3 (1:1). The reaction was refluxed for 24 hours and the desired product 
was isolated by precipitation with diethyl ether. The elemental analysis is consistent 
with the formation of the europium(III) complex with the empirical formula of 
[Eu2(C45H32N8O4)3]Cl6•3CHCl3•H2O. Two different techniques, ESI and MALDI, were 
used in order to record a mass spectrum of the complex, however no peak was observed 
corresponding to the synthesised compound. The UV/Vis spectrum of the complex 
shows a broad band located at ~ 308 nm (ε = 84700 mol-1dm3cm-1) nm.  
A very weak 
1
H NMR spectrum of the complex with broad proton resonances was 
obtained (not shown) and it has not been possible to fully assign it. Therefore to confirm 
the formation of the europium(III) complex, luminescence experiments were performed 
and the characteristic Eu(III) luminescent pattern upon excitation of the aminoquinoline 
units was recorded. The absorption spectrum of the europium(III) complex in DMSO 
showed the presence of a broad band for the aminoquinoline moieties (Fig. 2.34 (a)). 
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Excitation of this band resulted in an Eu(III) emission with λmax = 613 nm (Fig. 2.34 
(b)). 
 
 
 
 
 
 
 
Figure 2.34 (a) Absorption spectrum of Eu(III) complex of L5 (b) Excitation and luminescence 
spectra of europium(III) complex of L5 recorded in DMF. 
 
The characteristic fluorescence pattern of europium observed suggests that the 
europium(III) metal ions are bound to the ligand L5. The quinoline units act as antennae 
to transfer energy to the lanthanide ions resulting in sensitized lanthanide emission. 
Narrow emission bands of the Eu(III) complex are observed at 572, 587, 613, 643, 687 
nm respectively. 
The obtained europium(III) complex is not soluble in water but is soluble in 
DMSO and DMF. The insolubility in water as well as  poor yield of the europium(III) 
complex were the main drawbacks for performing DNA binding studies and other 
biological experiments and this was not pursued further. 
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2.6 Conclusions 
In this chapter, the synthesis and characterisation of novel metallo-helicates has 
been discussed. The additional metal binding units were introduced on to the outside of 
ligands L1, L2, L3, L4 to afford binding of cisplatin. The attempts to attach cisplatin to 
[Fe2(L3)3](PF6)4 and [Fe2(L4)3](PF6)4 complexes failed as the compounds fell apart. 
Remarkably, combining [Fe2(L3)3](PF6)4 complex with cisplatin was successful 
however the compound is poorly soluble in water and relatively stable only at low 
temperatures. The iron(II) triple-stranded helicate of ligand L2 did not form due to steric 
constraints, nevertheless double-stranded helicates of L2 with copper and silver 
tetrahedral metal ions were synthesized. 
The ligand L5 was designed to form luminescent europium(III) helicate. The 
formation of the complex was confirmed by elemental analysis and characteristic 
emission spectrum of europium(III) recorded in DMF.  
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3.1 Introduction 
The medicinal applications of metal complexes are of increasing interest due to 
their unique physico-chemical properties together with their biological activity. Thus, 
for example, transition metal complexes are being investigated as potential 
chemotherapeutic agents.
1
 It is believed that DNA is the main target for metallo-
anticancer drugs currently in the clinic. Molecules that are able to bind to the DNA can 
access cellular information and hence take part in controlling gene expression.  
The supramolecular iron(II) helicate designed in Hannon`s laboratory and formed by 
wrapping three ligand strands around transition metal ions was shown to bind to the 
major groove of the DNA, induce dramatic intermolecular coiling and exhibit biological 
activity in cancer cell lines. Circular and linear dichroism studies confirmed the binding 
of the complex to the DNA in an oriented fashion. Furthermore the iron(II) complex 
stabilises DNA three-way junctions with a helicate residing in the cavity of the junction. 
All these examples of the interaction of the iron(II) cylinder with DNA suggest that the 
biological activity of the complex can be associated with DNA as one of the main 
targets for the synthesised helicate.
2, 3 
By modulating the structure of the parent iron(II) cylinder, novel metallo-
supramolecular helicates have been synthesised and characterised in chapter 2 . In this 
chapter DNA binding studies of the helicates are explored using circular and linear 
dichroism, UV/Vis spectroscopy and gel electrophoresis techniques.  
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3.2 UV/Vis spectroscopy 
UV/Vis spectroscopy is used to provide information about the structure of the 
molecule and the electronic transitions occurring in the molecule upon excitation with 
light, as well as to perform quantitative analysis of the sample. Light is electromagnetic 
radiation. When radiation of wavelength between 200 to 700 nm (UV/Vis) interacts 
with a molecule it can stimulate the transition of p-, d- or π- electrons from bonding or 
lone pair orbitals to unfilled non-bonding or anti-bonding orbitals, increasing the energy 
of the sample.
4
 
The amount of light absorbed by the sample is proportional to the number of 
absorbing molecules in the solution and length of the light pathway. The absorbance of 
the sample can be calculated using the following equation: 
A = log10 (I0 / I) 
I0 is incident intensity of the light and I is transmitted intensity of the light.  
To define the concentration of the sample with known absorbance the Beer-Lambert law 
can be used.  
A = ε c l 
A – absorbance (arbitrary units), ε – molar absorption or extinction coefficient (mol-1 
dm
3
 cm
-1
), c – concentration of the sample (mol dm3), l is a length of the light pathway 
(cm). 
UV/Vis spectroscopy is utilised in the work herein to obtain information about the 
stability of the synthesised complexes, to define their molar absorption coefficients and 
to calculate the concentration of ct-DNA for circular and linear dichroism experiments. 
The characteristic UV/Vis spectrum of ct-DNA gives a maximum peak at 260 nm (Fig. 
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3.0) which corresponds to π→π* transitions of the delocalised electrons of the DNA 
bases.   
 
 
 
 
 
 
 
 
Figure 3.0 UV/Vis spectrum of 300 μM ct-DNA. 
 
The concentration of DNA can be calculated by measuring the absorbance at 260 nm 
and using the Beer-Lambert law with a known molar absorption coefficient (e.g. ε = 
6600 mol
-1
 dm
3
 cm
-1
 for ct-DNA at 260 nm).
4
 
 
3.3 Circular dichroism spectroscopy. 
The circular dichroism (CD) technique is applied to study chiral molecules and 
their interactions. Circular Dichroism is the difference in absorption of left and right 
circularly polarised light and can be expressed by the following equation: 
CD = AL – AR 
Achiral molecules and racemic mixtures do not give rise to a CD signal. Chiral 
molecules do not have a reflection plane and neither do their electrons, thus the 
electrons move in some kind of helix. In circularly polarized light electric field vectors 
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trace out helices. Therefore the interactions of the chiral molecule with left- and right-
circularly polarised light will be different.  
DNA is a chiral molecule due to the presence of chiral sugar units. Phosphates 
and the bases of the DNA are individually achiral but when bound all together with 
chiral sugars they become a part of the chiral molecule. When a CD spectrum of DNA 
is measured, a CD signal corresponding to transitions of the nucleobases (as a result of 
their coupling with backbone) is detected. The characteristic CD spectrum of the B-
DNA has a positive band at ~ 275 nm, a negative band at ~ 240 nm with the zero being 
around 258 nm (Fig. 3.1 (a)). 
 
 
 
 
 
 
 
 
Figure 3.1 Circular dichroism spectra of (a) B-DNA (b) A-DNA (c) Z-DNA.
5
  
 
A-DNA is characterized by a positive CD band at ~ 260 nm, a negative band at ~ 
210 nm and a very intense positive band at 190 nm (Fig. 3.1 (b)). 
Z-form DNA is formed for poly[d(G-C)]2 in the presence of highly charged 
cations. The CD spectrum of Z-DNA is characterised by a negative CD band at ~ 290 
nm and a positive band at ~ 260 nm (Fig. 3.1 (c)). 
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Many DNA binding molecules are achiral themselves and do not give rise to any 
CD signal. However, when they bind to DNA they experience a chiral environment and 
can exhibit a CD signal which indicates an interaction with the chiral DNA.  In this 
work CD titrations of the synthesised metal complexes with DNA have been performed. 
Any changes in the shape of the characteristic DNA CD spectrum imply DNA-metal 
complex interactions.
6
 
 
3.4 Linear dichroism spectroscopy 
Linear Dichroism (LD) is the difference in the absorption of light linearly 
polarised parallel and perpendicular to an orientation axis of the molecule. 
LD = A|| - A┴ 
In linearly polarised light all the photons have their electric component oscillating in 
one plane. In order to obtain an LD signal the molecule has to be oriented. Flow 
orientation is one of the methods used to orient the molecule. Orientation is achieved by 
viscous drag resulting from the flowing the solution between narrow walls. In this work 
a couette flow cell was used to orient the DNA molecule (Fig. 3.2).  
 
 
 
 
 
 
 
Figure 3.2 Schematic representation of couette flow cell.
6
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The molecule to be investigated is placed in a sample chamber between two 
quartz cylinders, one of which can rotate. When rotation is applied the sample is 
oriented by the direction of the flow. The speed of the rotation should be fast enough in 
order to orient molecules but not so fast as to cause turbulent flow. 
The LD signal for B-DNA is depicted in Figure 3.3. The bases of the DNA are 
arranged approximately at right angle to the direction of the orientation which in turn 
leads to a negative band at ~ 260 nm as the electronic transitions occur parallel to the 
DNA bases.   
 
Figure 3.3 Linear dichroism spectrum of 300 μM ct-DNA. 
 
LD measures an average signal from all the bases of oriented DNA. The DNA for 
LD experiments has to be at least 1000 base pairs in length to get a significant 
orientation. In this work linear dichroism is used to study interactions of different 
molecules with ct-DNA. Compounds that bind to the DNA in a specific way (major 
groove, covalent binding or intercalation between base pairs) will cause change in the 
DNA LD signal which is a characteristic of their interaction with DNA.
6
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3.5 CD and LD DNA binding studies 
3.5.1 DNA binding studies of [Fe2(L1)3]Cl4 
 
 
 
 
The synthesised [Fe2(L1)3]Cl4 is readily soluble in water which makes it a perfect 
candidate for DNA-binding studies. The stability of the complex was examined by 
UV/Vis spectroscopy in aqueous solution for 12 hours (Fig 3.4).  
 
 
 
 
 
 
 
 
Figure 3.4 UV/Vis stability test spectrum of [Fe2(L1)3]Cl4 complex recorded in water for 12 
hours (the spectra over 12 hours period overlay almost perfectly).   
 
The UV/Vis spectrum reveals that the [Fe2(L1)3]Cl4 complex is stable in water for 
12 hours. No significant changes are observed during this time period. Interestingly, the 
chloride salt of pyrazine analogue of the complex, with a hydrogen atom instead of the 
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methyl group in the imine position, is highly unstable and degrades within seconds of 
formation (data not shown).   
The [Fe2(L1)3]Cl4 complex does not give a CD signal itself because it exists as a 
racemic mixture. A 300 μM ct-DNA CD spectrum, recorded in aqueous-buffer solution, 
gave a characteristic B-DNA pattern below 300 nm with a negative band at 247 nm and 
a positive band at 278 nm. The CD titrations of the complex in to ct-DNA were 
performed at constant DNA concentration (Fig. 3.5). The experiments were carried out 
in a 1 cm cuvette in order to visualise better a weak signal in the MLCT region and in 1 
mm cuvette to avoid saturation of the signal between 200 and 300 nm that occurs at 
high concentrations of complex loading.    
 
 
 
 
 
 
 
 
Figure 3.5 CD spectra of ct-DNA in 1 cm and 1 mm cuvettes in the presence of [Fe2(L1)3]Cl4 
complex.  
 
The CD spectrum of the complex with DNA shows that the DNA has retained its 
B-conformation upon interacting with the iron(II) cylinder. There are slight changes in 
the intensity of the CD signal as the concentration of the complex is increased, however 
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these changes are not significant indicating that the cylinder binds to DNA and does not 
trigger any notable conformational alterations in the DNA structure. These changes in 
intensities of CD signals are initiated by the occupancy of several binding sites by the 
complex. There are three weak induced CD signals observed at ~ 330 and 413 nm 
(transitions from the ligand) and ~ 604 nm (MLCT) at high concentrations of the 
complex which confirm binding of the cylinder to ct-DNA.  
The LD experiment can give information about the binding mode of the 
[Fe2(L1)3]Cl4 complex to ct-DNA. The LD spectrum of the [Fe2(L1)3]Cl4 complex with 
ct-DNA is illustrated in Figure 3.6 (a).  
 
 
 
 
  
 
 
 
Figure 3.6 (a) LD spectrum of [Fe2(L1)3]Cl4 complex with ct-DNA (b) Change in LD signal at 
260 nm at various complex concentrations. 
 
When titrations of the [Fe2(L1)3]Cl4 complex to ct-DNA are performed, a decrease 
in the magnitude of the LD signal with respect to free DNA is observed at 260 nm 
indicating kinking/coiling of the DNA. The plot in Figure 3.6 (b) demonstrates changes 
in LD signal at various concentrations of the complex. At 4:1 ratio of DNA 
base:[Fe2(L1)3]Cl4, a 59 %  DNA orientation loss is observed compare with 90 % in 
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case of the parent iron(II) cylinder.
7, 8
 Flow LD orients DNA parallel to the direction of 
the flow and when the complex is bound to DNA in a specific orientation there is an 
induced LD signal observed in the MLCT region. The presence of induced LD signals 
in the spectrum at ~ 385 and 580 nm corresponding to iron(II) complex transitions 
confirms binding of the cylinder to DNA and this binding occurs in a specific 
orientation.  
 
3.5.2 DNA binding studies of [Fe2(L3)3]Cl4 
 
 
 
 
The [Fe2(L3)3]Cl4 complex is a water soluble compound. The stability of the 
complex in water was studied by UV/Vis spectroscopy over a 12 hour period (Fig. 3.7). 
 
 
 
 
 
 
 
 
Figure 3.7 UV/Vis stability test spectrum of [Fe2(L3)3]Cl4 recorded in water for 12 hours.     
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The UV/Vis stability test spectrum reveals that the [Fe2(L3)3]Cl4 complex 
undergoes degradation. There is a decrease in absorbance corresponding to the MLCT 
transition at 586 nm. However, the changes observed are not significant indicating the 
process of decomposition is relatively slow (decrease in UV/Vis absorption signal by ~ 
5 % in 12 hours). Nevertheless fresh solutions of the complex were made up for the 
DNA binding studies and used immediately.    
The CD spectrum of [Fe2(L3)3]Cl4 gives a flat line as the compound exists as a 
racemic mixture. CD titrations of the complex to ct-DNA were performed at varying 
ratios of DNA bases:complex at constant DNA concentration (Fig. 3.8).  
 
 
 
 
 
 
 
 
Figure 3.8 CD spectra of ct-DNA in 1mm and 1cm cuvettes in the presence of [Fe2(L3)3]Cl4 
complex. 
 
On addition of the complex to ct-DNA, changes in the intensity of the CD band at 
248 nm indicate binding of the cylinder to ct-DNA. The binding of the complex does 
not affect the secondary structure of the B-DNA. A dramatical change in DNA CD 
signal is observed at a ratio of DNA:complex 15:1 which results into a significant 
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perturbation of the DNA signal at 248 nm which could be due to DNA-ligand 
interactions. At high concentrations of the complex an induced CD signal is observed at 
~ 630 nm corresponding to the MLCT which confirms binding of the [Fe2(L3)3]Cl4 
complex to DNA. 
The LD titration experiment of [Fe2(L3)3]Cl4 was performed at constant ct-DNA 
concentration. The recorded spectrum is shown in figure 3.9 (a). 
 
 
 
 
 
 
 
 
Figure 3.9 (a) LD spectrum of [Fe2(L3)3]Cl4 complex with ct-DNA (b) Change in LD signal at 
260 nm versus concentration of [Fe2(L3)3]Cl4 complex. 
 
Upon titration of the complex to ct-DNA a significant loss of the signal is 
observed at 260 nm as a result of changes in DNA orientation induced by the binding of 
the complex to ct-DNA. The change in the LD signal versus loading of the complex is 
depicted in Figure 3.9 (b). The reduction of the LD signal indicates that binding of the 
complex causes kinking/coiling of the DNA. At 4:1 ratio of DNA base:[Fe2(L3)3]Cl4, a    
~ 73 %  DNA orientation loss is observed compare with 59 %  of the previously 
discussed [Fe2(L1)3]Cl4 complex, showing that the [Fe2(L3)3]Cl4 compound coils/kinks 
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DNA more effectively. The complex is bound to DNA in a specific orientation which is 
indicated by the presence of two induced positive bands in the spectrum at ~ 393 and ~ 
594 nm that arise from cylinder transitions that occur parallel rather than perpendicular 
to the direction of the average DNA orientation.  
 
3.5.3 DNA binding studies of [Fe2(L4)3]Cl4 
 
 
 
 
The synthesised [Fe2(L4)3]Cl4 complex is soluble in methanol and poorly in water. 
Upon addition of water the complex undergoes rapid degradation. The stability test of 
[Fe2(L4)3]Cl4 was recorded in methanol for 12 hours (Fig. 3.10). 
 
 
 
 
 
 
 
 
Figure 3.10 UV/Vis stability test spectrum of [Fe2(L4)3]Cl4 recorded in methanol for 12 hours.     
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The UV/Vis spectrum reveals a decrease in the intensity of the absorption at ~ 553 
nm (MLCT), ~ 295 nm and ~ 331 nm as the [Fe2(L4)3]Cl4 complex suffers degradation.  
Despite the instability of the [Fe2(L4)3]Cl4 complex in water, CD and LD titrations were 
performed to explore the DNA binding properties of the compound. The complex itself 
might be stabilised by binding and interacting with DNA as the parent iron(II) cylinder.
9
 
[Fe2(L4)3]Cl4 is poorly soluble in water therefore to prepare a stock solution of the 
complex it was dissolved in methanol and then diluted with water (~ 5 % methanol 
solution). A fresh stock solution was prepared before the addition of the complex to ct-
DNA and was kept refrigerated on ice. The CD titrations of the complex to ct-DNA 
have been performed at constant DNA concentration (Fig. 3.11). 
 
 
 
 
 
 
 
 
Figure 3.11 CD spectra of ct-DNA in 1cm and 1mm cuvettes in the presence of [Fe2(L4)3]Cl4 
complex. 
 
The CD spectrum shows that on addition of the [Fe2(L4)3]Cl4 complex to ct-DNA 
there is a slight perturbation in CD signal observed. However these changes are 
insignificant, suggesting interaction of the ligand with a DNA as the complex falls apart 
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in the solution and no stabilisation occurs. This is also demonstrated by the absence of 
an induced CD signal in the MLCT region. 
Flow LD titrations were performed at constant concentration of ct-DNA. The 
characteristic negative signal between 220 and 300 nm confirms B-conformation of the 
DNA (Fig. 3.12). As in the case of the CD experiment, no induced LD signal is 
observed. A small loss of the signal at 260 nm could be a result of interactions with the 
ligand L4. The CD and LD experiments reveal that no binding of the [Fe2(L4)3]Cl4 
complex is observed due to instability in aqueous solution. 
 
 
 
 
 
 
 
 
 
Figure 3.12 LD spectrum of [Fe2(L4)3]Cl4 complex with ct-DNA. 
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3.5.4 DNA binding studies of [Ni2(L4)3]Cl4 
The synthesised [Ni2(L4)3]Cl4 complex is soluble in water and is suitable for 
DNA-binding studies. The stability of the helicate in water was examined for 11 hours 
(Fig. 3.13). 
 
 
 
 
 
 
 
 
Figure 3.13 UV/Vis stability test spectrum of [Ni2(L4)3]Cl4 recorded in methanol for 11 hours.     
 
The UV/Vis spectrum demonstrates that the absorption band at ~ 330 nm is gradually 
decreasing (by ~ 12 % in 11 hours) indicating slow degradation of the complex.  
CD titrations of [Ni2(L4)3]Cl4 complex to ct-DNA were recorded at constant 
concentration of the DNA. At high loadings of the complex to DNA precipitation of the 
polynucleotide was observed. Therefore the stock concentration of the helicate was 
decreased from 600 μM to 400 μM. The CD spectrum of the [Ni2(L4)3]Cl4 complex is 
displayed in Figure 3.14.  
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Figure 3.14 CD spectra of ct-DNA in 1mm cuvette in the presence of [Ni2(L4)3]Cl4 complex. 
 
The CD spectrum demonstrates that the characteristic B-DNA pattern is retained 
during the titrations. Changes in the intensities of the CD band indicate binding of the 
complex to DNA. On addition of the nickel(II) helicate to ct-DNA a positive induced 
CD signal at ~ 330 nm  is observed which also confirms binding of the helicate to DNA. 
The change in CD signal at 248 and 330 nm plotted versus concentration is shown in 
Figure 3.15.  
 
 
 
 
 
 
 
Figure 3.15 CD signal plotted versus concentration at (a) 248 nm (b) 330 nm. 
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Flow LD titrations were performed at constant concentration of ct-DNA. A 
characteristic negative LD signal of DNA was observed between 220 to 300 nm. The 
addition of the nickel(II) triple-stranded helicate affects the spectroscopy of ct-DNA  
(Fig. 3.16 (a)).  
 
 
 
 
  
 
 
 
Figure 3.16 (a) LD spectrum of [Ni2(L4)3]Cl4 complex with ct-DNA (b) Change in LD signal at 
260 nm versus concentration of [Ni2(L4)3]Cl4 complex. 
 
The induced LD signal, which appears as a positive band at ~ 330 nm corresponds 
to cylinder transitions and indicates that these transitions are oriented more parallel 
rather than perpendicular. The loss of the signal at 260 nm demonstrates a change in the 
DNA orientation suggesting that the binding of the complex causes kinking/coiling of 
the DNA. The change in DNA LD signal plotted versus complex concentrations is 
shown in Figure 3.15 (b). Interestingly, at 4:1 ratio the intensity of the LD band at 260 
nm is decreased by 97 %. The obtained results demonstrate that the [Ni2(L4)3]Cl4 complex 
coils ct-DNA more effectively than [Fe2(L1)3]Cl4, [Fe2(L3)3]Cl4, [Fe2(L4)3]Cl4 and the 
parent iron(II) cylinder. 
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In this section of the chapter 3, CD and LD DNA binding studies of [Fe2(L1)3]Cl4, 
[Fe2(L3)3]Cl4, [Fe2(L4)3]Cl4 and [Ni2(L4)3]Cl4 were discussed.  The results of these 
studies demonstrate that the complexes [Fe2(L1)3]Cl4, [Fe2(L4)3]Cl4 and [Ni2(L4)3]Cl4 
bind to DNA and cause alterations in its orientation, although the conformation of the 
B-DNA is retained. There are no significant changes in the CD and LD spectra of the 
[Fe2(L4)3]Cl4 complex as it undergoes slow degradation. Binding of [Fe2(L4)3]Cl4 and 
[Ni2(L4)3]Cl4 compounds to DNA causes more effect to its orientation than 
[Fe2(L1)3]Cl4. This can be visualised by comparing changes in the intensities of LD 
signals at 260 nm as a result of increased drug loading (Fig. 3.17).   
 
 
 
 
 
 
 
 
Figure 3.17 Changes in the intensities of LD signal at 260 nm of Fe-L1 = [Fe2(L1)3]Cl4, Fe-L3 = 
[Fe2(L3)3]Cl4 and Ni-L4 = [Ni2(L4)3]Cl4 versus concentration. 
 
The graph demonstrates that in the presence of [Ni2(L4)3]Cl4 the DNA molecule is 
less oriented and loss of the LD signal at 260 nm is more dramatic than in the case of 
other complexes.  
The compounds were further investigated for their ability to unwind plasmid 
DNA and stabilise DNA three-way junction structures. 
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3.6 Agarose gel electrophoresis studies 
3.6.1 Introduction 
Agarose gel electrophoresis is a common technique used to separate biomolecules 
such as DNA, RNA and proteins based on their size, charge or conformation.
10
 DNA 
fragments can be separated by applying an electric field which causes the molecules to 
migrate through the pores of the gel. The shorter DNA fragments move faster than the 
longer ones. The conformation of the DNA is also crucial. In this work plasmid DNA 
pBR322 which contains 4361 base pairs was used. Plasmid pBR322 is a double-
stranded circular DNA that can be found in bacteria. The plasmids exist predominantly 
in a supercoiled conformation but there are also open circular and linear forms. These 
three various conformations of the plasmid will move with different speeds through the 
agarose gel.
11
 The supercoiled form moves faster than the open form whereas the linear 
form has an intermediate speed of migration (Fig. 3.18).  
 
 
 
  
 
 
 
 
 
Figure 3.18 Schematic representation of agarose gel electrophoresis of different conformations 
of plasmid DNA. 
Circular plasmid 
Linear plasmid 
Supercoiled plasmid 
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In this work the agarose gel electrophoresis technique was used to determine the 
ability of the synthesised compounds to unwind supercoiled plasmid DNA. The 
compounds were incubated with plasmid DNA for 1 hour at various ratios of DNA base 
pairs:helicate (Table 3.0). During the gel electrophoresis experiment the negatively 
charged DNA fragments move towards a positively charged electrode with a speed of 
migration depending on the conformation and size of the DNA. Visualisation of the gel 
bands is achieved by staining the gel with ethidium bromide and placing the gel under 
UV-light.  When ethidium bromide is intercalated between the base pairs of DNA it 
luminesces upon exposure to UV-light. The gel bands were detected using a UVIPro 
Platinum 2.0 system. 
Well 1 2 3 4 5 6 7 8 9 10 11 12 
Base 
pairs:helicate 
control 25:1 20:1 15:1 10:1 8:1 6:1 5:1 4:1 3:1 2:1 control 
Table 3.0 Ratios of plasmid DNA base pairs:helicate used in the experiment 
 
3.6.2 Results and discussion 
Ultrapure water was used to prepare various concentrations of the complexes 
[Fe2(L1)3]Cl4, [Fe2(L3)3]Cl4, and [Ni2(L4)3]Cl4. The compound [Fe2(L4)3]Cl4 and 
platinated complex [Fe2(L1)3]Cl4 were not soluble in water and therefore were dissolved 
in 2 % DMSO/water solutions. During the experiment the concentration of the complex 
was increased from 25:1 to 2:1 base pairs:helicate. The gel electrophoresis experiment 
was run for 3 hours at 120 V. The electrophoretic mobility of the plasmid DNA with 
synthesised compounds is shown in Figure 3.19.  
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Figure 3.19 Agarose gel electrophoresis of pBR322 with (a) [Fe2(L1)3]Cl4 (b) [Fe2(L3)3]Cl4 (c) 
[Ni2(L4)3]Cl4 (d) [Fe2(L4)3]Cl4 (e) [Fe2(L1)3]Cl4 with attached cisplatin. 
   (a) (b) 
   (c) (d) 
 [Fe2(L1)3]Cl4 
[Fe2(L1)3]Cl4 with 
attached cisplatin 
[Fe2(L3)3]Cl4 
[Fe2(L4)3]Cl4 
(e) 
   [Ni2(L4)3]Cl4 
  1   2    3   4    5   6   7   8   9   10  11  12 
  1   2   3    4   5    6   7   8   9  10  11  12 
    1   2   3   4    5   6   7   8   9  10  11 12 
 1   2   3   4   5   6   7   8   9  10  11  12   1   2   3   4   5   6   7   8    9   10  11  12 
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At low concentrations of the complex two conformations of plasmid are observed 
open circular and supercoiled. As the concentration of the complexes is increased there 
are no significant changes in the electrophoretic mobility of the supercoiled plasmid 
DNA detected. A slight blurring of the band corresponding to the supercoiled form is 
found for [Fe2(L3)3]Cl4 and [Fe2(L1)3]Cl4 with attached cisplatin suggesting a small 
decrease in the speed of migration of supercoiled DNA. Remarkably, there was no 
unwinding observed for the complex with attached cisplatin. Cisplatin itself causes 
unwinding of the DNA by 13 º (Fig. 3.20 (a)) by forming covalent bonds with purine 
DNA bases.
12, 13
 In the case of [Fe2(L1)3]Cl4 with attached cisplatin, the coordination of 
DMSO solvent molecules to cisplatin could affect the DNA unwinding.  
 
 
 
 
 
 
 
 
 
Figure 3.20 Unwinding of plasmid DNA by (a) Cisplatin ( lanes 1 and 2 control (non-modified 
DNA); lanes 2-9 cisplatin:DNA base ratio: 0.033, 0.050, 0.063, 0.083, 0.100, 0.125, 0.167, 
0.250)
13 
 (b) Iron(II) parent cylinder (lanes 1 and 12 control (non-modified DNA); lanes 2-11: 
cylinder:base ratio  = 0.008, 0.015, 0.023, 0.027, 0.030, 0.034, 0.038, 0.046, 0.053, 0.061, 
respectively).
14
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Interestingly, the dinuclear iron(II) parent helicate effectively unwinds plasmid 
DNA by 27 º (Fig. 3.20 (b)).
14
 The unwinding angle ϕ can be calculated using the 
following formula:  
 ϕ = -18σ/rb(c)  
σ – superhelicity constant, rb(c) – the ratio of the complex bound per nucleotide when 
supercoiled and open circular bands of plasmid co-migrate. The number of complex 
molecules bound per nucleotide was taken to be equal to the mixing ratios based on the 
assumption that all molecules of the compound present in the sample are completely 
bound to the DNA. The superhelicity constant for plasmid was found to be – 0.059.14 
The absence of plasmid DNA unwinding in the case of the synthesised 
[Fe2(L1)3]Cl4, [Fe2(L3)3]Cl4, [Fe2(L4)3]Cl4, [Ni2(L4)3]Cl4 complexes can be associated 
with the instability of compounds at high temperature, the bulky size or the nature of the 
helicates.  
 
3.7 Recognition of DNA three-way junction 
3.7.1 Introduction 
DNA encodes the genetic information of most living systems and is an attractive 
target for therapeutic treatment of many diseases, including cancer, which originate at 
the DNA level. Synthetic molecules that are able to recognise unusual DNA structures 
are of great interest for their inherent specificity. Thus, for example, synthetic iron(II) 
supramolecular helicate developed by Hannon and co-workers recognises DNA three 
way junction structures.
15
 
DNA junction structures are formed when two or more helices meet in one point. 
DNA junctions play an important role in many biological processes. The DNA four-way 
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junction, for instance, is a key intermediate in homologous recombination. Three-way 
junctions (3WJ) are the simplest and most prevalent of junctions and consist of three 
double helical strands connected at the junction point. Three-way junctions can be 
found both in RNA and DNA. In RNA these branched structures are involved in 
splicing and translation processes whereas in DNA they arise transiently during the 
process of DNA replication. Three-way junctions have been discovered to be present as 
intermediate structures in Huntington`s disease and myotonic dystrophy type 1.
16
 
Using an inexpensive approach Hannon et al. synthesised a tetracationic iron(II) 
triple-stranded helicate which binds to the DNA major groove and induces 
intramolecular DNA coiling. When the complex was crystallised with a DNA 
palindromic hexanucleotide 5`-d-(CGTACG)-3`, molecular recognition of the DNA-
three way junction was observed with a helicate located in the centre of the junction 
(Fig. 3.21).
17
 
 
 
 
 
 
 
Figure 3.21 Crystal structure of iron(II) tetracationic helicate with palindromic hexanucleotide 
(a) Top view of the helicate-DNA complex (b) Side view of the helicate-DNA complex.
17
 
 
The structure of the helicate does not undergo any conformational changes upon 
binding to the DNA junction. Non-covalent interactions play a key role in binding of the 
(a) (b) 
 
 
   
161 
 
iron(II) cylinder in the core cavity of the junction. The cylinder is positively charged 
and therefore is attracted to the negatively charged sugar-phosphate backbone of the   
DNA via electrostatic interactions (Fig. 3.22 (a)). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.22 Noncovalent recognition of the DNA three-way junction by the iron(II) helicate (a) 
Electrostatic interactions between positively charged helicate and negatively charged DNA 
junction (b) π-π Stacking interactions between phenyl rings B and C and central T3 and A4 bases 
of the junction (c) Interaction of terminal phenyl ring D with minor groove of the DNA.
16
 
 
The phenyl rings of the helicate form extensive π-π stacking interactions with 
adenine and thymine bases of the DNA three-way junction (Fig. 3.22 (b)). Due to the 
(a) (b) 
(c) 
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three-fold symmetry of the cylinder which corresponds the three-fold symmetry of the 
DNA junction, these stacking interactions are repeated three times. The terminal 
pyridine rings of the supramolecular structure are located in the minor groove and are 
sandwiched between two opposite sugar-phosphate moieties of the DNA (Fig. 3.22 (c)). 
Hydrogen bonding was found to be present between the imine hydrogen adjacent to the 
terminal phenyl rings D and the N3 nitrogen of the adenine. The non-covalent 
interactions present between the helicate and the DNA-three way junction stabilise the 
structure. 
As the DNA three-way junction is relevant to the replication fork formed during 
the process of replication of DNA, molecules that are able to recognise this type of 
DNA structure have potential to be used as therapeutics in treatment of various diseases. 
By binding to the cavity of the junction the potential drug may cease the replication 
resulting in cell apoptosis. Key characteristics of the DNA-recognition motif of the drug 
are the shape and the size of the molecule which should perfectly match that of the 
target. In the case of the iron(II) supramolecular helicate it has the right dimensions to 
fit the hydrophobic cavity of a DNA three-way junction. Changing the structure of the 
cylinder can alter the binding properties of the complex.
17  
  
In this section of chapter 3 the recognition of DNA three-way junctions by the 
[Fe2(L1)3]Cl4, [Fe2(L3)3]Cl4, [Fe2(L4)3]Cl4, [Ni2(L4)3]Cl4 complexes, in comparison with 
their parent analogues, using the gel electrophoresis technique will be explored. 
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3.7.2 Results and discussion 
3.7.2.1 Overview 
The recognition of the DNA three-way junction by the synthesised compounds 
was examined using the polyacrylamide gel electrophoresis technique (PAGE). PAGE 
is used in the analysis of short sequences of DNA and the sensitivity of this method is 
achieved by the radioactive labelling of one of the strands of the DNA. In this work one 
strand of the oligonucleotide was labelled with γ-phosphate of ATP containing 
radioactive phosphorus-32. Phosphorus-32 has a short half-life and it decays with 
emission of β-radiation. The penetrating properties of β-particles are higher than those 
of α-particles and therefore β-radiation can be easily detected outside of the analysed 
sample. The oligonucleotide was labelled at the 5` terminus and the reaction was 
catalysed by bacteriophage T4 polynucleotide kinase.
18
   
The PAGE experiment was performed using the facilities of the Functional 
Genomics and Proteomics Unit of the School of Bioscience at the University of 
Birmingham. A 14-mer nonpalindromic oligonucleotide was used to form a DNA three-
way junction with seven base pairs per arm (Fig. 3.23 (a)). This junction structure was 
found to be the minimum length of DNA required for a three-way junction lacking 
unpaired bases to be stable enough to perform a gel electrophoresis experiment on a 
native gel at low temperatures (~ 5 ºC).
19
 The autoradiogram of the gel was obtained by 
exposing the radiogel to a phosphor imaging plate and reading it with Molecular imager 
FX. In the absence of the supramolecular helicate no DNA junction should be observed 
on the autoradiogram, just a single strand of the DNA, whereas in the presence of the 
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cylinder the stabilisation of the DNA three-way junction should occur giving rise to a 
band on the autoradiogram (Fig. 3.23 (b)). 
 
 
 
 
 
 
 
 
 
Figure 3.23 (a) Oligonucleotide sequences used for DNA three-way junction formation (b) 
Schematic representation of polyacrylamide gel electrophoresis experiment. 
 
3.7.2.2 Recognition and stabilisation of DNA three-way junction by helicates 
The synthesised compounds [Fe2(L1)3]Cl4, [Fe2(L3)3]Cl4, [Fe2(L4)3]Cl4 and 
[Ni2(L4)3]Cl4 were incubated with nonpalindromic sequences of the DNA and PAGE 
experiments were performed to analyse the samples. The autoradiogram for complexes 
[Fe2(L3)3]Cl4 and [Fe2(L4)3]Cl4 is shown in Figure 3.24. The S3* oligonucteotide strand 
was labelled with radioactive 
32
P. Wells containing oligonucleotides S3*, S3*+S2, 
S3*+S2+S1 and S3*+S2+S1 with magnesium chloride or parent cylinder [Fe2(Lp)3]Cl4 
were used as a control. Magnesium ions and the parent cylinder are known to promote 
the formation of DNA three-way junctions and stabilise them.
19 
 
 
(a) (b) 
  Single strand 
3WJ 
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Figure 3.24 Autoradiogram of PAGE experiment with complexes [Fe2(L3)3]Cl4 and  
[Fe2(L4)3]Cl4. Lanes 1-4 and 9-12 correspond to S3*, S3*+S2, S3*+S2+S1, S3*+S2+S1+MgCl2  
respectively. Lanes 5-8: S3*+S2+S1 with parent cylinder [Fe2(Lp)3]Cl4 (Lp = parent ligand)  
and [Fe2(L3)3]Cl4; lanes 13-15: S3*+S2+S1 with [Fe2(Lp)3]Cl4 and [Fe2(L4)3]Cl4. DNA: 
complex ratio used in the experiment was 3:1. 
 
The autoradiogram demonstrates that the [Fe2(L3)3]Cl4 complex promotes the 
formation of the DNA three-way junction. The observed bands are very weak compared 
to the bands of the parent analogue. The [Fe2(L4)3]Cl4 complex did not form the 3WJ 
structure apparently due to the instability of the complex in water. In order to calculate 
the percentage of DNA 3WJ formed for each complex, the intensities of the gel bands 
were quantified utilising the quantity one programme and calculated using the following 
formula: 
% 3WJ = (I3WJ/(Iss + I3WJ)) *100 
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I3WJ and Iss are the intensities of the gel bands corresponding to the DNA three-way 
junction and the single stranded DNA respectively. The bar graph displayed in the 
Figure 3.25 shows the percentage of DNA 3WJ formed for complexes [Fe2(L3)3]Cl4 (Fe-
L3) and [Fe2(Lp)3]Cl4 (Fe-Lp). 
 
 
 
 
 
 
 
 
 
 
Figure 3.25 Bar graph displaying the percentage of DNA 3WJ formed by complexes 
[Fe2(L3)3]Cl4 (Fe-L3) and [Fe2(Lp)3]Cl4 (Fe-Lp). 
 
The graph demonstrates that the Fe-L3 complex induces the formation of ~ 20 %  
DNA 3WJs compared to the parent analogue which is more effective and forms ~ 60 % 
of 3WJs. The dimensions of the helicate are crucial criteria for binding of the complex 
to the core cavity of the junction. By introducing various substituents onto the pyridine 
ring of the ligand we can alter the binding properties of the helicate.  
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The autoradiogram recorded for complexes [Fe2(L1)3]Cl4 and [Ni2(L4)3]Cl4 is shown in 
Figure 3.26. The compounds were analysed in comparison with their parent analogues. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.26 Autoradiogram of PAGE experiment of complexes Fe2(L1)3]Cl4 and [Ni2(L4)3]Cl4 
in comparison with [Fe2(Lp)3]Cl4, [Ni2(Lp)3]Cl4 (Lp = parent ligand), [Fe2(Lm)3]Cl4 (Lm = 
parent ligand with methyl group in place of imine hydrogen). Lanes 1-4: S3*, S3*+S2, 
S3*+S2+S1, S3*+S2+S1+MgCl2. Lanes 5 and 12: S3*+S2+S1 with [Fe2(Lp)3]Cl4; lanes 6-8: 
S3*+S2+S1 with [Fe2(L1)3]Cl4; lanes 9-11: S3*+S2+S1 with [Ni2(L4)3]Cl4; lanes 12-14: 
S3*+S2+S1 with [Fe2(Lm)3]Cl4; lanes 16-17: S3*+S2+S1 with [Ni2(Lp)3]Cl4. DNA:complex 
ratio used in the experiment is 3:1. 
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The autoradiogram reveals that all of the complexes form DNA 3WJs however 
with different effectiveness. In order to compare the obtained results the intensities of 
the gel bands were quantified (Fig. 3.27). 
 
 
 
 
 
 
 
 
 
 
Figure 3.27 Bar graph displaying the percentage of 3WJ formed by [Ni2(Lp)3]Cl4 (Ni-Lp), 
[Fe2(Lp)3]Cl4 (Fe-Lp), [Ni2(L4)3]Cl4 (Ni-L4), [Fe2(Lm)3]Cl4 (Fe-Lm), [Fe2(L1)3]Cl4 (Fe-L1) 
complexes. 
 
The graph demonstrates that the Ni-Lp and Ni-L4 complexes promote the 
formation of the DNA 3WJ comparable to the parent cylinder Fe-Lp, whereas the Fe-Lm 
and Fe-L1 compounds showed less percentage of the junction formed. This could be the 
result of replacing the imine hydrogen with a more sterically demanding methyl group. 
Thus, for example, Siriporn Phongtongpasuk from Hannon`s group examined the parent 
cylinder with phenyl and pyridine groups at the imine position of the parent ligand (Fig. 
3.28 (a, b)) by PAGE experiment. 
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Figure 3.28 Chemical structures of ligands with various substituents (a) with pyridine ring at 
the imine position (b) with phenyl ring at the imine position (c) with bulky CF3 groups in the 
middle of the spacer. 
 
The results demonstrated that the parent cylinder with the phenyl substituent 
promoted the formation of DNA 3WJ though less effectively than the parent complex. 
No 3WJ was formed by the complex with the pyridine group at the imine position.
20
 
Brabec et al. have previously shown that the parent cylinder with bulky CF3 groups 
introduced in the middle of the spacer in the ligand (Fig. 3.28 (c)) did not induce the 
formation of 3WJ structures as the diameter of the cylinder was too big to fit into the 
cavity of the junction.
19
 These examples demonstrate that various substituents on the 
parent ligand can affect the formation and stabilisation of the DNA three-way junction. 
The effect of different metal ions on the formation of the DNA 3WJ was 
investigated by PAGE experiment using iron(II), nickel(II) and cobalt(II) parent 
compounds which were synthesised according to a published literature procedure.
21
 The 
results of the experiments are shown in Figure 3.29.  
(a) 
(c) 
(b) 
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Figure 3.29 Autoradiogram of PAGE experiment of iron(II), nickel(II) and cobalt(II) parent 
compounds. Lanes 1-4: S3*, S3*+S2, S3*+S2+S1, S3*+S2+S1+MgCl2. Lanes 5, 8, 11: 
S3*+S2+S1 with [Fe2(Lp)3]Cl4; lanes 6, 9, 12: S3*+S2+S1 with [Ni2(Lp)3]Cl4; lanes 7, 10, 13: 
S3*+S2+S1 with [Co2(Lp)3]Cl4. 
 
All the complexes were found to induce the formation of the DNA 3WJ, however for 
the iron(II) and nickel(II) compounds more intense 3WJ gel bands were observed. 
Quantification of the gel (Fig. 3.30) supported the obtained results.  
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Figure 3.30 Bar graph displaying the percentage of DNA 3WJ formed by [Fe2(Lp)3]Cl4 (Fe-
Lp), [Ni2(Lp)3]Cl4 (Ni-Lp) and [Co2(Lp)3]Cl4 (Co-Lp) parent cylinders. 
 
The percentage of DNA 3WJ formed for the cobalt cylinder was lower, ~ 36 %, 
compared to the nickel and iron cylinders ~ 60 % and ~ 62 % respectively. Such a 
significant difference in the percentage of 3WJ formation could be a result of low 
stability of cobalt(II) complex in aqueous solution. In order to confirm the proposed 
hypothesis, UV/Vis stability tests were performed over a 12-hour period on iron(II), 
nickel(II) and cobalt(II) parent complexes. The recorded spectra are shown in Figure 
3.31. 
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Figure 3.31 UV/Vis stability test spectra recorded in water over a 12-hour period for (a) 
[Ni2(Lp)3]Cl4 (b) [Fe2(Lp)3]Cl4 (c) [Co2(Lp)3]Cl4. 
 
The recorded UV/Vis spectra confirm that the [Co2(Lp)3]Cl4 complex is less 
stable than the iron(II) and nickel(II) analogues and suffers degradation. [Ni2(Lp)3]Cl4 
and [Fe2(Lp)3]Cl4 compounds are relatively stable over a 12 hour period although slight 
changes in the spectra are also observed. Thereby, low stability of cobalt(II) parent 
compound in aqueous solution explains the lower percentage of 3WJ formation in 
comparison with iron(II) and nickel(II) parent cylinders.  
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3.8 Conclusions 
In this chapter various techniques such as circular and linear dichroism, UV/Vis 
spectroscopy and gel electrophoresis were applied to analyse the DNA binding 
properties and stability of the synthesised complexes. All the compounds were 
relatively stable aside from the [Fe2(L4)3]Cl4 complex which degrades rapidly in water.  
The CD titrations to ct-DNA revealed that the [Fe2(L3)3]Cl4, [Fe2(L1)3]Cl4 and 
[Ni2(L4)3]Cl4 complexes bind to the DNA which was further confirmed by the LD 
experiment. At high concentrations of the drug loading a loss of LD signal was 
observed as well as induced LD signals in the MLCT region indicating binding of the 
complexes to ct-DNA in a specific orientation and bending/coiling it. The loss of LD 
signal in the DNA region was more significant for complexes [Fe2(L3)3]Cl4 and 
[Ni2(L4)3]Cl4 with a nickel(II) complex leading to a 97 % loss of the signal at 260 nm at 
4:1 ratio. Moreover, high concentrations of the nickel complex caused precipitation of 
ct-DNA.  
The agarose gel electrophoresis results demonstrate that none of the synthesised 
complexes unwind plasmid DNA which can be related to the nature of the compounds 
or their instability at high temperatures.  The data obtained from the PAGE experiments 
reveal that the [Fe2(L1)3]Cl4, [Fe2(L3)3]Cl4, and [Ni2(L4)3]Cl4 complexes induce the 
formation of the DNA 3WJ. The percentage of the 3WJ formed by the nickel complex 
was comparable to its iron(II) and nickel(II) parent analogues. The [Fe2(L1)3]Cl4 and 
[Fe2(L3)3]Cl4 compounds were less effective in the formation of the DNA 3WJ than the 
[Ni2(L4)3]Cl4 complex which can be elucidated by the influence of various substituents 
on the structure of the ligand. It was previously shown that the presence of substituents 
in the structure of the ligand as well as the shape and size of the cylinder affect the 
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binding properties of the complexes to the DNA 3WJ.
19
 The [Fe2(L4)3]Cl4 complex did 
not promote the formation of the junction structure for the reason of instability in 
aqueous solution. The effect of different metal ions on the formation of the DNA 3WJ 
was investigated using iron(II), cobalt(II), nickel(II) parent cylinders. The cobalt(II) 
complex promoted lower percentage of 3WJ formation compared to the iron(II) and 
nickel(II) parent compounds due to the poor stability in aqueous solution. Both 
nickel(II) and iron(II) are relatively stable and induced ~ 60 % of 3WJ.  
The focus of the next chapter is the cytotoxic activity of the synthesised 
complexes using an MTT colorimetric assay.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
175 
 
 
3.9 References:  
1. N. P. Farrell in: J. A. McCleverty, T. J. Meyer, Comprehensive Coordination 
Chemistry II, vol. 9, Elsevier Ltd., Oxford, 2004. 
2. M. J. Hannon, V. Moreno, M. J. Prieto, E. Moldrheim, E. Sletten, I. Meistermann, C. 
J. Isaac, K. J. Sanders and A. Rodger, Angew. Chem., Int. Ed., 2001, 40, 879-884. 
3. A. Oleksi, A. G. blanco, R. Boer, I. Uson, J. Aymami, A. Rodger, M. J. Hannon, M. 
Coll, Angew. Chem,. Int. Ed., 2006, 45, 1227-1231.   
4. T. Owen, Fundamentals of modern UV-visible spectroscopy: Primer, Agilent 
technologies, Germany, 2000.  
5. J. Kypr, I. Kejnovska, D. Renčiuk, M. Vorlíčková, Nucleic Acids Res., 2009, 37, 
1713-1725. 
6. A. Rodger and B. Nordén, Circular and linear dichroism, Oxford University press, 
New York, 1997.    
7. M. J. Hannon, V. Moreno, M. J. Prieto, E. Moldrheim, E. Sletten, I. Meistermann, C. 
J. Isaac, K. J. Sanders, A. Rodger, Angew. Chem., Int. Ed., 2001, 40, 879-884.    
8. S. Vitorino, PhD thesis, University of Birmingham, 2011. 
  
9. I. Meistermann, V. Moreno, M.J. Prieto, E. Moldrheim, E. Sletten, S. Khalid, P.M. 
Rodger, J.C. Peberdy, C.J. Isaac, A. Rodger and M.J. Hannon, Proc. Natl. Acad. Sci., 
USA, 2002, 99, 5069-5074.  
10. D. S. Kryndushkin, I. M. Alexandrov, M. D. Ter-Avanesyan, V. V. Kushnirov, J. 
Biol. Chem., 2003, 278, 49636-49643.  
11. K. Triantafillidi, K. Karidi, O. Novakova, J. Malina, A. Garoufis, Dalton. Trans., 
2011, 40, 472-483. 
 
   
176 
 
 
12. S. F. Bellon, J. H. Coleman, S. J. Lippard, Biochemistry, 1991, 30, 8026-8035.   
13. M. Huxley, PhD Thesis, University of Warwick, 2006. 
 
14. J. Malina, M. J. Hannon, V. Brabec, Nucleic Acids Res., 2008, 36, 3630-3638.  
 
15. M. J. Hannon, Chem. Soc. Rev., 2007, 36 280-295.  
 
16. S. Muhuri, K. Mimura, D. Miyoshi, N. Sugimoto, J. Am. Chem. Soc., 2009, 131, 
9268-9280. 
17. A. Oleksi, A. G. Blanco, R. Boer, I. Uson, J. Aymami, A. Rodger, M. J. Hannon, M. 
Coll, Angew. Chem., Int. Ed., 2006, 45, 1227-1231.  
18. C. C. Richardson, in Procedures in nucleic acid research, eds. G. L. Cantoni and D. 
R. Davies, Harper and Row, New York, Edn., 1971, Vol. 2, 815-828. 
19. J. Malina, M. J. Hannon, V. Brabec, Chem. Eur. J., 2007, 13, 3871-3877. 
 
20. S. Phongtongpasuk, PhD Thesis, University of Birmingham, 2010. 
 
21. C. Painting, PhD Thesis, University of Warwick, 1999. 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
Chapter 4 
 
Biological studies in vitro
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4.1 Introduction 
The evaluation of the biological activity of synthesised compounds is of great 
importance as it determines whether the synthesised molecule can be used as a potential 
drug. The biological effects of the compounds are explored using various assays. The 
cytotoxic activity of the drug, for example, can be assessed by using the LDH assay
1
 
(lactate dehydrogenase cell viability assay, measures integrity of the membrane), the 
SRB assay
2
 (the method used to determine the antitumour activity of the molecule by 
measuring cellular proteins), the MTT colorimetric assay
3
 (used to assess cell viability) 
etc. In this work the MTT assay was used to assess the antitumour activity of the 
synthesised complexes by measuring the inhibitory effect of the compounds on the 
proliferative activity of various cell lines. 
  
4.2. Cell culture 
4.2.1 Cell growth 
To study the potential anticancer activity of the synthesized compounds in vitro, 
cytotoxic experiments were carried out using different human cancer cell lines: MDA-
MB-231 human breast adenocarcinoma, SKOV-3 human epithelial ovarian carcinoma, 
A2780 human epithelial ovarian carcinoma and A2780cisR cisplatin-resistant human 
epithelial ovarian carcinoma. Cells were grown as monolayers in complete growth 
medium (RPMI 1640 or DMEM depending on a cell line) in tissue culture flasks in a 
humidified incubator at 37 ºC, 5 % CO2 to simulate in vivo conditions.
4
 The growth 
medium provides essential nutrients such as amino acids, fatty acids, sugars, ions, trace 
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elements, vitamins, and etc. that are essential for cell division and maintenance of the 
chemical environment for the cell. 
Cells go through several growth phases. The initial phase is the quiescent or lag 
phase when cells recover from subculture, attach, and spread. The cells then enter the 
log phase where the number of cells begins to increase exponentially and they have the 
highest metabolic activity. The stationary phase is the phase where number of cells is 
constant, this is characteristic of a confluent population (where all growth surfaces are 
covered), the growth rate then slows down or stops. When cells reach their confluency 
they undergo a process called “cell splitting” or subculturing. Ideally, cells should be 
split when they are in a semi-confluent state and are still in the log phase. Cells that are 
not subcultured and are allowed to grow to a confluent state can sometime lag for a long 
period of time and some may never recover. Most cells are split (or at least fed) three 
times a week. In order to split cells, they are detached from the surface of the flask by 
trypsinization. The resultant cell suspension is then divided into fresh cultures.
5 
 
 
4.2.2 Cell counting and treatment 
Determining the correct number of cells is crucial in performing accurate 
experiments. A device used for counting the number of cells per unit volume of a 
suspension is called a counting chamber or hemocytometer (Fig. 4.0), as originally it 
was designed to count blood cells.6 The central platform of the hemocytometer is 
divided into two counting grids. Each 3 x 3-mm grid is etched on a mirror-like surface. 
The grid is divided into large nine squares and each square has a surface area of 1 x 1 
mm. The four corner squares and the central square are used for cell counting. Cells are 
counted in selected squares in a way that the total number of cells is 100 or so (it is 
   
180 
 
necessary in order to get good statistics). The cells should be uniformly distributed and 
not overlap each other. If the cells overlap the gridline, a cell is counted if it overlaps 
the top or right gridline and not counted if it overlaps the bottom or left gridline.
5, 6
 
 
 
 
 
 
 
 
 
Figure 4.0 Hemocytometer (improved Neubauer) with a cover slip.
6  
 
To count the number of cells per 1 mL (NCells/mL) the following formula is used: 
NCells/mL = NA x 10
4
 x dilution factor 
NA - average number of cells per square, 10
4
 - volume correction factor for the 
hemocytometer. 
To assess the number of viable cells trypan blue is used (Fig. 4.1). Trypan blue is 
a diazo dye. It is a vital stain that colours dead cells blue whereas living cells with an 
intact membrane do not absorb the dye and thus are not coloured.
7
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Figure 4.1 Structure of trypan blue. 
 
To calculate the percentage of viable cells (Cv) the following equation is used: 
Cv = NL/NTot x 100 
NL - number of living cells, NTot - number of total cells counted. 
To calculate the number of cells needed for an experiment to seed in a 96 flat-bottom 
well plate the following formula is used: 
VS = NR/NC x VM 
VS - volume of cell suspension for seeding, NR - number of cells per 1 mL required 
(depends on the cell density and is defined experimentally; for different cell lines this 
value varies), NC - number of viable cells per 1 mL counted with hemocytometer, VM - 
volume of medium per plate.  
100 µL of suspension with the correct amount of cells is then distributed with a 
multichannel micropipette in each well of a 96 well microtiter plate and the plates are 
placed in the incubator for 24 hours to allow adhesion. The cells are then treated with 
various concentrations of complexes (200 µM, 100 µM, 50 µM, 25 µM, 12.5 µM) and 
incubated for 72 hours. After 72 hours of incubation the MTT assay is performed. 
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4.2.3 MTT assay 
To examine cell proliferation and viability, the MTT colorimetric assay is used. 
The MTT assay also helps to determine the cytotoxicity of the synthesized compounds 
as they can inhibit or stimulate cellular growth and viability. The MTT assay was first 
introduced by Mossman as a quantitative measure of mammalian cell survival and 
proliferation.3 MTT or 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide is 
a yellow tetrazolium salt which is converted into a purple formazan by dehydrogenases 
in the mitochondria of living cells (Fig. 4.2 (a)). The ability of cells to reduce MTT 
indicates the mitochondrial integrity which can be interpreted as a measure of cell 
viability. 
 
 
 
 
 
 
 
 
 
Figure 4.2 (a) Reduction of MTT to formazan (b) 96-Well plate with dissolved formazan 
crystals.  
(a) 
(b) 
MTT    Formazan 
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The MTT assay interpretation is based on the principle that the amount of 
formazan produced is proportional to the number of live cells. The formed purple 
crystals of formazan can be measured by a spectrophotometer plate reader after 
solubilization with DMSO (Fig. 4.2 (b)).
8
 The absorbance of the coloured solution of 
formazan can be quantified by measuring at a certain wavelength, usually between 500-
600 nm.
9,
 
10
 
In this work, after dissolving the formed purple crystals of formazan with DMSO 
the absorbance at 590 nm was recorded using a plate reader machine (BioRad). The 
results obtained from cells treated with a compound were compared with results of 
untreated control cells, and the effectiveness of the agent was defined through the 
production of a dose-response curve. 
 
4.2.4 Dose-response curve and IC50 
The potency of a compound or a drug is defined by the IC50 value. An IC50 or 
inhibitory concentration is the concentration of a compound required to inhibit a given 
biological process by half. IC50 values are important as they give information about the 
biological activity of a compound. The lower the IC50, the higher the biological activity 
of the drug or compound and the lower the concentration of drug that is required to 
inhibit the maximum biological response.
11
 
To calculate IC50 values a dose-response curve is produced. The x-axis represents 
different concentrations of the drug whereas the y-axis represents the response to the 
drug or compound (percentage cell growth). The IC50 value is then obtained from the 
point at which cell growth is inhibited by 50 %. 
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In this work the Microsoft Office Excel program was used to plot the dose-
response curve and calculate IC50 values. An example of dose-response curve produced 
for cisplatin is displayed in Figure 4.3. 
 
 
 
 
 
Figure 4.3 Dose-response curve for cisplatin in MDA-MB-231 cell line. 
 
Change of the x-axis of the graph to natural logarithm allows better fitting of the 
dose-response curve to a straight line. Compounds with IC50 values higher than 100 µM 
were considered to be inactive. All experiments were repeated at least three times to 
ensure the consistency of the IC50 values. The data were then averaged and standard 
deviation (SD) was calculated. The evaluation of biological activity of synthesized 
complexes was carried out using the facilities of the School of Biosciences at the 
University of Birmingham provided by Prof. Kevin Chipman, Dr. Chris Bunce and Dr. 
Nikolas Hodges. 
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4.3 Results and discussion 
A number of compounds were tested for anticancer activity, some of these were 
prepared in this thesis and others supplied by other researchers in the group. The 
compounds supplied by others are discussed first and then the complexes of this thesis.  
 
4.3.1 Cytotoxic activity of the peptide conjugated iron(II) cylinders 
Iron(II) peptide conjugated helicates were synthesised by Lucia Cardo from 
Hannon`s group, by attaching short amino acids to the iron(II) cylinder (Fig. 4.4) in 
order to improve the specificity of the metal complexes to DNA. The compounds were 
provided as their water soluble chloride salts for biological testing in cancer cell lines. 
 
 
 
 
 
 
                                                                                                                              
Figure 4.4 Chemical structures of ligand La, developed by Lucia Cardo, and conjugated 
amino acids.  
La 
X = D-Ser, L-Ser, D-Arg, L-Arg, Gly-Gly-Ser 
 
Glycine (Gly) 
Serine (Ser) 
Arginine (Arg)    
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 Amino acids are components of proteins and play an important role in the 
recognition of specific sites of the DNA.
12, 13
 Most sequence-specific DNA binding 
proteins bind in the major groove by using a simple secondary structure, usually an α-
helix, which is complementary to the structure of the B-DNA major groove.
14
 The 
amino acid sequences employed were chosen from those that can be found in natural 
systems and take part in DNA recognition. The peptides were conjugated to the cylinder 
at the 5-position of the pyridine ring after considering possible steric constraints. The 
compounds were shown to bind to the DNA and induce DNA bending/coiling
15
 as well 
as promote DNA three-way junction formation, with arginine conjugates being more 
effective than the other compounds of this series.  
The cytotoxic activity of cylinder-peptide conjugates was explored using A2780 
ovarian and MDA-MB-231 breast cancer cell lines. The iron(II) parent complex and 
cisplatin were used as controls. The results of the experiments are shown in Table 4.0 
and chart (Fig. 4.5). 
 
 
 
 
 
 
 
 
 
Table 4.0 IC50 values of peptide-conjugated cylinders.  
Compound MDA-MB-231, IC50 (μM) A2780, IC50 (μM) 
D-Arg 26±1 6±3 
L-Arg 35±7 9±2 
D-Ser 29±3 5±2 
L-Ser 23±1 7±3 
Gly-Gly-Ser 34±6 9±2 
Parent cylinder 27±3 14±2 
Cisplatin 27±3 4±2 
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Figure 4.5 Schematic illustration of IC50 values from Table 4.0. The data represent mean values 
± 1SD of three repeats.   
 
The obtained IC50 values reveal that all of the peptide-cylinder conjugates possess 
antineoplastic activity. D-Arg and L-Arg iron(II) complexes are not stable in aqueous 
solution and gradually degrade, however low stability did not affect their cytotoxic 
profile. The activity of the complexes in the MDA-MB-231 cell line is similar however 
the IC50 values for the L-Arg and Gly-Gly-Ser cylinders were slightly higher. This 
could be due to lower affinity of the Gly-Gly-Ser conjugate to DNA shown by CD and 
LD studies.
15
 The L-Arg complex forms the helicate in a P-conformation which causes 
the complex to be a slightly less effective DNA binder and this could affect the activity 
of the complex. The conjugated cylinders showed a good cytotoxic profile in ovarian 
cancer cell line A2780. The IC50 values for these complexes in A2780 cells were lower 
than those of the parent cylinder and comparable with cisplatin. The components of the 
ligand (the 4,4’-methylene dianiline spacer and peptide functionalised aldehydes) were 
also tested for potential anticancer activity by MTT assay. The results demonstrated 
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IC50 values higher than 100 μM indicating that the activity of the complexes arises just 
from the conjugate cylinders themselves.  
 
4.3.2 Cytotoxic activity of Pt(II) and Pd(II) non-helical complexes 
Several platinum(II) and palladium(II) complexes, synthesised by Philipp von 
Grebe a PhD student  from Professor Bernhard Lippert`s group at the University of 
Dortmund, Germany, were supplied for evaluation of their cytotoxic activity. The 
structures of the complexes are shown in Figure 4.6. 
 
 
 
 
 
 
 
 
 
Figure 4.6 Structures of platinum(II) and palladium(II) complexes synthesised by Philipp von 
Grebe. 
WS858-2 
WS-SS-19 
AG127  AK66 
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These compounds are supramolecular polycations of very different structure to the 
cylinders and with cyclic polyaromatic frameworks they may either fit into the major 
groove or bind at a DNA junction point. To this extent they are intriguing comparisons 
for the metal complexes being explored herein. A related tetraplatinum supramolecular 
square octacations has been shown to bind to quadruplex DNA
16
 and to be cytotoxic to 
cancer cell lines.
17
 
Moreno et al. reported studies on antitumour properties of supramolecular 
platinum squares (Fig. 4.7).
17
 
 
 
 
 
 
 
 
 
 
Figure 4.7 Supramolecular squares tested for anticancer activity (a) Moreno platinum square 
(Pt-M) (b) Fujita platinum square (Pt-F). 
 
The anticancer activity of these two platinum complexes was explored by MTT 
assay in HL-60 leukemia cell line. The results of the experiments as IC50 values are 
presented in Table 4.1 and chart (Fig. 4.8).  
 
 
(a) (b) 
Pt-M 
Pt-F 
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Compound 
HL-60         
IC50 (μM) 
Pt-M 5 ± 2 
Pt-F 3±1 
Fe-Lp 18±3 
Cisplatin 2±1 
 
Table 4.1 IC50 values (μM) of supramolecular platinum squares
17
 in comparison with Hannon 
iron(II) supramolecular helicate
18
 (Fe-Lp) and cisplatin. 
 
 
 
 
 
 
 
 
Figure 4.8 Schematic illustration of IC50 values from Table 4.1. 
 
As it is listed in Table 4.1 and shown in the chart (Fig. 4.8) compound Pt-F 
exhibits cytotoxic activity comparable to that of cisplatin and they are approximately 
two-fold more active than compound Pt-M. It is unsurprising, because according to CD 
studies compound PT-F modifies the secondary and tertiary structures of DNA more 
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dramatically than compound PT-M apparently due to its smaller size.
17
 The iron(II) 
supramolecular helicate is 3- to 5-fold less active in HL-60 cells than Pt-F and Pt-M.  
Reports on biological studies of supramolecular cyclic polycations are relatively 
rare due to poor solubility in aqueous solutions. Therefore it was intriguing to perform 
cytotoxicity tests on compounds supplied by P. von Grebe which are water soluble 
polynuclear metal complexes. 
The MTT assay of the platinum(II) and palladium(II) compounds was performed 
on A2780cisR, MDA-MB-231 and SK-OV-3 cancer cell lines. The results of the 
experiments are displayed in Table 4.2 and chart (Fig. 4.9). 
 
 
 
 
 
 
 
Table 4.2 IC50 values (μM) of platinum(II) and palladium(II) complexes synthesised by Philipp 
von Grebe in comparison with Hannon iron(II) cylinder (Fe-Lp) and cisplatin.  
 
                                                          
1
 Only one experiment was performed with this complex due to insufficient quantities. 
 
Compound 
A2780cisR 
IC50 (μM) 
MDA-MB-231 
IC50 (μM) 
SK-OV-3 
IC50 (μM) 
AG127 13±3 >100 79
1
 
AK66 23±8 >100 >100 
WS858-2 18±1 >100 >100 
WS-SS-19 18±3 14±5 17±4 
Fe-Lp 13±2
19
 27±3 54±6 
Cisplatin 6±2 23±5 10±3 
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Figure 4.9 Schematic illustration of IC50 values from Table 4.2. The data represent mean values 
± 1SD of three repeats.   
 
The results of the assay demonstrate that all of the compounds are active in the 
A2780cisR cell line. Interestingly, the WS-SS-19 complex is the only compound of 
these series that showed good antitumour activity in MDA-MB-231 (IC50 values lower 
than cisplatin) and SK-OV-3 cells whereas the rest of the complexes were found to be 
inactive. Palladium metal complexes are generally considered to be less active than their 
platinum counterparts due to rapid hydrolysis of leaving groups, promoting the 
formation of very reactive species that are unable to reach their pharmacological targets. 
Increased structural integrity of a palladium drug can be reached by stabilising the 
molecule with a strong coordination to a nitrogen ligand and a suitable leaving group, 
leading to a higher activity.
20
 Palladium metal complexes are known to be capable of 
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interacting with DNA enabling formation of the cross-links, inhibition of DNA 
synthesis as well as inducing apoptosis.
21
 There is evidence that some palladium 
compounds can bind to an electron transport protein, cytochrome c, in mitochondria 
which is involved in the apoptosis process and acts as a death messenger. The 
compounds alter its conformation and cause release of the protein from its biological 
membrane.
22
 Though the complex AG127 showed slight activity in the SK-OV-3 cell 
line, there is not enough evidence to prove the activity of this complex as the MTT 
experiment was performed only once due to an insufficient amount of the compound. 
 
4.3.3 Cytotoxic activity of Rh(III) complexes. 
Rhodium(III) complexes were provided by Susana Vitorino from Hannon`s group 
who synthesized and characterized these metal compounds. Dinuclear Rh(III) single 
stranded complexes are formed by linking together two Rh(III) metal centers with a bis-
bidentate Lazo ligand and attaching a diimine (phen or bpy) ligand. The mononuclear 
Rh(III) complexes are based on a 2-phenylazopyridine ligand with an attached diimine 
ligand (Fig. 4.10). The bidentate ligand Lazo was chosen instead of the analogous imine 
ligand due to its greater stability.
23
  
Works of Sheldrick and Lorenz et al. have shown that rhodium complexes are 
capable of inhibiting cell proliferation and thus possess antineoplastic activity.
24, 25
 For 
this reason the synthesized Rh(III) complexes were investigated for their potential 
antitumour properties. 
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Figure 4.10 Crystal structures of the Rh(III) complexes used for biological evaluation.
23
 
 
The MTT assay of the Rh(III) compounds was performed on A2780 and MDA-
MB-231 cancer cell lines. The results of the experiments are displayed in Table 4.3 and 
chart (Fig. 4.11). 
 
rac-(Rh2(Lazo)(phen)2Cl2]Cl2 (Isomer I) 
and meso-isomer (Isomer II not shown) 
cis-(Rh2(Lazpy)(phen)Cl2]Cl 
(Rh-Phen) 
cis-(Rh2(Lazpy)(bpy)Cl2]Cl  
(Rh-Bpy) 
Lazo Lazpy 
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Table 4.3 IC50 values of the Rh(III) complexes synthesised by Susana Vitorino.  
 
Figure 4.11 Schematic illustration of IC50 values from Table 4.3. The data represent mean 
values ± 1SD of three repeats.   
 
The results of the MTT assay demonstrate that the mononuclear Rh(III) 
compound with attached phenanthroline ligand is the most effective cytotoxic agent 
among the tested rhodium complexes. The compound exhibited a good antitumour 
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Compound 
A2780          
IC50 (μM) 
MDA-MB-231 
IC50 (μM) 
Isomer I >100 65±5 
Isomer II >100 57±14 
Rh-Bpy >100 >100 
Rh-Phen 26±2 23±2 
Cisplatin 4±3 26±3 
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profile in both cell lines with IC50 values comparable to that of cisplatin in the MDA-
MB-231 cell line. Remarkably, DNA binding studies and gel electrophoresis showed 
that the complex did not significantly perturb the DNA structure or cause DNA plasmid 
unwinding as did its dinuclear analogues. According to the data obtained, it may be 
concluded that DNA is not the primary target of the Rh-Phen complex and the cytotoxic 
activity of the complex is associated with another cellular mechanism. One of the 
possible mechanisms is the suppression of DNA synthesis via inhibition of enzymes 
which take part in the DNA synthesis.
26
 Some rhodium complexes are also known to 
cause oxidative damage to mitochondrial DNA which promotes specific changes in 
protein-DNA interactions and is thus identified by the mitochondrial protein 
machinery.
27
 It is striking that the Rh-Bpy analogue did not exhibit any activity in 
cancer cell lines. By substituting the phenanthroline ligand with 2,2’-bipyridine, the 
biological activity of the complex was dramatically affected. The activity of the Rh-
Phen complex can also be linked to the ligand. Phenanthroline itself is highly cytotoxic 
towards neoplastic cell lines. The IC50 values of phenanthroline in L1210 (cisplatin-
sensitive murine leukemia) and A498 (human kidney adenocarcinoma) cancer cell lines 
are reported as 4.5, and 5.5 μM respectively. In leukemia cell lines phenanthroline is 
less active than cisplatin, whereas in other cell lines it shows 3.3- and 2.5-fold enhanced 
activity.
28
  
Dinuclear Rh(III) compounds Isomer I and Isomer II exhibited moderate 
antitumour activity in the MDA-MB-231 cell line and no activity in the SK-OV-3 cell 
line. Both compounds were shown to bind to ct-DNA and cleave plasmid DNA. Thus 
the activity of these complexes can be associated with their ability to interact with a 
DNA or inhibit DNA synthesis. 
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4.3.4 Antitumour activity of supramolecular helicates with additional metal-
binding units.  
Turning to the compounds prepared in this thesis: the antineoplastic activity of 
[Fe2(L1)3]Cl4, [Fe2(L1)3]Cl4 with attached cisplatin, [Fe2(L3)3]Cl4, [Fe2(L4)3]Cl4 and 
[Ni2(L4)3]Cl4 was evaluated using MDA-MB-231 and SK-OV-3 cancer cell lines and 
compared to the parent analogues [Fe2(Lp)3]Cl4, [Ni2(Lp)3]Cl4 and [Co2(Lp)3]Cl4. As an 
aide-mémoire the structures of L1, L3, L4, Lp ligands are presented in Figure 4.12. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12 Structures of L1, L3, L4 and Lp ligands. 
 
 The results of the MTT experiments are displayed in Table 4.4 and chart (Fig. 
4.13). 
 
 
Lp L1 
L3 
L4 
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Table 4.4 IC50 values for a range of the helicates. 
 
The Fe-L1Pt compound was partially dissolved in DMEM medium and was not 
soluble in RPMI-1640 medium. Therefore evaluation of the cytotoxic activity of this 
complex was performed only using MDA-MB-231 cell line. To help to solubilise the 
compound an ultrasonicator was used. The Fe-L4 complex was dissolved by addition of 
2 % DMSO due to its insolubility in medium.  
 
 
 
Compound 
SK-OV-3             
IC50 (μM) 
MDA-MB-231                       
IC50 (μM) 
Fe-L1 >100 >100 
Fe-L1Pt 
- 39±19 
Fe-L3 21±6 17±1 
Ni-L4 52±5 55±10 
Fe-L4 >100 58±15 
Fe-Lp 54±6 27±3 
Ni-Lp >100 >100 
Co-Lp 10±6 10±1 
Cisplatin 11±1 32±4 
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Figure 4.13 Schematic illustration of IC50 values from Table 4.4 (Fe-L1 = [Fe2(L1)3]Cl4, Fe-L1Pt 
= [Fe2(L1)3]Cl4 with attached cisplatin, Fe-L3 = [Fe2(L3)3]Cl4, Ni-L4 = [Ni2(L4)3]Cl4, Fe-L4 = 
[Fe2(L4)3]Cl4, Fe-Lp = [Fe2(Lp)3]Cl4, Co-Lp = [Co2(Lp)3]Cl4, Ni-Lp = [Ni2(Lp)3]Cl4). The data 
represent mean values ± 1SD of three repeats.   
  
The obtained data reveals that the Fe-L3 and Co-Lp complexes are the most active 
of all tested compounds of these series in both cancer cell lines. It should be noted that 
the Fe-L3 complex showed an excellent antitumour profile in the MDA-MB-231 cell 
line with IC50 values two-fold lower than cisplatin. The activity of the compound can be 
attributed to its ability to interact with DNA. CD and LD studies demonstrated that the 
complex is an effective DNA binder, however according to the results from gel 
electrophoresis experiments, the Fe-L3 helicate induces a low percentage of DNA three-
way junction and does not unwind plasmid DNA when compared to its parent analogue 
Fe-Lp. This suggests that other cellular mechanisms may be involved which are 
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responsible for the antiproliferative activity of this compound. Thus, for instance, the 
antineoplastic activity of some iron(II) complexes is linked to DNA damage by active 
radical species produced by the compounds. Iron(II) ions are thought to be converted in 
cancer cells to iron(III) ions which are then involved in the production of active 
hydroxyl radicals.
29
 
 The Co-Lp complex exhibits potent antiproliferative activity in both cancer cell 
lines with IC50 values three-fold lower for MDA-MB-231 cells and comparable to 
cisplatin in SKOV-3 cancer cells. According to the gel electrophoresis results, the 
cobalt cylinder promoted a lower percentage of DNA three-way junction formation than 
the iron and nickel analogues which can be elucidated by its low stability in the aqueous 
solution. The activity of the cobalt complex can be linked to different cellular 
mechanisms. Cobalt compounds are known to form reactive oxygen species in an 
hypoxic tumour environment which attack the biomolecules of cancer cells such as 
lipids, proteins and DNA.
30
 Thus treatment of cancer cells with cobalt complexes 
produces DNA strand breaks. Numerous breaks in DNA strands trigger the cellular 
death pathways. In addition, cobalt(II) compounds were found to be enzyme 
topoisomeraseII poisons. Topoisomerases are enzymes that control the unwinding and 
winding of DNA to facilitate DNA replication and recombination. TopoisomeraseII 
poisons convert topoisomeraseII from an essential enzyme to a cellular toxin that 
produces strand breaks in the genetic material.
31
 Additional testing is required to 
elucidate the activity of the cobalt helicate and understand the mechanism of its action. 
The nickel parent cylinder was found to be inactive in both cell lines which is 
striking as the ability of the complex to induce the formation of a DNA three-way 
junction is comparable to that of its iron counterpart. Remarkably, Qu et al. performed 
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MTT assay with M and P enantiomers of nickel parent cylinder on K562 leukemia cell 
line and both of the enantiomers were found to be active with IC50 values of 55 μM for 
P-enantiomer and 60 μM for M enantiomer.32 The activity of the complexes was 
attributed to the ability of these compounds to inhibit telomerase activity and up 
regulate of p21 and p16 expression which are key effectors of cellular senescence.  
The Ni-L4 complex effectively inhibited cell proliferation in both cancer cell lines. 
CD and LD studies and gel electrophoresis experiments confirmed that the complex is 
an effective DNA binder and promoter of DNA 3WJ structures. According to literature 
reports, the activity of nickel compounds is associated with the ability to suppress DNA 
replication through inhibition of DNA polymerase α activity and transcription processes 
in vitro and in vivo and causing a non-random assault on DNA resulting in 
chromosomal aberrations.
33
 Moreover, nickel complexes are known to bind proteins 
that are associated with DNA and are capable of cleaving DNA in the presence of 
oxidising agents through a production of reactive radical species. Although nickel is in 
the same group as platinum, it has not been shown significant anticancer properties. The 
ligands used to form nickel complexes can improve the biological properties of nickel.
34
 
This could be one of the reasons why the Ni-L4 complex exhibited activity in cancer cell 
lines. The synthesised ligand L4 is based on imidazole units linked to pyridine by an 
alkyl group. Imidazole derivatives are known to possess anti-inflammatory, antibacterial 
and anticancer properties.
35
 Thus, for example, N-fused aminoimidazoles showed potent 
anticancer activities in kidney and breast cancer cell lines with low toxicity to normal 
cells.
36
  
The iron(II) complex of L4 showed moderate activity in the MDA-MB-231 cell 
line and no activity in the SK-OV-3 cell line. The stability of the complex did not affect 
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the activity of the compound. It can be suggested that the complex falls apart in the 
medium and the structural components of the cylinder inhibit cell proliferation by 
affecting various cellular processes.  
Interestingly, the Fe-L1 compound is not active in any of the cell lines used in the 
experiments. The absence of inhibitory activity on cancer cell growth can be attributed 
to lower affinity of the complex to ct-DNA. CD and LD studies demonstrated that the 
complex binds to the DNA in a less effective way than parent analogue or Fe-L3. The 
complex did not show any DNA plasmid unwinding and caused ~ 15 % of DNA 3WJ 
formation. However, the Fe-L1 compound with attached cisplatin showed antitumour 
activity in MDA-MB-231 cell line with IC50 values comparable to cisplatin. From the 
obtained results it can be concluded that the activity of the platinated iron(II) complex 
arises just from cisplatin alone.  
In order to examine whether the iron(II) helicate mixed with cisplatin induces 
synergysm in activity, additional testing was performed by mixing 200 μM of parent 
iron(II) cylinder with 50 μM of cisplatin. The activity of the prepared mixture was 
tested in SK-OV-3 and A2780 cancer cell lines. The results of the experiments are 
presented in Table 4.5 and chart (Fig. 4.14). 
 
Table 4.5 IC50 values of Fe-Lp:cisplatin mixture (Fe-Lp = [Fe2(Lp)3]Cl4). 
Compound SK-OV-3, IC50 (μM) A2780, IC50 (μM) 
Fe-Lp:cisplatin (4:1) 
30±3 
 
4±1 
Fe-Lp 54±6 14±2 
Cisplatin 8±3 4±2 
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Figure 4.14 Schematic illustration of IC50 values from Table 4.5. The data represent mean 
values ± 1SD of three repeats.   
 
The IC50 values of the iron(II) parent cylinder mixed with cisplatin show 
improved cytotoxic activity in both cancer cell lines compared to those of the cylinder 
alone, however there was no synergism of the two components observed. Interestingly, 
in A2780 cell line the IC50 value of the FeLp:cisplatin mixture is comparable to that of 
cisplatin in contrast to SK-OV-3 cells where no such effect was present. Additional 
testing is required to support the obtained results.  
 
 4.4 Conclusions 
The biological evaluation of cytotoxic activity of a series of compounds was 
performed using MTT colorimetric assay. The IC50 values calculated gave preliminary 
information about the antiproliferative activity of the synthesised complexes. 
Modifications in ligand structure as well as variations in metal ions affected biological 
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activity and properties of compounds. The cytotoxic activity of most of the tested 
compounds was comparable to or lower than cisplatin. Only three compounds, 
palladium(II) complex WS-SS-19, cobalt(II) complex [Co2(Lp)3]Cl4 and iron(II) helicate 
[Fe2(L3)3]Cl4, were more toxic than cisplatin in the MDA-MB-231 cancer cell line. The 
[Fe2(L1)3]Cl4 compound with attached cisplatin exhibits antitumour activity in MDA-
MB-231 cells, however the activity arises just from cisplatin itself. It should be noted 
that the results obtained by in vitro testing may not correspond to results obtained by in 
vivo testing, as the environment of the experiments is different and many other factors 
should be taken into account. Additional experiments are required to be performed in 
order to understand cellular uptake and the mechanism of action of the synthesised 
compounds. 
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Chapter 5 
 
Conclusions and future work 
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5.1 Conclusions 
As highlighted in chapter 1, supramolecular chemistry is a powerful tool in the 
creation of fascinating and complex metallo-supramolecular architectures by utilising 
spontaneous self-assembly processes which occur though molecular recognition of the 
structural components.
1, 2
 Simple metal-ligand interactions allow the development of 
synthetic supramolecular assemblies with interesting biological properties that have 
potential to be used as therapeutic agents. 
In chapter 2, the synthesis of novel supramolecular helicates and attempts to 
combine them with cisplatin have been described. Additional metal-binding units were 
introduced onto the surface of the helicates to afford coordination of a cisplatin moiety 
however attempts to attach cisplatin to the helicates were unsuccessful due to instability 
of the synthesised compounds. Remarkably, the introduction of a methyl group in the 
imine position of one of the helicates improved the stability and allowed the formation 
of the complex with cisplatin to be achieved. Nevertheless the main drawback of this 
compound was poor solubility in water and instability at room temperature.  
A fluorescent europium(III) helicate was synthesised as an attractive bioprobe 
however poor yield and insolubility in water were the main drawbacks in performing 
DNA binding studies and other biological experiments therefore they were not pursued 
further.     
In chapter 3, stability tests and DNA binding studies of the synthesised helicates 
were investigated. The UV/Vis stability experiment revealed that most of the 
compounds undergo slow degradation upon standing in water. CD and LD studies 
demonstrated that the helicates bind to DNA inducing alterations in DNA orientation, 
however retaining its B-conformation. The gel experiments have shown that the 
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synthesised helicates do not unwind plasmid DNA however they induce the formation 
of DNA three-way junction structures with the nickel complex being the most effective. 
As DNA three-way junction structures represent the replication fork formed during the 
replication process, compounds that bind to and stabilise these structures can possibly 
affect cellular processes leading to apoptosis. 
In chapter 4, the cytotoxic activity of a series of compounds provided by co-
workers and synthesised helicates described in this work were explored using the MTT 
colorimetric assay. The evaluation of antineoplastic activity revealed that most of the 
compounds were active in cancer cell lines but less active than cisplatin. Only three 
compounds, the palladium(II) complex provided by Philipp von Grebbe from Professor 
Bernhard Lippert group, cobalt complex [Co2(Lp)3]Cl4 and the synthesised iron(II) 
helicate [Fe2(L3)3]Cl4, were more cytotoxic in the MDA-MB-231 cell line than cisplatin. 
When combined supramolecular cylinder and cisplatin in one molecule the cytotoxic 
effect seemed to be just from cisplatin as the cylinder modification had turned off its 
activity. Interestingly, tests with cisplatin simply mixed with cylinder showed some 
activity enhancement in both cancer cell lines compared to that of cylinder alone, 
however there was no synergism of the two components observed. 
 
5.2 Future work 
In this work the synthesis of novel supramolecular helicates was described. The 
structural similarity with parent complex was retained whilst additional metal binding 
units were employed onto the ligand structure to afford additional coordinative binding. 
Upon binding of the anticancer agent to the helicates they fell apart. The instability 
problems could be overcome by synthesising analogous ruthenium complexes. 
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Ruthenium compounds are known to be much more stable and inert than their iron 
counterparts. The stability of the helicates can be partially improved by introducing 
alkyl substituents in the imine position of the ligand which are known to induce the 
positive inductive effect and stabilise the molecule. This explains, for instance, the 
relative stability of the synthesised [Fe2(L1)3]Cl4 complex alone as well as with attached 
cisplatin. 
An interesting approach would be the synthesis of an iron or ruthenium helicate 
based on 4-(1H-imidazol-1-yl)-2-pyridinecarboxaldehyde as a potent antineoplastic 
activity was found for its derivatives.
3
 The attempts to synthesise this complex through 
a multiple-step procedure have already been made however they were unsuccessful. An 
alternative two-step synthesis could be performed (Scheme 5.0). 
 
 
 
 
 
 
 
 
 
Scheme 5.0 Proposed synthesis of 4-(1H-imidazol-1-yl)-2-pyridinecarboxaldehyde based 
helicate. 
 
4-(1H-imidazol-1-yl)-2-pyridinecarboxylic acid can be reduced to the 
corresponding aldehyde by a reported procedure using lithium tri(tert-butoxy)aluminum 
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hydride.
3
 The obtained aldehyde can then be reacted with 4,4’-methylene dianiline to 
form the ligand. 
The poor water solubility of some of the synthesised compounds limits their 
application. In order to overcome this negative effect, the structure of the molecule 
could be modified by reducing lipophilicity or introducing solubilising moieties which 
are polar functional groups such as alcohol, sulfonic acid, phosphate groups, amine, 
carboxylic acids, etc. These groups are capable of increasing solubility of a compound 
by interacting with water molecules by means of the hydrogen bonds.
4
 
In chapter 4, the activity of the synthesised complexes was assessed in various 
cancer cell lines by the MTT assay. Additional testing can be performed to measure 
cellular uptake of the compounds. The cellular uptake of non-luminescent complexes is 
measured by inductively coupled plasma mass spectrometry (ICP-MS) and atomic 
absorption spectroscopy (AAS).
5
  Flow cytometry
6
 and confocal microscopy
7
 could be 
employed to measure the cellular uptake of luminescent compounds. Comet assay can 
be used for the measurement of DNA damage caused by active radical species produced 
by some of the complexes.
8
 Further studies are required to understand the mechanism of 
action and difference in activity of the synthesised compounds in various cancer cell 
lines. 
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6.1 General 
 
All chemicals and reagents were purchased from Sigma-Aldrich, Fisher Scientific, 
Fluorochem, Appollo Scientific, Alfa Aesar, Fluka and were used without further 
purification. All reactions were performed under an atmosphere of nitrogen unless 
otherwise stated. 
1
H NMR spectra were obtained by using ACIII-300, AVIII-400, and 
DRX 500 Bruker spectrometers. The spectra were recorded in deuterated solvents 
purchased from Goss Scientific and analysed by MestReNova software. The 
experiments on recording 
1
H NMR experiments at variable temperatures were 
performed by Dr. Neil Spencer. Electrospray Ionisation (ESI) analyses were performed 
by Mr. Peter Ashton and Mr. Nick May on a Micromass LCT Time of Flight Mass 
Spectrometer in a positive and negative ionisation mode. Matrix-Assisted Laser 
Desorption Ionization (MALDI) data were recorded using a Bruker Bi-flex MALDI 
Time of Flight mass spectrometer. Elemental analyses were performed on a CE 
Instruments EA1110 elemental analyser by Mrs. Lianne Hill. X-ray crystal structure 
data were obtained by the National Crystallography Service in Southampton using 
Bruker-Nonius KappaCCD diffractometers and analysed by Dr. Louise Male at the 
University of Birmingham. UV/Visible spectra were recorded on a Cary 5000 Varian 
spectrophotometer using 1 cm quartz cuvettes. IR spectra were obtained using a Perkin 
Elmer Spectrum 100 FT-IR Spectrometer. High-pressure liquid chromatography 
(HPLC) was carried out with an assistance of Mr. Graham Burns on a Dionex Summit 
HPLC system with a Summit P580P high pressure binary gradient pump and a Summit 
UVD 170s UV/VIS Multi-Channel Detector with Prep flow cell.  Fluorescence 
experiments were conducted on a FS920 steady state fluorimeter with a Xe lamp 
(Xe900) and F900 software with the assistance of Doctor Dave Lewis. 
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6.2 Synthesis of L1
1
 
 
 
To a stirred solution of acetylpyrazine (90 mg, 0.74 mmol) in methanol (10 mL), 4,4’-
methylenedianiline (70 mg, 0.37 mmol) and a few drops of acetic acid was added. The 
reaction was heated to reflux for 3 hours, cooled and the solvent reduced in vacuo to 
yield a yellow oil. The NMR spectrum revealed that the resulting mixture contained the 
desired product which was contaminated with unreacted starting materials and half-
ligand. Attempts to purify the ligand by column chromatography failed. Therefore a one 
pot direct synthesis of the complex was carried out without isolation of the pure ligand. 
1
H NMR (300 MHz, CD3CN, 298 K): δ = 9.67 (d, 2H, J = 1.1 Hz, H3), 8.78 (s, 2H, 
H5/6), 8.77 (s, 2H, H5/6), 7.39 - 7.35 (m, 8H, H11, H12), 4.07 (s, 2H, H14), 2.46 (s, 6H, 
H8). 
Mass Spectrum (ESI): m/z = 429 [C25H22N6 + Na]
+
 
 
6.2.1 Synthesis of [Fe2(L1)3](PF6)4
1 
To a stirred solution of acetylpyrazine (90 mg, 0.74 mmol) in methanol (20 mL), a 
methanolic solution (3 mL) of 4,4’-methylenedianiline (73 mg, 0.37 mmol) and a few 
drops of acetic acid was added. The reaction was heated under reflux for 3 hours. 
Iron(II) chloride tetrahydrate (50 mg, 0.25 mmol) was added and the reaction mixture 
was maintained at the same temperature for 1h. The resulting purple solution was 
cooled down, concentrated in vacuo and placed in H-tubes with a saturated methanolic 
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solution of ammonium hexafluorophosphate for crystal growth. After 5 days dark 
purple crystals were collected, washed with methanol and dried in vacuo (52 mg, 29 %). 
1
H NMR (300 MHz, CD3CN, 298 K): δ = 9.66 (s, 2H, H3), 8.80 (d, 2H, J = 2.6 Hz, 
H5/6), 7.38 - 7.35 (m, 4H, H5/6, H11/12), 6.75 (d, 2H, J = 7.7 Hz, H11/12), 5.56 (d, 2H, J = 
7.7 Hz, H11/12), 4.64 (d, 2H, J = 7.7 Hz, H11/12), 4.02 (s, 2H, H14), 2.45 (s, 6H, H8). 
Mass Spectrum (ESI): m/z = 332 [Fe2(C25H22N6)3]
4+ 
Elemental analysis calculated (%) for [Fe2(C25H22N6)3](PF6)4•H2O; C, 46.7; H, 3.5; N, 
13.1. Found: C, 46.2; H, 3.4; N, 13.2. 
IR: 3648 (br), 1590 (w), 1504 (w), 1466 (w), 1412 (w), 1339 (w), 1381 (w), 1223 (w), 
1175 (w), 819 (s), 786 (m), 760 (m), 741 (m), 555 (s) cm
-1
.  
UV/Vis (CH3CN), λ (ε/mol
-1
dm
3
cm
-1
): 227 (97500), 278 (65600), 570 (16500) nm. 
 
6.2.2 Combining [Fe2(L1)3](PF6)4 with cisplatin. 
 
 
     
 
                                                                                                                                                                                                                                                                                                                                                                     
To a solution of cis-diamminedichloroplatinum(II) (10 mg, 0.033 mmol) in DMF         
(1 mL) a solution of silver nitrate (5.4 mg, 0.032 mmol) in DMF (1 mL) was added. The 
mixture was stirred overnight at room temperature with light exclusion. The white 
precipitate of silver chloride that had formed was removed by filtration through celite. 
The filtrate was cooled to -18 C using propan-2-ol/dry ice bath. [Fe2(L1)3](PF6)4 
complex (11 mg, 0.005 mmol) in DMF (2 mL) was added dropwise over a period of 10 
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min. The reaction was stirred for 3 hours at -18 C and then 1 hour at room temperature. 
The solvent was removed under reduced pressure and the residue was washed with 
methanol, acetonitrile and ether and dried in vacuo to yield the desired complex as a 
blue solid (17 mg, 79 %). 
1
H NMR (300 MHz, d6-DMF, 298 K): δ = 10.12 (s, 2H, H3), 9.23 (t, 2H, J = 3.9 Hz, 
H5/6), 8.25 (d, 2H, J = 3.9 Hz, H5/6), 7.59 (d, 2H, J = 7.7 Hz, H11/12), 6.85 (d, 2H, J = 7.7 
Hz, H11/12), 6.12 (d, 2H, J = 7.7 Hz, H11/12), 5.35 (s, 6H, NH3), 4.97 (s, 6H, NH3), 4.78 
(d, 2H, J = 7.7 Hz, H11/12), 4.13 (s, 2H, H14), 2.94 (s, 6H, H8). 
Elemental analysis calculated (%) for [Fe2(C25H22N6(Pt2Cl2(NH3)4))3](PF6)4(NO3)6: C, 
23.3; H, 2.7; N, 13.0. Found: C, 23.5; H, 2.8; N, 13.0. 
IR: 3210 (br), 3107 (br), 1658 (w), 1599 (w), 1503 (m), 1324 (br), 1221 (w), 1187 (w), 
1112 (w), 1080 (w), 1039 (w), 827 (s), 789 (m), 740 (w), 674 (w), 695 (w), 556 (s) cm
-1
.  
UV/Vis (DMF), λ (ε/mol-1dm3cm-1): 344 (35900), 599 (9400), 695 (6800) nm. 
 
 
6.2.3 Synthesis of cis-bis(dimethylsulphoxide)dichloroplatinum(II)
2 
 
Potassium tetrachloroplatinate(II) (285 mg, 0.70 mmol) was dissolved in water (3 mL). 
To the resulting red aqueous solution dimethylsulfoxide (167 mg, 2.1 mmol) was then 
added.  The mixture was left standing overnight at room temperature to form yellow 
crystals. The crystalline solid was filtered off, washed with ice cold water, ethanol and 
diethyl ether and dried in vacuo (214 mg, 74 %). 
1
H NMR (CDCl3, 300 MHz, 298 K): δ = 3.56 (s, 12H, CH3). 
Elemental analysis calculated (%) for C4H12PtCl2S2O2: C, 11.4; H, 2.9. Found: C, 11.7; 
H, 2.7. 
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IR: 3037 (w), 3010 (m), 2917 (m), 1399 (m), 1314(m) 1299(m), 1153 (s), 1130 (s), 
1016(s), 981 (m), 941 (m), 736 (m), 765 (w), 689 (m) cm
-1
. 
 
6.2.4 Combining [Fe2(L1)3]Cl4 with cis-bis(dimethylsulphoxide)dichloro-
platinum(II). 
 
 
 
 
 
 
Before performing the experiment the [Fe2(L1)3](PF6)4 complex was converted to 
[Fe2(L1)3]Cl4 using chloride form of Dowex 1x8 ion exchange resin. To a suspension of 
cis-bis(dimethylsulphoxide)dichloroplatinum(II) (43 mg, 0.10 mmol) in methanol (5 
mL), a solution of  [Fe2(L1)3]Cl4 (25 mg, 0.021 mmol)  in methanol (3 mL) was added 
dropwise over a period of 10 minutes and the mixture was stirred at room temperature 
for 24 hours. The resulting violet precipitate was collected by filtration and washed with 
methanol and ether and dried in vacuo (47 mg, 78 %).   
1
H NMR (CH3CN, 300 MHz, 298 K): δ = 9.72 (s, 2H, H3), 8.90 (d, 2H, J = 3.1 Hz, 
H5/6), 7.44 (m, 4H, H5/6, H11/12), 6.79 (dd, 2H, J = 8.2, 2.3 Hz, H11/12), 5.61 (dd, 2H, J = 
8.2, 2.3 Hz, H11/12), 4.68 (dd, 2H, J = 8.2, 2.3 Hz, H11/12), 4.07 (s, 2H, H14), 3.30 (d, 
12H, J = 5.4 Hz, CH3 (DMSO)), 2.52 (d, 6H, J = 4.5 Hz, H8). 
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 IR: 3503 (br), 3005 (w), 2917 (w), 1592 (m), 1502 (m), 1465 (m), 1411 (m), 1376 (m), 
1337 (m), 1302 (m), 1221 (m), 1186 (m), 1128 (s), 1020 (s), 921 (w), 838 (m), 787 (m), 
733 (w) cm
-1
.  
 
6.3 Synthesis of L2 
 
 
To a solution of quinoxaline-2-carboxaldehyde (100 mg, 0.58 mmol) in methanol (10 
mL), 4,4’-methylendianiline (58 mg, 0.29 mmol) in methanol (2 mL) was added 
dropwise and the reaction mixture was stirred at room temperature overnight. The 
yellow precipitate that had formed was filtered off, washed with methanol and dried in 
vacuo (76 mg, 55 %). 
1
H NMR (CDCl3, 300 MHz, 298 K) δ = 9.75 (s, 2H, H3), 8.83 (s, 2H, H11), 8.21 – 8.11 
(m, 4H, H6, H9), 7.87 – 7.79 (m, 4H, H7, H8), 7.40 – 7.30 (m, 8H, H14, H15), 4.13 (s, 2H, 
H17). 
13
C NMR (CDCl3, 400 MHz, 298 K): δ = 158.1 (2C11), 148.9 (2C2), 148.4 (2C13), 144.1 
(2C3), 142.9 (2C5/10), 141.9 (2C5/10), 140.6 (2C16), 130.9 (2C7), 130.4 (2C8), 129.9 
(4C14/15), 129.6 (2C6), 129.4 (2C9), 121.6 (4C14/15), 41.2 (2C17). 
Melting point: 243 – 245 °C 
Mass spectrum (ESI): m/z = 501 [C31H22N6  +  Na]
+
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Elemental analysis calculated (%) for C31H22N6: C, 77.8; H, 4.6; N, 17.6. Found: C, 
77.5; H, 4.6; N, 17.6. 
IR: 3023 (br), 1623 (w), 1552 (w), 1492 (m), 1464 (w), 1415 (w), 1369 (w), 1319 (w), 
1201 (m), 1113 (m), 1126 (m), 1012 (m), 976 (m), 960 (m),  898 (m), 860 (m), 845 (m), 
818 (m), 761 (s), 638 (w), 603 (m) cm
-1
. 
 
6.3.1 Synthesis of {[Ag(C31H22N6)](PF6)}n 
Ligand L2 (50 mg, 0.10 mmol) and silver acetate (17 mg, 0.10 mmol) were refluxed in 
methanol (10 mL) for 3 hours with light exclusion. The resulting yellow solution was 
filtered and the filtrate treated with a saturated solution of ammonium 
hexafluorophosphate. The yellow precipitate that had formed was collected by filtration, 
washed with methanol and diethyl ether and dried in vacuo (49 mg, 66 %). 
1
H NMR (300 MHz, d6-DMF, 298 K): δ = 9.80 (s, 2H, H3), 9.79 (s, 2H, H11),  8.34 (d, 
2H, J = 8.5 Hz, H6), 8.19 (d, 2H, J = 8.5 Hz, H9), 8.07 (H7 signal is evident in the edge 
of the solvent peak), 7.86 (t, 2H, J = 7.5 Hz, H8), 7.78 (d, 4H, J = 8.2 Hz, H14/15),  7.43 
(d, 4H, J = 8.2 Hz, H14/15) 4.07 (s, 2H, H17). 
Mass Spectrum (ESI): m/z = 1317 [[Ag2(C31H22N6)2](PF6)]
+
, 586 [Ag2(C31H22N6)2]
2+
. 
Elemental analysis calculated (%) for {[Ag(C31H22N6)](PF6)}n: C, 50.9; H, 3.0; N, 
11.5. Found: C, 50.8; H, 2.9; N, 11.4. 
IR: 3655 (br), 1590 (w), 1495 (w), 1370 (w), 1344(w), 1214 (w), 1128 (m), 1024 (w), 
940 (w), 874 (w), 829 (s), 775 (m), 760 (m), 625 (w), 610 (w), 556 (s) cm
-1
.    
UV/Vis (DMF), λ (ε/mol-1dm3cm-1): 354 (55800) nm. 
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6.3.2 Synthesis of [Cu2(L2)2](PF6)2 
To a stirred solution of the ligand L2 (50 mg, 0.10 mmol) in methanol (10 mL) 
[Cu(MeCN)4](PF6) (39 mg, 0.10 mmol) was added to give a dark brown solution . The 
reaction mixture was heated under reflux overnight and then cooled to room 
temperature. The brown precipitate that had formed was filtered off, washed with 
methanol and ether and dried in vacuo (38 mg, 54 %). 
1
H NMR (CD3CN, 300 MHz, 298 K): δ = 9.64 (s, 2H, 2H11), 9.60 (s, 2H, H3), 8.27 (d, 
2H, J = 8.4 Hz, H6), 7.93 (t, 2H, J = 7.6 Hz, H7), 7.78 (br s, 2H, H9), 7.65 (br t, 2H, J = 
8.0 Hz, H8), 7.49 (d, 4H, J = 8.2 Hz, H14/15), 7.24 (d, 4H, J = 8.2 Hz, H14/15), 3.89 (s, 2H, 
H17). 
Mass Spectrum (ESI): m/z = 542 [Cu2(C31H22N6)2]
2+
 
Elemental analysis calculated (%) for [Cu2(C31H22N6)2](PF6)2: C, 54.2; H, 3.2; N, 12.2. 
Found:  C, 54.4; H, 3.6; N, 11.7. 
IR: 3649 (w), 3034 (w), 1606 (w), 1572 (w), 1518 (m), 1489 (m), 1463 (w), 1421 (w), 
1367 (m), 1340 (m), 1173 (w), 1214 (m), 1129 (m), 1028 (m), 944 (m), 831 (s), 759 (s) 
cm
-1
. 
UV/Vis (CH3CN), λ (ε/mol
-1
dm
3
cm
-1
): 250 (80500), 349 (56500), 577 (2200) nm. 
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6.4 Ligand L3 
6.4.1 Synthesis of 2-methyl-4,4’-bipyridine3, 4 
 
 
4,4’-bipyridine (15.6 g, 100 mmol) was dissolved in a solution of 98 % sulfuric acid (5 
mL) in water (70 mL). Subsequently, acetic acid (30 g, 483 mmol) and a solution of 
silver nitrate (1.70 g, 10 mmol) in water (20 mL) were added to the solution of 
bipyridine. The resulting mixture was heated to 110 C and maintained at that 
temperature for 30 min. At this point ammonium persulfate (22.8 g, 100 mmol) was 
added portionwise. When the vigorous evolution of carbon dioxide had finished, the 
solution was heated at reflux for 30 min, allowed to cool, and made alkaline to a pH 
value of about 8 by the addition of ammonia. The reaction products were extracted with 
diethyl ether (6 x 150 mL). The combined extracts were dried over MgSO4 and 
evaporated in vacuo, to yield a yellow solid. The crude yellow solid was purified by a 
Dionex Summit HPLC system using a Phenomenex C18 column (250 mm x 30 mm) 
packed with Luna 10 μm using water-methanol (60:40) as an eluent. The desired 
product was obtained as an off white solid (2.8 g, 17 %). 
1
H NMR (CDCl3, 300 MHz, 298 K): δ = 8.60 – 8.73 (m, 6H, H6, H2’, H6’), 7.52 – 7.32 
(m, 8H, H3, H3’, H5, H5’), 2.65 (s, 3H, CH3). 
13
C NMR (CDCl3, 400 MHz, 298 K): δ = 159.5 (C2), 150.5 (C2’, C6’), 150.0 (C6), 145.8 
(C4, C4’), 121.4 (C3’, C5’), 120.9 (C5), 118.5 (C3). 
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Melting point: 89 – 92 °C (lit.4 92 - 93 °C). 
Mass Spectrum (EI): m/z = 170 [C11H10N2]
+ 
Elemental analysis calculated (%) for C11 H10N2: C, 77.6; H, 5.9; N, 16.5. Found: C, 
77.6; H, 5.8; N, 16.6. 
IR: 3398 (br), 3030 (m), 2920 (w), 1944 (w), 1593 (s), 1537 (m), 1474 (m), 1447 (w) 
1394 ( m), 1293 (m) , 1218 (m), 1080 (w), 1065 (w), 987 (m), 860 (m), 815 (s), 750 
(w), 739 (w), 666 (w), 618 (s), 601 (m), 552 (m) cm
-1
.  
 
6.4.2 Synthesis of (Z)-2-methyl-(N-dimethylaminovinyl)-[4,4’]-bipyridine 
 
 
  
 
 
 
To a stirred solution of 2-methyl-4,4’-bipyridine (1g, 5.9 mmol, 1 equiv.) in DMF (10 
mL), tert-butoxybis(diethylamino)methane (3 mL, 14.8 mmol, 2.5 equiv.) was added. 
The reaction mixture was heated to 140 C and maintained at that temperature for 18 h. 
On cooling to room temperature the orange-brownish solution was hydrolyzed with 
water (20 mL) and extracted with dichloromethane (5 × 20 mL). The organic layers 
were collected and dried over MgSO4 and the solvent was removed under reduced 
pressure. The resulting orange solid was recrystallized from dichloromethane-pentane to 
give the desired product as an orange crystalline material (Yield: 0.37 g, 28 %).  
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1
H NMR (CDCl3, 300 MHz, 298 K): δ = 8.69 (dd, 2H, J = 4.5, 1.7 Hz, H2’, H6’), 8.41 
(d, 1H, J = 5.2 Hz, H6), 7.56 (d, 1H, J = 13.2 Hz, Hb), 7.51 (dd, 2H, J = 4.5, 1.7 Hz, H3’, 
H5’), 7.09 (dd, J = 1.7, 0.8 Hz, H3), 7.01 (dd, 1H, J = 5.2, 1.7 Hz, H5), 5.23 (d, 1H, J = 
13.2 Hz, Ha), 2.92 (s, 6H, CH3). 
13
C NMR (CDCl3, 400 MHz, 298 K): δ = 159.8 (C2), 150.3 (C2’, C6’), 149.7 (C6), 146.7 
(C4/4’), 145.4 (C4/4’), 144.4 (Cb), 121.4 (C5’, C3’), 116.6 (C3), 115.1 (C5), 95.7 (Ca), 40.6 
(2CH3). 
Melting point: 122 – 126 °C 
Mass Spectrum (EI): m/z = 226 [C14H15N3 + H]
+
 
Elemental analysis calculated (%) for C14H15N3: C, 74.6; H, 6.7; N, 18.6. Found:  C, 
74.5; H, 6.5; N, 18.4.  
IR: 3077 (w), 2913 (w), 2804 (w), 1625 (m), 1579 (s), 1524 (s), 1501 (m), 1467 (m), 
1423 (s), 1405 (m), 1361 (s), 1290 (m), 1215 (m), 1183 (m), 1102 (m), 1066 (m), 985 
(m),  960 (m),  878 (m), 861 (m),  829 (s), 795 (s), 778 (m), 671 (m), 638 (m), 611 (m) 
cm
-1
.  
 
6.4.3 Synthesis of 2-formyl-[4,4’]-bipyridine5 
 
 
 
 
 
 
(Z)-2-methyl-(N-dimethylaminovinyl)-[4,4’]-bipyridine (100 mg, 0.44 mmol) and an  
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aqueous solution of sodium periodate (0.34 g, 1.6 mmol) were stirred in THF (60 mL) 
at 40C for 18h. After cooling to room temperature, the solvent was removed under 
reduced pressure. The residue was dissolved in DCM (20 mL), washed with water (2 × 
30 mL), dried (MgSO4) and the solvent was removed in vacuo. Purification by column 
chromatography using silica and a mixture of DCM-Methanol (97:3) as an eluent gave 
the desired aldehyde as a white solid (54 mg, 66 %). 
1
H NMR (CDCl3, 300 MHz, 298 K): δ = 10.17 (s, 1H, CHO), 8.92 (dd, 1H, J = 5.0, 0.8 
Hz, H6), 8.79 (dd, 2H, J = 4.5, 1.7 Hz, H2’, H6’), 8.23 (dd, 1H, J = 1.9, 0.8 Hz, H3), 7.78 
(dd, 1H, J = 5.0, 1.9 Hz, H5), 7.60 (dd, 2H, J = 4.5, 1.7 Hz, H3’, H5’). 
13
C NMR (CDCl3, 400 MHz, 298 K): δ = 193.0 (CHO), 153.7 (C2), 151.1 (C6), 150.9 
(C2’, C6’), 146. 9 (C4/4’), 144.4 (C4/4’), 125.3 (H5), 121.3 (C3’, C5’), 119.2 (C3). 
Mass Spectrum (EI): m/z = 184 [C11H8N2O]
+
 
Elemental analysis calculated (%) for C11H8N2O·0.4H2O: C, 69.0; H, 4.6; N, 14.6. 
Found: C, 69.1; H, 4.6; N, 14.1. 
IR: 3042 (br), 2922 (w), 2858 (m), 1964 (w), 1708 (s), 1591(m), 1536 (m), 1473 (w), 
1408 (m), 1375 (w), 1311(w), 1227 (w), 1197 (m), 1058 (w), 990 (m), 904 (m), 872 
(w), 819 (s), 740 (m), 670 (m), 661 (m), 598 (m), 611 (s) cm
-1
. 
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6.4.4 Synthesis of L3   
 
 
 
 
 
 
To a stirred solution of 2-formyl-[4,4’]-bipyridine (27 mg, 0.15 mmol) in ethanol (2 
mL) at room temperature, an ethanolic solution of 4,4’-methylendianiline (14.5 mg, 
0.73 mmol) was added dropwise. The reaction mixture was stirred for 24 hours at room 
temperature and the resultant yellow precipitate was collected by filtration, washed with 
cold ethanol and diethyl ether and dried in vacuo (26 mg, 67 %).   
1
H NMR (CDCl3, 300 MHz, 298 K): δ = 8.84 (dd, 2H, J = 5.1, 0.8 Hz, H6), 8.80 (dd, 
4H, J = 4.5, 1.7 Hz, H2’, H6’), 8.72 (s, 2H, H7), 8.51 (dd, 2H, J = 1.8, 0.8 Hz, H3), 7.67 
(dd, 4H, J = 4.5, 1.7 Hz, H3’, H5’), 7.64 (dd, 2H, J = 5.1, 1.8 Hz, H5), 7.32 (H10, H11 
signals are evident in the edge of the solvent peak), 4.09 (s, 2H, H13). 
13
C NMR (CDCl3, 400 MHz, 298 K): δ = 159.6 (2C7), 155.7 (2C2), 150.8 (2C2’, 2C6’), 
150.5 (2C6), 148.8 (2C9), 146.4 (2C4/4’), 146.2 (2C4/4’), 140.0 (2C12), 129.9 (4C10/11), 
122.6 (2C5), 121.5 (4C10/11, 2C3’, 2C5’), 119.3 (2C3), 41.1 (C13). 
Melting point: 143 – 145 °C 
Mass Spectrum (EI): m/z = 553 [C35H26N6 + Na]
+
 
IR: 3343 (br), 3221 (br), 1668 (w), 1626 (w), 1590 (m), 1536 (m), 1502 (m), 1473(m), 
1404 (m), 1352 (w), 1193 (w), 1072 (m), 992 (m), 929 (w), 851 (m), 817 (s), 779 (w),   
736 (w), 655 (w), 616 (s), 582 (w) cm
-1
. 
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6.4.4.1 Synthesis of [Fe2(L3)3](PF6)4 
To a stirred solution of L3 (21 mg, 0.0395 mmol) in methanol (1 mL), a methanolic 
solution of iron(II) chloride tetrahydrate (5.3 mg, 0.027 mmol) was added dropwise to 
give a dark violet solution. The mixture was stirred for 3 hours at room temperature and 
then treated with a saturated solution of ammonium hexafluoropfosphate to form a 
violet precipitate. The violet solid was collected by vacuum filtration, washed with 
methanol and diethyl ether and dried in vacuo (23 mg, 75 %). 
1
H NMR (CD3CN, 300 MHz, 298 K): δ = 8.95 (br s, 2H, H7), 8.92 (br s, 6H, H6, H2’, 
H6’), 8.07 (br d, 2H, J =  4.2 Hz, H5) 7.92 ( br s, 4H, H3’, H5’), 7.53 ( br d, 2H, J = 3.9 
Hz, H3), 7.01 (br s, 4H, H10/11), 5.63 (br s, 4H, H10/11), 4.07 (br s, 2H, H13). 
Mass Spectrum (EI): m/z = 426 [Fe2(C35H26N6)3]
4+
 
Elemental analysis calculated (%) for [Fe2(C35H26N6)3](PF6)4•2H2O: C, 54.4; H, 3.6; 
N, 10.5. Found: C, 54.1; H, 3.6; N, 10.9. 
IR: 3365 (br), 3035 (br), 1595 (m), 1502 (m), 1471 (m), 1409 (m), 1303 (w), 1203 (w), 
1246 (w), 1110 (br), 1072 (w), 1017 (m), 815 (s), 745 (w) cm
-1
.    
UV/Vis (CH3CN), λ (ε/mol
-1
dm
3
cm
-1
): 241sh (108600), 287sh (41700), 586sh (15100) 
nm. 
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6.5 Ligand L4 
6.5.1 Synthesis of 1-pyridine-2-ylmethyl-1H-Imidazole carboxaldehyde
6, 7 
 
 
 
 
 
 
To a stirred solution of 2-imidazolecarboxaldehyde (0.55 g, 5.67 mmol) and 2-
(bromomethyl)pyridine hydrobromide (1.58 g, 6.24 mmol) in DMF (20 mL), N,N – 
diisopropylethylamine (3.0 mL, 17.01 mmol) was added. The reaction mixture was 
heated at 80 ºC overnight. After cooling to room temperature, the reaction was 
quenched with a saturated aqueous solution of NaHCO3 (20 mL) and extracted with 
DCM (4 x 20 mL). The combined organic layers were washed with brine (30 mL), dried 
(MgSO4), filtered, and concentrated under reduced pressure to afford brown oil. The 
crude mixture was purified by a Dionex Summit HPLC system using a Phenomenex C18 
column (250 mm x 21.2 mm) packed with Luna 10 μm on a solvent gradient starting 
from 100 % water to 33 % of acetonitrile over 30 minutes to give the desired product as 
a yellow powder (0.13 g,  14 %).   
1
H NMR (CDCl3, 300 MHz, 298 K):  δ = 9.82 (d, 1H, J = 0.9 Hz, CHO), 8.55 (ddd, 1H, 
J = 4.8, 1.7, 0.9 Hz, H11), 7.66 (td, 1H, J = 7.7, 1.8 Hz, H9), 7.37 (br s, 1H, H4/5), 7.32 
(1H, d, J = 0.9 Hz, H4/5), 7.19 - 7.25 (m, 2H, H10, H8), 5.71 (s, 2H, H6). 
13
C NMR (CDCl3, 400 MHz, 298 K): δ = 180.3 (CHO), 153.3 (C7), 147.8 (C11), 141.2 
(C2), 135.3 (C9), 130.0 (C4/5), 125.2 (C4/5), 121.3 (C10), 120.4 (C8), 50.4 (C6). 
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Mass Spectrum (EI): m/z = 187 [C10H9N3O]
+ 
Melting point: 52 – 54 °C 
Elemental analysis calculated (%) for C10H9N3O: C, 64.2; H, 4.8; N, 22.0. Found: C, 
64.1; H, 4.7; N, 22.0. 
IR:  3103 (w), 2844 (w), 1672 (s), 1586 (m), 1569 (m), 1472 (m), 1412 (s), 1336 (m), 
1303 (m), 1253 (m), 1287 (m), 1148 (m), 994 (m), 916 (m), 803 (m), 771 (s), 758 (s), 
724 (m),  688 (m), 596 (m) cm
-1
. 
 
6.5.2 Synthesis of L4 
 
 
 
An ethanolic solution of 4,4’-methylendianiline (15.4 mg, 0.077 mmol) was added 
dropwise to a solution of imidazole-2-carbaxaldehyde (29 mg, 0.155 mmol) in ethanol 
(5 mL). The reaction mixture was stirred at room temperature overnight. The off-white 
precipitate that had formed was collected by filtration, washed with cold ethanol and 
ether and dried in vacuo (25 mg, 59 %). 
1
H NMR (CDCl3, 300 MHz, 298 K): δ = 8.60 (ddd, 2H, J = 4.8, 1.7, 0.9 Hz, H11), 8.57 
(s, 2H, H13), 7.62 (td, 2H, J = 7.7, 1.8 Hz, H9), 7.29 (H4/5 signal is evident on the edge of 
the solvent peak), 7.25 (br s, 2H, H4/5), 7.23 - 7.19 (m, 6H, H10, H16/17), 7.14 – 7.03 (m, 
6H, H8, H16/17), 5.99 (s, 4H, H6), 4.00 (s, 2H, H19).  
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13
C NMR (CDCl3, 400 MHz, 298 K): δ = 156.8 (2C7), 150.5 (2C11), 149.5 (2C13), 148.8 
(2C2), 143.2 (2C15), 139.6 (2C18), 136.9 (2C9), 130.7 (2C4/5), 129.7 (4C16/17), 125.2 
(2C4/5), 122.6 (2C10), 121.8 (2C8), 121.1 (4C16/17), 52.7 (2C6), 41.0 (C19). 
Mass Spectrum (EI): m/z = 559 [C33H28N8 + Na]
+
 
Melting point: 168 – 170 °C 
Elemental analysis calculated (%) for C33H28N8: C, 73.9; H, 5.3; N, 20.9. Found: C, 
73.6; H, 5.7, N, 21.2. 
IR: 3094 (w), 3048 (w), 1625 (m), 1594 (m), 1570 (m), 1502 (m), 1467 (m), 1436 (m),  
1279 (m), 1208 (m), 1106 (m), 1048 (m), 996 9m), 851 (m), 877 (s), 787 (m), 765 (s), 
745 (s), 712 (m), 698 (m), 605 (m) cm
-1
. 
 
6.5.2.1 Synthesis of [Fe2(L4)3](PF6)4 
To a stirred solution of L4 (17 mg, 0.032 mmol) in ethanol (5 mL), an ethanolic solution 
of iron(II) chloride tetrahydrate (4.2 mg, 0.021 mmol) was added dropwise and the 
mixture was stirred at room temperature for 30 minutes. The resulting solution was 
treated with a saturated solution of ammonium hexaphlorophosphate and the purple 
precipitate that formed was collected by filtration, washed with methanol and diethyl 
ether and dried in vacuo (19 mg, 79 %). 
1
H NMR (CD3CN, 300 MHz, 298 K):  δ = 15.19 (s, 2H, H4/5), 13.65 (s, 4H, H4/5, H13), 
8.66 (dd, 2H, J = 2.7, 1.1 Hz, H11), 7.89 (td, 2H, J = 7.2, 1.1 Hz, H9), 7.35 - 7.19 (m, 
4H, H8, H10), 6.93 (br s, 4H, H16/17), 6.57 (br s, 4H, H16/17), 4. 69 (d, 2H, J = 15.4 Hz, 
H6a/b), 3.30 (s, 2H, H19), 3.02 (d, 2H, J = 15.4 Hz, H6a/b). 
Mass Spectrum (EI): m/z = 430 [Fe2(C33H28N8)3]
4+
, 622 [[Fe2(C33H28N8)3](PF6)]
3+
, 
1006 [[Fe2(C33H28N8)3](PF6)2]
2+
. 
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Elemental analysis calculated (%) for [Fe2(C33H28N8)3](PF6)4•3H2O: C, 50.5; H, 3.9; 
N, 14.3. Found: C, 50.6; H, 3.7, N, 13.8.  
IR: 3354 (w), 3124 (w), 3062 (w), 1615 (m), 1594 (m), 1502 (m), 1479 (m), 1438 (s), 
1330 (w), 1288 (m), 1208 (m), 1132 (m), 1016 (w), 967 (m), 899 (m), 819 (m), 752 (s), 
688 (m), 592 (m) cm
-1
.  
UV/Vis (CH3OH), λ (ε/mol
-1
dm
3
cm
-1
): 268 (57600), 295 (79100), 331 (86900), 553 
(2400) nm. 
 
6.5.2.2 Synthesis of [Ni2(L4)3]Cl4 
To a stirred solution of ligand L4 (18 mg, 0.034 mmol) in methanol (5 mL), nickel(II) 
chloride hexahydrate (5.3 mg, 0.022 mmol) in methanol (2 mL) was added and the 
mixture was refluxed overnight. After cooling to room temperature diethyl ether was 
added, the resulting orange precipitate was collected by filtration, washed with diethyl 
ether and dried in vacuo (12 mg, 57 %). 
Mass Spectrum (EI): m/z = 432 [Ni2(C33H28N8)3]
4+
, 588 [[Ni2(C33H28N8)3]Cl]
3+
, 898 
[[Ni2(C33H28N8)3]Cl2]
2+
. 
Elemental analysis calculated (%) for [Ni2(C33H28N8)3]Cl4•8H2O: C, 59.1; H, 5.0; N, 
16.7. Found: C, 59.5; H, 5.0; N, 16.8.    
IR: 3344 (br), 3053 (w), 1592 (m), 1532 (w), 1484 (m), 1437 (s), 1331 (m), 1292 (m), 
1210 (m), 1134 (m), 997 (w), 969 (m), 904 (m), 861 (w), 815 (w), 752 (s) cm
-1
.   
UV/Vis (H2O), λ (ε/mol
-1
dm
3
cm
-1
): 260 (32600), 328 (55600) nm. 
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6.6 Ligand L5 
6.6.1 Synthesis of 2,6-pyridinecarboxylic acid monobenzyl ester
8, 9 
 
 
 
To a stirred solution of ion exchange resin DOWEX 50W-X8 H
+
 20-50 mesh in BnOH 
(120 mL) was 2,6-pyridinedicarboxylic acid (11.5 g, 69 mmol) was added and the 
mixture was heated to 150 Cº for 1.5 hour. The reaction mixture was then cooled; the 
ion exchange resin was filtered off and washed twice with toluene. The filtrate was 
extracted with saturated aqueous NaHCO3 (4 x 400 mL). The aqueous layers were 
combined, acidified with H2SO4 and extracted with DCM (3 x 200 mL). The organic 
layers were combined, washed with brine (400 mL), dried over MgSO4 and evaporated 
in vacuo. The desired product was obtained by recrystallization from AcOEt (100 mL) 
and hexane (500 mL) as a white powder (4.22 g, 24 %).    
1
H NMR (CDCl3, 300 MHz, 298 K): δ = 8.44 – 8.37 (m, 2H, H4, H6), 8.12 (t, 1H, J = 
7.8 Hz, H5), 7.53 - 7.35 (m, 5H, H12, H13, H14), 5.48 (s, 2H, H10).  
13
C NMR (CDCl3, 400MHz, 298K): δ = 163.7 (C3), 163.6 (C8), 146.8 (C2), 146.6 (C7), 
139.6 (C5), 135.0 (C11), 128.9 (C6), 128.8 (2C13, 2C14), 128.6 (C12), 127.0 (C4), 68.1 
(C10).    
Melting point: 130 – 131 °C (lit.8 132 – 133 °C) 
Mass Spectrum (EI): m/z = 256 [C14H11NO4 – H]
+
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Elemental analysis calculated for (%) C14H11NO4: C, 65.4; H, 4.3; N, 5.4. Found: C, 
65.4; H, 4.2; N, 5.6. 
IR: 3064 (w), 2880 (br), 2559 (br), 1736 (s), 1695 (s), 1575 (m), 1467 (w),  1499 (w), 
1467 (m), 1417 (m), 1329 (m), 1289 (m), 1244 (s),  1152 (s), 1084 (m), 994 (m), 958 
(m), 941 (m), 856 (m), 839 (w), 797 (w), 784 (w),  754 (s), 728 (s), 711 (s), 691 (s), 648 
(m), 584 (w), 570 (w) cm
-1
. 
 
6.6.2 Synthesis of 6-(quinoline-6-ylcarbamoyl) picolinate 
 
 
 
To a stirred solution of 6-aminoquinoline (0. 56 g, 3.9 mmol) in 30 mL anhydrous THF, 
HOBt (0.53, 3.9 mmol) and monobenzyl ester (1 g, 3.9 mmol) were added at 0 ºC. After 
stirring for 30 min at 0 ºC, EDCI•HCl (0.79 g, 4.1 mmol) followed by triethylamine 
(0.57 mL, 4.1 mmol) were added and the mixture was stirred for an additional 30 min at 
0 ºC and then at room temperature for 18h. The insoluble material was filtered off and 
the solvent removed under reduced pressure. Purification of the crude mixture by flash 
column chromatography on silica, using 2 % methanol in DCM solution as an eluent, 
gave the desired product as a white solid (0.78 g, 52 %). 
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1
H NMR (CDCl3, 500 MHz, 298 K): δ = 10.31 (s, 1H, NH), 8.87 (dd, 1H, J = 4.1, 1.4 
Hz, H2), 8.60 (d, 1H, J = 2.3 Hz, H6), 8.51 (d, 1H, J = 7.7 Hz, H14), 8.31 (d, 1H, J = 7.7 
Hz, H16), 8.17 (d, J = 8.1 Hz, H4), 8.12 (d, J = 9.0 Hz, H9), 8.08 (t, 1H, J = 7.8 Hz, H15), 
7.85 (dd, 1H, J = 9.0, 2.3 Hz, H8),  7.55 (d, 2H, J = 7.3 Hz, H22), 7.49 - 7.38 (m, 4H, H3, 
H23, H24), 5.52 (s, 2H, H20).   
13
C NMR (CDCl3, 500MHz, 298K): δ = 163.9 (С18), 161.4 (C12), 149.8 (C13), 149.5 
(C2), 146.5 (C17), 145.7 (C10), 138.9 (C15), 135.8 (C4), 135.3 (C7, C21), 130.3 (C9), 128.8 
(C5), 128.7 (2C23), 128.6 (C24), 128.3 (2C22), 127.6 (C16), 125.5 (C14), 123.3 (C8), 121.6 
(C3), 116.2 (C6), 67.7 (C20). 
Melting point: 143 – 145 °C  
Mass Spectrum (EI): m/z = 383 [C23H17N3O3]
+
 
Elemental analysis calculated (%) for C23H17N3O3: C, 72.1; H, 4.5; N, 11.0. Found: C, 
72.1; H, 4.3; N, 10.9. 
IR: 3461 (w), 3220 (br), 1727 (s), 1670 (m), 1627 (w), 1574 (m), 1540 (s), 1498 (m), 
1468 (m), 1448 (m), 1430 (m), 1381 (m), 1364 (m), 1294 (s), 1238 (s), 1221 (m), 1164 
(m), 1143 (m), 1112 (w), 1077 (m), 1032 (w), 1001 (m), 947 (m), 925 (m), 908 (m), 873 
(m), 840 (m), 797 (m), 755 (s), 742 (s), 718 (m), 698 (s), 687 (s), 651 (m), 589 (m) cm
-1
.     
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6.6.3 Synthesis of 6-(quinoline-6-ylcarbamoyl) picolinic acid 
 
 
 
6-(quinoline-6-ylcarbamoyl) picolinate (0.60 g, 1.57 mmol) was stirred in a mixture of 
MeOH/THF (10 mL, 1:1) with 10 % Pd/C catalyst (0.1 equivalent) at room temperature 
under a hydrogen gas atmosphere. The completion of the reaction was followed by 
TLC. The solution was filtered through a pad of celite to remove the catalyst and the 
solvent was evaporated under reduced pressure to give the desired product as a yellow 
solid (0.33 g, 72 %). 
 
1
H NMR (d6-DMSO, 500 MHz, 298 K): δ = 11.7 (s, 1H, NH), 8.84 (dd, 1H, J = 4.1, 
1.5 Hz, H2), 8.56 (d, 1H, J = 2.2 Hz, H5), 8.45 (dd, 1H, J = 7.2, 1.7 Hz, H14), 8.37 - 8.32 
(m, 2H, H4, H16), 8.29 (t, 1H, J = 7.7 Hz, H15), 8.15 (dd, 1H, J = 9.1, 2.3 Hz, H7), 8.07 
(d, 1H, J = 9.1 Hz, H8), 7.52 (dd, 1H, J = 8.3, 4.2 Hz, H3). 
13
C NMR (d6-DMSO, 500 MHz, 298 K): δ = 165.0 (C18), 161.8 (C12), 149.5 (C2), 149.0 
(C13), 146.8 (C17), 145.1 (C9), 140.1 (C15), 135.9 (C6), 135.6 (C4), 129.5 (C8), 128.2 
(C10), 127.1 (C16), 125.6 (C14), 124.2 (C7), 121.9 (C3), 116.9 (C5). 
Melting point: decomposes above 292 °C 
Mass Spectrum (EI): m/z = 293 [C16H11N3O3]
+ 
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Elemental analysis calculated for (%) C16H11N3O3: C, 65.5; H, 3.8; N, 14.3. Found: C, 
65.2; H, 4.0; N, 14.1.  
IR: 3377 (br), 3209 (br), 3051 (br), 1678 (w), 1622 (w), 1594 (m), 1502 (m), 1476 (m), 
1437 (m), 1357 (w), 1287 (w), 1207 (w), 1131 (w), 996 (w), 826 (m), 750 (m) 555 (s) 
cm
-1
.  
 
6.6.4 Synthesis of L5 
 
 
 
 
 
To a stirred solution of 4,4’- diaminodiphenylmethane (93 mg, 0.47 mmol) in THF (15  
mL), 6-(quinoline-6-ylcarbamoyl)picolinic acid (300 mg, 1.0 mmol) was added 
followed by HOBt (133 mg, 0.99 mmol) at 0 °C and the resulting mixture was stirred 
for 15 minutes at the same temperature. EDCI•HCl (189 mg, 0.98 mmol), triethylamine 
(0.14 mL, 0.98 mmol) and DMAP (69 mg, 0.57 mmol) were then added to the reaction 
mixture and the solution was stirred for 18h at room temperature The insoluble material 
was filtered off and the solvent was removed under reduced pressure. The residue was 
purified by flash column chromatography on silica, using 5 % methanol in DCM 
solution as an eluent, to afford L5 as a white powder (140 mg, 37 %). 
1
H NMR (d6-DMSO, 400 MHz, 298 K): δ = 11.34 (s, 2H, H11), 11.09 (s, 2H, H19), 8.86 
(dd, 2H, J = 4.1, 1.5 Hz, H2), 8.68 (d, 2H, J = 2.2 Hz, H5), 8.48 - 8.38 (m, 6H, H4, H14, 
H16), 8.33 (t, 2H, J = 7.7 Hz, H15), 8.23 (dd, 2H, J = 9.1, 2.2 Hz, H7), 8.11 (d, 2H, J = 
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9.1 Hz, H8), 7.80 (d, 4H, J = 8.4 Hz, H21/22), 7.54 (dd, 2H, J = 8.3, 4.2 Hz, H3), 7.36 (d, 
4H, J = 8.4 Hz, H21/22), 4.02 (s, 2H, H24). 
13
C NMR (d6-DMSO, 400 MHz, 298 K): δ = 162.0 (2С12), 161.5 (2C18), 149.5 (2C2), 
149.0 (2C13), 148.6 (2C17), 145.1 (2C9), 140.0 (2C15), 137.5 (2C20), 136.0 (2C6, 2C23), 
135.7 (2C4), 129.4 (2C8), 129.0 (4C21/22), 128.2 (2C10), 125.4 (2C14, 2C16), 125.3 (2C7), 
121.9 (2C3), 121.4 (4C21/22), 117.2 (2C5), 40.1 (C24). 
Melting point: 250 – 252 °C 
Mass Spectrum (EI): m/z = 771 [C45H32N8O4 + MeOH]
+ 
Elemental analysis calculated (%) for C45H32N8O4: C, 72.2; H, 4.3; N, 15.0. Found: C, 
71.7; H, 4.8; N, 14.7.  
IR: 3303 (br), 3229 (br), 1686 (m), 1658 (m), 1587 (m), 1525 (s), 1445 (m), 1409 (m), 
1380 (m), 1322 (m), 1220 (m), 1114 (m), 1128 (m), 1072 (m), 1000 (m), 929 (m), 871 
(m), 829 (m), 719 (m), 677 (m), 649 (m) cm
-1
. 
 
6.6.4.1 Synthesis of [Eu2(L5)3]Cl6 
To a flask containing a solution of CH3OH/CHCl3 (8 mL, 1:1), ligand L5 (26 mg, 0.035 
mmol) and europium(III) chloride hexahydrate (8.5 mg, 0.023 mmol) were added and 
the resulting mixture was heated under reflux for 24 hours. The mixture was cooled 
down to room temperature, and the resulting pale yellow solid was collected by 
filtration, washed with ether and dried in vacuo (7.8 mg, 24 %). 
Elemental analysis calculated (%) for [Eu2(C45H32N8O4)3]Cl6•3CHCl3•H2O: C, 52.9; 
H, 3.2; N, 10.7. Found: C, 52.6; H, 3.5; N, 10.3. 
IR: 3209 (br), 3085 (br), 2618 (br), 1627 (br), 1583 (s), 1554 (m), 1510 (m), 1434 (m), 
1375 (m), 1279 (m), 1110 (br), 1019 (s), 945 (w), 820 (w), 759 (m), 729 (m) cm
-1
.   
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UV/Vis (DMSO), λ (ε/mol-1dm3cm-1): 308 (84700) nm. 
 
6.7 Experimental procedure for DNA binding studies 
All experiments were carried out using ultrapure water (molecular biology reagent). 
Stock solutions of calf thymus DNA (ct-DNA) (10 mg per 20 mL), sodium chloride (40 
μM), and sodium cacodylate (4 μM) were prepared and stored frozen until the day of 
the experiment. Fresh samples containing ct-DNA (300 μM), sodium chloride (20 mM) 
and sodium cacodylate (2 mM) were prepared on the day of the experiment. In order to 
determine the concentration of ct-DNA the absorbance spectrum of the DNA sample 
was recorded. The absorbance at 260 nm, with a known molar extinction coefficient of ε 
= 6600 mol
-1
 dm
3
 cm
-1
, was identified and the concentration of ct-DNA was calculated 
using the Beer-Lambert Law.  
Circular Dichroism (CD) spectra were recorded in 1 cm and 1 mm cuvettes using a 
Jasco J-715 spectropolarimeter.  Titrations of the complex with the solution of ct-DNA 
were carried out at constant concentration of DNA. In order to keep the concentration of 
the DNA constant during the experiment, a stock solution with a double concentration 
of ct-DNA (600 μM) and buffer (NaCl 40 μM and 4 μM sodium cacodylate) was 
prepared. After adding X μL of the metal complex solution to the 300 μM ct-DNA, X 
μL of ct-DNA stock of double concentration (600 μM) was added. The concentration of 
the metal complex was increased during the experiment. By varying the concentration 
of the metal complex, different ratios of DNA base/metal complex with a range from 
60:1 to 4:1 were obtained. 
Linear dichroism (LD) spectra were collected on a Jasco J-715 spectropolarimeter 
adapted for LD measurements. The concentration of ct-DNA for the experiment was 
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determined in a similar way as described above for the CD experiment. Unlike in the 
CD experiment, a flow cuvette cell consisting of two cylinders with an annular gap of 
0.5 mm, giving a 1 mm path length, was used for LD measurements. The speed of the 
cuvette rotation during the spectra measurements was maintained at approximately 1200 
rpm. The DNA concentration was kept constant throughout the experiment. 
 
6.8 Experimental procedure for agarose gel electrophoresis 
Plasmid DNA pBR322 was purchased from Fermentas and kept frozen until the day of 
use. To prepare the gel 2 g of agarose was dissolved in 200 mL of Tris-Acetate EDTA 
(1X) buffer (TAE) by heating in a microwave for a few minutes and then the gel was 
allowed to cool down and set. The plasmid was dissolved in ultrapure water and the 
complex was added to the solution. The total prepared solution of 20 μL contained 2 μL 
of pBR322 (stock concentration was 0.5 μg/μL), 1.03 to 12.83 μL of the complex 
solution (stock concentration was 60 μM) and was made up with water. Compounds that 
were not very soluble in water were dissolved in 1 - 5 % DMSO/water solution. The 
samples were incubated for 1 hour at 37 ºC. After incubation, 4 μL of loading buffer 
containing 30 % glycerol, 0.05 % bromophenol blue and 0.025 % cyanol xylene was 
added to each sample and 18 μL of the prepared solutions was loaded on the agarose 
gel. The gel experiment was performed using an Amersham Biosciences HE99X Maxi 
submarine kit. The gel was run in TAE (1X) buffer at a constant voltage of 120 V (6 
Vcm
-1
) for 180 minutes. After the electrophoresis was finished, the gel was stained with 
ethidium bromide (0.5 mg mL
-1
) for 10 - 15 minutes. The gel was visualized using an 
UVidoc Platinum System (UViDoc, Cambridge, UK) at 312 nm.  
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6.9 Experimental procedure for polyacrylamide gel (PAGE) 
6.9.1 Radioactive labelling 
4.8 μL of ultrapure water, 1 μL of 10x bacteriophage T4 polynucleotide kinase buffer, 
1.2 μL of 100 μM oligonucleotide (S3), 1 μL of bacteriophage T4 polynucleotide kinase 
(purchased from New England Biolab) and 2 μL of γ-32P ATP (6000 Ci/mmol) 
(obtained from Perkin Elmer) were mixed together in an eppendorf and incubated at 37 
ºC for 40 minutes. In order to deactivate the action of polynucleotide kinase the solution 
was then heated to 80 ºC and maintained at that temperature for 3 minutes. A QIAquick 
nucleotide removal kit (QIAGEN) was used to purify the radioactive-labelled DNA 
fragments from unreacted ATP. 10 volumes of PN buffer were added to 1 volume of the 
reaction sample. Then the solution was introduced onto a QIAquick spin column with a 
2 mL collection tube and the mixture was centrifuge for 1 minute at 6000 rpm. The 
flow-through was discarded after centrifugation. The QIAquick spin column was 
introduced into a new collection tube and 500 μL of PE buffer was added. The mixture 
was centrifuged at 6000 rpm and the flow-through was discarded. The addition of      
500 μL PE buffer was repeated.  The column was then centrifuged at 13,000 rpm for 1 
minute to remove the remaining buffer.  The column was placed into an eppendorf and 
30 μL of ultrapure water was added onto the column. The solution was allowed to stand 
for 5 minutes and then was centrifuged at 13,000 rpm for 2 minutes to obtain an 4 μM 
stock solution of radiolabelled DNA. 
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6.9.2 Polyacrylamide gel preparation 
To prepare 15 % native polyacrylamide gel, 100 mL of 10X buffer containing 892 mM 
of tris(hydroxymethy) amino methane and 890 mM of boric acid was mixed with 375 
mL of 40 % acrylamide (29:1) (from Geneflow) and 525 mL of ultra-pure water. The  
15 % native gel was prepared before the experiment and kept at 4 ºC. On the day of the 
experiment 50 mL of 15 % gel was mixed with 250 μL of 10 % (w/v) ammonium 
persulphate and 25 μL of tetramethylenediamine (TEMED) in a 50 mL falcon 
centrifuge tube. The prepared solution was poured onto the set of glass plates and the 
gel was left to polymerise for 30 – 40 minutes. Before use in the experiment, the excess 
residues of the gel were removed and each well of the gel was first washed with water 
and then with a TB running buffer. 
 
 
6.9.3 PAGE electrophoresis experiment 
The oligonucleotide sequences used in the experiments, S1: CGGAACGGCACTCG, 
S2: CGAGTGCAGCGTGG, S3: CCACGCTCGTTCCG, were purchased from Eurofins 
(Germany). 2 μM stock solutions of oligonucleotide strands S1, S2 and S3 were 
prepared. The oligonucleotide sequences were mixed with the complexes in TB buffer 
containing 89 mM tris(hydroxymethy) amino methane, 89 mM boric acid and 1 M 
sodium chloride. The prepared samples were incubated for 1 hour at room temperature 
and then placed on ice for 15 - 20 minutes. 5 μL of 30 % glycerol was added to each 
eppendorf and 13 μL of each sample was loaded onto 15 % polyacrylamide gel. The 
experiment was performed for 4 hours at 120 V using Gel System equipment (Thermo 
Scientific, UK). The gel was exposed on a phosphor imaging plate for 1 - 16 hours 
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depending on how fresh the radioactive ATP was used. The radiogel image was 
obtained from a Molecular imager FX (Bio-Rad). The quantification of the gel was 
carried out using the Quantity One programme. 
 
6.10 Cell Culture  
6.10.1 Materials and Methods 
DMEM and RPMI medium and FBS were obtained from Invitrogen. Antibiotic 
antimycotic solution, L-glutamine, trypsin-EDTA, HEPES buffer ((4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid) solution, sodium pyruvate, MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) and DMSO were obtained 
from Sigma-Aldrich, UK. Tissue culture flasks and 96 well microtiter plates were 
obtained from Appleton Woods, UK. A2780, A2780cisR, MDA-MB-231 and SK-OV-3 
cell lines were purchased from the Health Protection Agency, European collection of 
cell cultures (ECACC). All reagents for cell culture were autoclaved before use. 
Manipulations with cells were carried out in sterile conditions in a class 1 tissue culture 
hood (Aura B4, Bio Air, Italy). 
 
6.10.2 Cell growth conditions 
Different types of media were used for different cell lines. A2780, A2780cisR and SK-
OV-3 ovarian cancer cell lines were grown in Roswell Park Memorial Institute medium 
(RPMI-1640) and the MDA-MB-231 cell line in Dulbecco`s Modified Eagle`s medium 
(DMEM). The media was supplemented with 10 % FBS, 1 % L-glutamine, 1 % HEPES 
buffer, 1 % sodium pyruvate and 1 % antibiotic. Phenol red is added to media as a pH 
indicator. Cells were grown as monolayers in medium and maintained in an incubator 
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(MCO-15AC, Sanyo, Japan) at 37 C° and humidified atmosphere (5 % CO2, 95 % air). 
Cells were refreshed every 2 days and regularly checked for the absence of 
contamination.  
 
6.10.3 Medium preparation 
70 mL of fresh medium was removed from the bottle (500 mL, purchased from 
Initrogen) and discarded. 5 ml of antibiotic antimycotic, 15ml of GSH (5 mL of L-
glutamine, 5 mL of sodium pyruvate, 5 mL of HEPES buffer) and 50 mL of FBS (fetal 
bovine serum) were added to the medium.  
 
6.10.4 Defrosting cells  
Cells were kept in a cryovessel in liquid nitrogen. To defrost the cells they were taken 
out of the cryovessel and warmed up to 37 °C in a water bath. The cells were added to a 
falcon centrifuge tube and resuspended with fresh medium. The cells with medium were 
then placed in flasks (15 mL of cells with medium for 75 cm
2
 flask) and left overnight 
in the incubator to attach to the flask surface. The next day medium was refreshed to 
remove DMSO, which is a component of a freezing medium, and cells were placed in 
the incubator for growing. 
 
6.10.5 Cell passaging 
Medium, Trypsin-EDTA solution and PBS were warmed to 37 ºC in a water bath before 
use. Cells were taken out of the incubator and medium was removed from the flask. 
Cells were washed with 10 mL of PBS solution and then 2.5 mL (for 75 cm
2
 flasks) of 
trypsin-EDTA solution was added. The flask with cells was then placed in the incubator 
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for 3 - 4 minutes. The cells were detached from the flask surface by gently hitting the 
flask with a hand.  The action of trypsin was neutralized by addition of medium 3 times 
volume of trypsin (7.5 mL). The suspension of cells with medium was transferred to a 
50 mL falcon tube and cells were centrifuged at 1000 rpm at 25 ºC for 7 minutes. The 
medium was removed from the tube and discarded. The formed pellet of cells was 
resuspended in fresh medium and cells were split depending on cell density and type of 
cell line (1:3 to 1:6 for MDA-MB-231; 1:2 to 1:3 SK-OV-3; 1:3 to1:6 A2780; 1:5 to 
1:20 A2780cisR). Cells with fresh medium were placed in the incubator for growing. 
 
6.10.6 Cell counting and seeding 
The procedure for cell passaging was performed before cell counting was carried out. 
The pellet of cells formed as a result of centrifugation was resuspended in 1 mL of fresh 
medium and the cells were counted using an improved Neubauer counting chamber. To 
count cells, 190 μL of Trypan blue dye was added to an eppendorf. 10 μL of cell 
suspension was added and the solution was mixed well. 10 μL of the cells with dye was 
introduced on to each side of the counting chamber and cell counting was performed 
using a microscope. The amount of cells necessary for the experiment was calculated 
and aliquots with a right amount of cells in the medium were prepared.  MDA-MB-231 
and SK-OV-3 cell lines were seeded at a density of 8000 – 10000 cells per well, A2780 
and A2780cisR cell lines were seeded at a density of  4000 – 6000 cells per well. 100 
μL of the prepared aliquots of cells in medium was seeded in each well of the 96 
flatbottom mocrititer well plates.  Plates were incubated at 37 ºC for 24 hours to allow 
cells to attach to the flask surface before treatment with the synthesized compounds. 
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6.10.7 Cell testing procedure 
200 μM stock solutions of the metal complexes in medium were prepared. After the 
plates had been incubated for 24 hours they were treated with 100 μL of six different 
concentrations of the complex (200 μM, 100 μM, 50 μM, 25 μM, 12.5 μM). 100 μL of 
fresh medium was added to the control wells and the plates were incubated for 72 hours.  
 
6.10.8 MTT assay 
After 72 hours of incubation, 50 μL of MTT solution (5 mg/mL in PBS) was added to 
each well of the plate except for 3 wells of the control and then incubated for a further 2 
hours. Medium with MTT was removed subsequently and formed purple crystals of 
formazan were dissolved by the addition of 200 μL of DMSO in each well of the plate. 
The plates were left for 15 minutes to ensure full solubilisation of the purple crystals. 
The absorbance was measured using a microplate reader (Bio Rad) set at 590 nm. 
 
6.10.9 Cells freezing procedure   
When cells were no longer needed they were frozen gradually by placing in a freezer at 
-70 ºC and then in a cryovessel with liquid nitrogen. The procedure for freezing cells is 
similar to the one of cell passaging, however after the centrifugation and removal of the 
medium, the cells were resuspended in a 10 % DMSO/FBS solution. 1 mL of cells in 
freezing medium was placed in a cryovial and frozen. 
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A - Crystallographic data of the [Cu2(L2)2](PF6)2 complex 
 
Empirical Formula  C62H44Cu2N12, 2PF6 
Formula Weight  1374.11 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal System  Monoclinic 
Space Group  P 21 
Unit Cell Dimensions a = 10.633(2) Å α = 90° 
 b = 20.396(4) Å β = 99.966(9)° 
 c = 16.328(3) Å γ = 90° 
Volume 3487.5(12) Å
3
 
Z 2 
Density (calculated) 1.309 Mg/m
3
 
Absorption Coefficient 0.733 mm
-1
 
Crystal Size 0.18 x 0.05 x 0.02 mm
3
 
Reflections Collected 19669 
Independent Reflections 10977 [R(int) = 0.0799] 
Data / Restraints / Parameters 10977 / 1240 / 827 
  Goodness-of-fit on F2 1.175 
 
Final R indices [I>2sigma(I)] R1 = 0.1580, wR2 = 0.3775 
R indices (all data) R1 = 0.2483, wR2 = 0.4239 
Largest diff. Peak and hole 0.662 and -0.849 e.Å
-3
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B - Crystallographic data of the [Fe2(L4)3](PF6)4 complex 
 
Empirical Formula                      C99 H84 Fe2 N24, 4(P F6) 
Formula Weight  2448.25 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal System  Triclinic 
Space Group  P-1 
Unit Cell Dimensions a = 14.6717(4) Å            γ = 66.665(2)° 
 b = 18.6418(5) Å            β = 83.538(2)° 
 c = 22.0009(4) Å            γ = 80.3500(10)° 
Volume 5439.9(2) Å
3
 
Z 2 
Density (calculated) 1.495 Mg/m
3
 
Absorption Coefficient 0.429 mm
-1
 
Crystal size 0.20 x 0.08 x 0.05 mm
3
 
Reflections collected 74537 
Independent reflections 19136 [R(int) = 0.0847] 
Data / restraints / parameters 19136 / 2060 / 1624 
Goodness-of-fit on F2 1.084 
Final R indices [I>2sigma(I)] R1 = 0.1032, wR2 = 0.1782 
R indices (all data) R1 = 0.1676, wR2 = 0.2127 
Largest diff. peak and hole 1.035 and -0.766 e.Å
-3
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C - Crystallographic data of the [Ni2(L4)3](PF6)4 complex 
 
Empirical Formula  C99 H84 N24 Ni2, 4(PF6) 
Formula Weight  2463.42 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal System  Triclinic 
Space Group  P -1 
Unit Cell Dimensions a = 13.3692(9) Å          α = 113.514(3)° 
 b = 22.2187(16) Å        β = 102.465(3)° 
 c = 22.4798(18) Å         γ = 97.137(4)° 
Volume 5811.4(7) Å
3
 
Z 2 
Density (calculated) 1.408 Mg/m
3
 
Absorption Coefficient 0.476 mm-1 
Crystal size 0.05 x 0.05 x 0.02 mm
3
 
Reflections Collected 68732 
Independent Reflections 20085 [R(int) = 0.2118] 
Data / restraints / parameters 20085 / 1612 / 1481 
Goodness-of-fit on F
2
 1.023 
Final R indices [I>2sigma(I)] R1 = 0.1796, wR2 = 0.3672 
R indices (all data) R1 = 0.3444, wR2 = 0.4462 
Largest diff. peak and hole 0.824 and -0.519 e.Å
-3
 
 
